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ABSTRACT 
The Hepatitis B virus (I-IBV) possesses a partially double-stranded 
circular DNA genome. 	The virions carry an endogenous polymerase that 
uses the minus strand as a template to fill in the single-stranded gap. 
Since attempts to purify this enzyme have been unsuccessful the origin 
of this DNA polymerase has not been established. 	It may be virally 
encoded or a host polymerase which is encapsulated during maturation 
of the virion. Sequence analysis of the viral genome revealed the 
presence of a long open reading frame (L.ORF) with the coding capacity 
of 93kd, the expected size of a DNA polymerase. 	The predicted amino 
acid sequence of the L.ORF revealed the existence of amino acid 
homologies with the reverse transcriptase of some other viruses. The 
size, and the belief that HBV replication involves a reverse 
transcriptase activity of the endogenous polymerase led to the 
assignment of the long ORF as the putative polymerase gene. 
Segments of the putative polymerase gene were fused in frame to 
the 3' end of the -galactosidase gene of Escherichia coli, and 
expressed as fusion proteins. 	Antisera raised to these fusion 
proteins recognise distinct epitopes in the amino and central regions 
of the putative polymerase gene product. Using immunoblotting, 
convalescent sera from chimpanzees infected with HBV were shown to 
contain antibodies that cross-reacted with the fusion proteins. These 
antibodies were found only transiently, and reached a maximum titre 
about 25 weeks after inoculation with the virus at which stage the 
animals still exhibited HBe antigenaemia, but were also producing 
antibodies to all the HBV antigens. 	Antibodies that cross-reacted 
with the fusion protein were not found in the serum of a chimpanzee 
that had been vaccinated prior to inoculation with HBV. Furthermore, 
(iv) 
antibodies raised to HBV surface, core, e and X antigens did not react 
with the -ga1actosidase-po1yrnerase fusion product. 
Extracts of E.coli expressing the gene fusion products were also 
shown to exhibit a polymerase activity with the characteristics of the 
endogenous Hepatitis B polymerase. 
These experiments show that the HBV long ORE encodes a protein with 
polyrnerase activity; also the gene is expressed during viral infection 
and antibodies to its product are found in convalescent sera during HBV 
infection. 	These findings leave little doubt that the endogenous 
polymerase associated with HBV is indeed encoded by the long ORE and is 
not a host polymerase. 
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The first reference to epidemic jaundice has been ascribed to 
Hippocrates (460-375 BC). 	Many epidemics have been described since. 
However, it was not until 1940 that epidemic jaundice was found to be 
caused by inflammation of the liver, i.e. hepatitis. 	A virus was 
later discovered by Blumberg to be the causative agent of this severe 
form of hepatitis (Blumberg, et al., 1967). This virus is now known 
as Hepatitis B virus (HBV). 
Evidence of infection with HBV has been obtained in every 
population in the world irrespective of geographical location, but the 
prevalence of HBV infection varies according to the region of the world 
(Fig.1.1a). In many African and Asian countries infection is almost 
universal. 	In South America, North Africa, Middle East and South 
Eastern Europe around 1%-5% of the population is infected while the 
lowest incidence of HBV infection (0.3% of the population) is found in 
the developed countries of Western Europe, U.S.A., Canada, Australia, 
New Zealand and the Scandinavian countries. 
1.1. The Virus 
Three distinct structures can be consistently detected in the 
serum of HBV individuals infected with HBV: 	a) small spherical 
particles approximately 22rim in diameter, 	b) tubular structures that 
are approximately 22nm in diameter and vary in length, and c) enveloped 
particles with a diameter of approximately 42nm (Fig.1.1b). 	This 42nm 
enveloped particle was later shown to be the infectious agent (also 
known as the Dane particle). 	It possesses an inner nucleocapsid 
structure, approximately 28nm in diameter, which contains the genetic 
information of the virus (a partially double-stranded, partially single 









H6sAQ rates (%) 	 / 
3-5 
— 6-10 




C antigen i H&,-%g ,. 
fret to circulation as  
small protein, Or 
compkxed to ft, 
niokculrt 
r antigen 	crspt 
component of core 
Particle, revealed by 
SUS and pronw 
treatment; 
,urlace anhigets HBs.\g 
group tpecificstv a, 
subtype 5F)CIcificitics div. 
wfr; 2 major 
pohpeptides gp 2IwIu 
r.m.m. p 231Mk1 r.m.rn. 
circular DNA molecule, 
2 x  10  1mm.. with 
satiable gap in one 
strand 
DNA -dependent DNA 
polymerasr enzyme 
(Robinson 1977, Kaplan et al., 1973). 	The smaller particles and 
tubular structures associated with infection contain no viral genetic 
material and result from the over-production, during infection, of the 
viral coat proteins which subsequently aggregate to form these 
structures. 
1.2 Components of the Virus Particle 
1.2.1 	The envelope and surface structure. 
The virion is surrounded by an envelope, which is proposed to 
originate from the endoplasmic reticulum (Persing et al., 1986). The 
surface antigen protein and the glycoproteins are embedded in the lipid 
bil ayer. 
The three surface proteins of the virion, and of the spherical and 
tubular structures are pre Si (p39), pre S2 (p31) and the major surface 
protein (p24). 	These 3 proteins share the same carboxy terminus but 
have different amino termini reflecting the different translational 
start sites used within the surface ORE, which has 3 inframe AUG 
initiation codons at the beginning of the surface gene (Fig.1.2a). The 
distribution of these 3 proteins is not equal among the circulating 
forms of HB5Ag. The pre Si protein is found in higher abundance in 
viral particles and filaments than in the more numerous 22nm subviral 
particles, while the converse is true of the more abundant preS2 and S 
proteins. These findings suggest that pre Si determinants may be 
important in virus assembly and/or infectivity (Persing et al., 1987). 
The major surface protein is 226 amino acids in length. 	It has two 
forms; a protein of 24kd (p24) and a glycosylated form with a molecular 
weight of 27kd (GP27). 	The latter possesses a complex N-linked glycan 
at ASN146. HBsAg is an extremely hydrophobic molecule rich in cysteine 
2 
FIGURE 1.2(a) 	Structure of the HBV surface antigen showing 
the location and sizes of the three major domains 
(Harrison et al., 1986). 
FIGURE 1.2(b) 	The genome of HBV. 	Heavy lines denote the DNA 
strands, the broken line showing the region of variable 
length of the short strand. 	Arrows represent the four 
open reading frames (as coding sequences) with the numbers 
of initiation and termination triplets in the system 
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and praline residues. 	The transmembrane region of the protein is 
between amino acid residues 80-100 (Valenzuela et al., 1982). The 
central part of the protein contains 2 hydrophilic domains at 
positions 45-80 and 110-150, the latter region containing the main 
group epitope and subtype determinants. 	1-IBsAg is a conformational 
antigen, the dimer linked by disulphide bridges representing the 
structural unit that bears full HBsAg antigenicity (Tiollais et al., 
1985). 
The pre S2 protein is 281 amino acids long with a molecular weight 
of 31kd (p31) composed of the 24kd surface protein and an additional 55 
amino acids of the pre S region. 	It can undergo two types of 
glycosylation to produce either GP33 which has an additional glycan 
unit at residue 4 or GP36 which has a second additional glycan attached 
near the amino terminus. 	Both glycosylated forms also contain the 
glycan that occurs at ASN146 in GP27 (Machida et al., 1983). 	An 
immunodominant epitope resides on the hydrophillic 55 amino acid region 
of the pre S2 protein and antibodies which react with this determinant 
have been found in both humans and chimpanzees recovering from HBV 
infection (Neurath et al., 1985). 
The pre S protein is composed of the pre Si, pre S2 and surface 
region. The length of the protein varies according to the subtype of 
virus. 	It can be either 389 or 400 amino acids long and with a 
corresponding molecular weight of 39kd (p39) or 42kd which represents 
the glycosylated form (Tiollias et al., 1985). 	The most variable 
region between hepadna viruses occurs at the N-terminal region of the 
pre Si protein, and has been implicated in attachment of FIBV to 
hepatocytes (Neurath et a]., 1985). 
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1.2.2 	The Nucleocapsid 
The nucleocapsid of the virus encloses the viral DNA, and has 
associated with it the DNA polymerase activity and a protein kinase 
activity (Robinson 1975; Kaplan et al., 1973 and Albin and Robinson, 
1980). 
The nucleocapsid of the virion is composed of one major 
polypeptide, the core antigen HBcAg, p22, which has a molecular weight 
of 22kd. 	The deduced polypeptide sequence of the core gene is 
interesting as the carboxy terminal region (residues 150-183) has 
extensive homology with protamines; 16 out of 34 amino acids are 
arginines 	(Pasek et al., 1979). 	This feature infers that the C- 
terminal region binds the HBV DNA within the nucleocapsid while the 
rest of the protein participates in other structural roles. 	The 
core protein contains four cysteine residues with the potential for 
both intra- and inter-molecular disulphide bridge formation, which 
offers a possible explanation for some of the higher molecular weight 
values observed for core antigen. 	The major core protein p22 is also 
phosphorylated by the protein kinase associated with the nucleocapsid. 
Determination of the complete viral DNA sequence revealed the presence 
of a second inframe initiation site 87 nucleotides upstream from the 
initiating AUG of the major core protein. This region, known now as the 
pre core region,encodes a largely hydrophobic amino acid sequence 
resembling a peptide leader sequence (Pasek et al., 1979). 	This was 
shown to be cleaved after synthesis of the pre core protein in vitro 
(Enders et al., 1985). 	Expression studies in bacteria (Stahl et al., 
1982) and in eukaryotic cells (Will et a]., 1984) have shown that this 
region is not necessary for the production of the core antigen or for 
assembly of core particles which are structurally and morphologically 
similar to the virus core particles (Cohen and Richmond,1982), although 
these core particles have not been shown to interact with other viral 
components in the assembly of virus particles. 
In the sera of infected patients there is no circulating core 
antigen. 	There is, however, a soluble antigen distinct from the 
surface and core antigen known as the HBeAg. 	The origin of this 
antigen was unknown for a long time.The presence of HBeAg was not 
detected on the surface of the virion and anti HBeAg was shown not to 
precipitate the virions (Takahashi et al., 1979). However, when the 
nucleocapsid of the virion was treated with either proteolytic enzymes 
or SDS, the presence of HBeAg was detected. (Ohari et al., 1979). This 
demonstrates that HBeAg existes in a cryptic form on the nucleocapsid 
of the virions. 	The definitive experiment that showed that HBeAg was 
found on the core protein was performed by Mackay et al., (1981). 
They found that HBcAg produced by bacterial cells could be converted to 
HBeAg by treatment with proteolytic enzymes or reducing agents thereby 
showing HBeA9 is a cryptic form of HBcAg. 	Two distinct e epitopes 
have been localized on the HBcAg polypeptides which are exposed when 
the molecule is unfolded (Ferns and Tedder, 1986). These are called 
HBeA9/1 and HBeAg/2. 
HBeAg resides on a polypeptide of 15.5kd (Takahashi et al., 1979). 
Amino acid sequencing of the C-terminal sequence revealed that the C-
terminus of this protein lies 33 amino acids from the carboxy end of 
the major core polypeptide (Tiollais et al., 1985). Miller (1977) 
proposed that HBeAg may be produced by proteolytic self-cleavage 
of the core protein as a protease-like amino acid sequence was 
identified at the amino terminus of the core sequence. As well as the 
two HBeAg epitopes in this polypeptide there is also a distinct epitope 
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for the core antigen. 
HBeAg in the serum occurs either as a 15.5kd pol,ypeptide or in 
association with IgG. 	Analyses of HBeAg purified from the Dane 
particles and the serum have shown that they are practically identical 
in amino acid composition and antigenic determinants (Takahashi et al., 
1979). 	Despite their close relationship, HBeAg has been accepted as 
an entity separate from HBcAg since HBeAg may be detected in sera that 
contain anti-FIBcAg in high titres. 	High levels of HBeAg are accepted 
as an indication of high titres of virions and of relative infectivity 
(Zuckerman,1982). 
HBe antigen is postulated to be secreted from the infected cells 
via the pre core region. Ou and Rutter (1985) expressed the core 
protein with and without the pre core region in eukaryotic cells, and 
showed that the pre-core region is not required for expression 
of core antigen or HBe antigen. 	However, it is required for the 
secretion of HBeAg. 
The nucleocapsid core also contains a DNA polymerase activity 
(Kaplan et al., 1973). 	This DNA polymease will fill in the single- 
stranded gap in the viral genome in vitro when supplied with deoxy- 
nucleotide triphosphates (dNTP). 	The origin of this polymerase has 
not yet been determined. 	Attempts to purify the polymerase from the 
virus particle have failed and comparative studies of the properties of 
the HBV and mammalian polymerases are inconclusive (Hirschman and 
Garfinkel, 1977(b); Hess et al., 1981; Goto et al., 1984). 
An uncharacterized protein is bound to the 5' terminus of the long 
strand (Gerlich and Robinson, 1980) which has been proposed to be 
encoded by the X gene. 	Recent experiments have shown that this gene 
is expressed by the virus and antibodies directed against it are 
produced during HBV infection. (Gough and Murray 1982, Pugh et al., 
1986; Moriarty et al., 1985; Kay et al., 1985, Meyers et al., 1986). 
Although these experiments have demonstrated that the virus uses this 
gene, its function remains unknown. 
1.3 Structure of the Viral Genome and its Genetic Organisation 
HBV is the prototype of a family of viruses called Hepadnaviruses. 
Other members of this family include: Woodchuck Hepatitis Virus (WHV) 
(Summers et al., 1978), Ground Squirrel Hepatitis Virus (GSHV) (Marion 
and Robinson, 1983), Duck Hepatitis B Virus (DHBV) (Mason et al., 
1980) and Tree Squirrel Hepatitis B Virus (THBV) (Feitelson, et al., 
1986). All viruses of the family have a narrow host range and are not 
readily propagated in cell culture. 	They possess a partially double- 
stranded, partially single-stranded circular DNA genome (see Fig.1.2b) 
(Marion et al., 1980). 	Neither strand is a covalently closed circle, 
but the circular configuration is maintained by a 5' complementary 
sequence at the termini of the two strands. 	By heating under the 
appropriate conditions, the circular genome can be converted to a 
linear form with single-stranded cohesive ends (Sattler and Robinson, 
1979). The single-stranded portion varies in length from approximately 
15-50% of the circle length with a preferred minimum length of 650-700. 
nucleotides. The shorter of the two strands has a fixed 5' terminus 
and a variable 3' terminus (Delius et al., 1983). In HBV the longer of 
the two strands is approximately 3200 nucleotides in length and has a 
nick at a unique site, with a protein bound at its 5' terminus (Gerlich 
and Robinson, 1980). At both sides of the cohesive ends there is an 
llbp direct repeat, DR1 and DR2. The nucleotide sequence of cloned HBV 
defined the major viral coding regions (Pasek et al., 1979). 	The 
organisation of the genetic information is compact, with four open 
reading frames (ORE) found in the longer of the two strands (minus 
strand). 	The assignment of the ORFs to the viral proteins was based 
on partial amino acid sequencing of purified HBsAg (Peterson et al., 
1977) and the expression of HBcAg in Escherichia coil (Burrell et al., 
1979). 	As the virion carries an endogenous polymerase (Kaplan et al., 
1973) and there is a long ORF coding for a protein that is the expected 
size for a polymerase, this has been assumed to be the polymerase gene. 
The last and smallest ORE is referred to as the X gene. 	The short 
strand has one small open reading frame but this is not conserved in 
all sub-types, or across the hepadna virus family. 
1.4 Mode of Transmission 
HBV is present in blood and other body fluids, including saliva, 
seminal fluids, menstrual and vaginal discharges. 	Transmission of 
infection has been associated with transfusion of contaminated blood, 
sexual intercourse, and the use of contaminated syringes and hypodermic 
needles. 	Transmission occurs through the inoculation of blood with 
either blood or body fluids contaminated with the virus. 	Infection 
has also been shown to be transmitted vertically, from infected mother 
to child shortly after birth (Gust and Crowe, 1986). 
The primary site of replication of HBV in the infected host is the 
liver. However, in both ducks and humans infected with DHBV and HBV 
respectively, all forms of viral DNA and RNA which are characteristic 
of active synthesis of the virus have also been found in the pancreas 
and kidneys (Halpern et al., 1983, Dejean et al., 1984). 
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1.5 Disease 
The incubation period of HBV varies from 14-180 days. 
There are two major forms of HBV infection; the first is short-
lived and is known as acute hepatitis; the second, chronic hepatitis, 
is defined as a persistent infection (Zuckerman, 1982). 
An acute infection with HBV is marked by the appearance of the 
following in the serum: surface antigen appears first (see Fig.1.3a), 
followed by the viral polymerase activity and the e antigen. 
Detection of these in the serum precedes an increase in the level of 
amino transferase and the development of jaundice. Antibodies against 
core antigen can be detected 2-4 weeks after the appearance of surface 
antigen and is followed by the production of antibodies against e 
antigen and finally, antibodies against surface antigen (Burrell, et 
al., 1980). 
Chronic hepatitis (carrier state) develops from acute hepatitis 
in approximately 10% of infected adults and 98% of infected new-born 
children (see Fig.1.3b) (Lever and Thomas, 1986). 	This form of 
infection is characterised by the persistence of surface antigen in the 
serum and absence of antibodies against surface antigen (Floofnagle et 
al., 1973). The carrier state can be life-long and is associated with 
liver damage, ranging from minor changes in the nuclei of hepatocytes 
to chronic persistent hepatitis (CPH), chronic active hepatitis (CAH) 
and cirrhosis (Wright, 1980). 	In total, 50% of carriers will 
die of a liver-related disease and 5% will develop primary hepato-
cellular carcinoma (Lever and Thomas, 1986). 
Within the population, there are well defined groups which have 
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FIGURE 1.3 (a) 	Serological markers presented in the serum, 
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FIGURE 1.3 (b) 	Clinical manifestations of HBV infection. 
CAH - chronic active hepatitis; CHP - chronic 
persistent Hepatitis. 
those infected at a young age, and those who suffer from natural or 
acquired immune deficiencies. 	Figures have also revealed that males 
are more likely than females to develop chronic hepatitis, the ratio 
of male to female carriers being 2:1 (Beasley and Hiwang, 1984). 
Sero-epidemiological surveys reveal that in the world today there 
are at least 200 million carriers of Hepatitis B (Zuckermann, 1982). 
These carriers represent a serious medical problem as they act as a 
large reservoir for the infectious virus. 	Approaches to eradicate 
this virus require an understanding of its life cycle at a molecular 
level. 	However, progress has been hindered until recently by the lack 
of a cell culture system for HBV. 	Nevertheless, some of the basic 
strategies employed by the virus during its life cycle are now 
understood and are discussed below. 
1.6 Life Cycle of the virus 
1.6.1 	Attachment and Entry 
The first step in the life cycle of HBV is the attachment of the 
virus to the hepatocyte. 	Several theories have been proposed to 
explain the mechanism of attachment. 
It was shown by several groups that the 55 amino acids at the N-
terminus of the pre S2 protein have the capacity to bind polymerised 
human serum albumin (pHSA). 	This protein was shown to bind only 
polymerised albumin from animals susceptible to HBV. (Machida et al., 
1983; Tiollais et al., 1985). 	It was also found that hepatocytes 
have the ability to bind pHSA (Machida et al., 1983). 	Hence it was 
proposed that HBV attaches to the hepatocyte via a polymeric albumin 
bridge, and the HBV polyalbumin complex is then internalised by 
endocytosi s. 
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Recently, however, Ishihara et al., 1987 have demonstrated that 
the interaction between HBsAg particles and pHSA is inhibited by 
physiological concentrations of mature serum albumin. Also, Neurath et 
al., 1985 found that antibodies to pHSA did not affect binding of HBsAg 
(HBV) to a human hepatocyte cell line. 	These latter results indicate 
that the ability of pre S2 to bind to pHSA may not play a role in virus 
uptake as has previously been suggested. Neurath et al., 1986, showed 
that antibodies to the pre S region, but not to the surface region, 
inhibited the binding of HBV to Hep G2 cells (human hepatoma cells), 
indicating that the pre S region may be essential for recognition of 
the Hep G2 cell receptor. 	Further investigation, using synthetic 
peptides from pre Si and pre S2 regions, showed that the antisera 
against synthetic peptides from pre Si region very strongly inhibited 
binding of HBV, while antisera to synthetic peptides from pre S2 
inhibited binding by only 50%. 	This would suggest that pre Si has a 
region essential for HBV binding hepatocytes while pre S2 sequence has 
only an ancilliary role in HBV binding to the cells. 
Interestingly, there is very little amino acid sequence homology 
between pre S regions of the different hepadna viruses. In contrast, 
the major surface gene between these viruses is very well conserved. 
This may be the region that affords the tight host specificity within 
the hepadna virus family. At present some groups are trying to make 
viable recombinants between GSHV and WHBV which will be very useful in 
discovering the region of the virus responsible for species specificity. 
Once the virus is attached to the surface of the hepatocyte, 
penetration of the virus could occur via two mechanisms. 	Firstly, by 
endocytosis of intact virions with subsequent release from endosomes, 
or secondly, by fusion of the viral envelope and liver cell plasma 
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membrane with penetration of the nucleocapsid into the cytoplasm. 	As 
yet, no evidence supporting either mechanism exists. 
1.6.2 	Transcription 
After the virus enters the hepatocyte the DNA reaches the nucleus 
where transcription can occur. 	The template for transcription is a 
supercoiled viral genome produced by conversion of the partially 
double-stranded DNA into a supercoiled form by the endogenous DNA 
polymerase activity (Kaplan et al., 1973). 	The genomic structure of 
the virus with the single-stranded region and the nick has been shown 
to be unnecessary for initiating HBV infection. 	This was demonstrated 
by Catteneo et al., (1984a) who were able to initiate acute viral 
hepatitis in chimpanzees when they injected liver cells transformed 
with the cloned double-stranded FIBV molecules directly into their 
livers. 
The mammalian hepadna viruses contain coding information for at 
least seven distinct proteins. 	The HBV sequence provides some 
information on potential transcription signals such as 5'-TATTAAA-3' 
boxes and AATAAA directed polyadenyJation sites. 	However, these are 
not sufficient to define the actual viral transcription units. 	The 
exact location of HBV promoters has been hampered by the lack of a 
tissue culture system for the propagation of HBV although the recent 
demonstration of the production of virus in transformed hepatoma cell 
lines could solve this problem (Surrea et al., 1986). Various 
approaches, including the transcription of HBV DNA in cell-free 
transcription systems and the introduction into mammalian cells of HBV 
DNA via viral vectors or by co-transformation have led to an increased 
understanding of the expression of HBV and the tentative identification 
of some promoters. 
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The first attempts to analyse the expression of HBsAg were 
performed in cell lines that were found to express the surface antigen. 
One particular cell line PLC/PRF/5 (Alexander et al., 1976), has been 
extensively used to analyse expression of the surface gene, a 2.3 kb 
HBV-specific minus strand transcript, which hybridised to the HBsAg 
gene, has been assigned as the HBsAg messenger RNA (mRNA) (Edman et 
al., 1980; Pourcel et al., 1982; Chakrabarty et al., 1980). 	Further 
analysis has shown that two classes of mRNA exist for HB5Ag. One class 
initiates upstream of pre Si and can encode the 39 kd pre Si protein. 
The other initiates within the pre S2 region and can encode both the 
pre S2 and major surface proteins (Fig.1.4). 
Gough and Murray (1982) and Pourcel et al., (1982) using permanent 
fibroblast cell lines transformed with HBV, mapped the 5'initiation 
site of 1-IBsAg mRNA and found that it initiated upstream of the pre Si 
region. 	The results from in vitro experiments agreed with these 
results and showed that 1-IBsAg mRNA initiated upstream of the pre Si 
region between nucleotides 900-910 in accordance with the numbering 
system of Pasek et ai.,(1979), Schaul et ai.,(1983), Rail et al., 1983) 
(Fig.1.4). This mRNA has the potential to produce the 39kd pre Si 
protein. 	Sequence analysis of the region upstream from this mRNA 
start site identified a consensus 5'-TATTAAA-3' box at position 876 
which could form part of the promoter which expressed this mRNA. 
However, mapping experiments performed by Cattaneo et al.,(1983) with 
HBsAg mRNA isolated from infected chimpanzee livers and from rat cell 
lines transformed with HBV disagreed with the above findings suggesting 
that the 5' initiation start site for HBsAg mRNA was at nucleotide 
position 1256, i.e. within the pre S2 region (Fig.1.4). Standring et 
al.,(1984), Enders et al.,(1985) and Buscher et al., (1985), using HBV, 
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FIGURE 1.4 	Transcription map of HBV.(drawing by R. Jackson). 
GSHV and DHBV systems respectively, all showed the presence of a mRNA 
species initiating within the pre S2 region and also demonstrated that 
this mRNA displayed 5' heterogeneity. 	This mRNA could produce the pre 
S2 (p31).Upstream from this 5' start site there were no TATA box-like 
sequences. However, at position 1215 there is a sequence which bears 
strong homology with the late promoter of Simian virus 40. This 
promoter controls the transcription of a major structural protein of 
5V40 and interestingly also exhibits 5' heterogeneity for initiation of 
transcription (Brady, 1982). Perhaps these regions represent an 
unusual viral control sequence. 
The fact that the 5' heterogeneity exhibited by the HB5Ag mRNA, 
initiating around the p31 AUG. occurs in all systems and for all 
hepadna viruses studied tends to support the theory that variability 
in initiation of this mRNA has functional significance for hepadna 
virus gene expression. 
Siddiqui et al., (1987), by putting the promoter sequences 
upstream of the bacterial chioramphenicol acetyl transferase (CAT) 
marker gene and measuring the relative levels of CAT produced, showed 
that both the promoters described for HBsAg mRNA are equally active and 
show little cellular specificity. 	However, these results may not 
reflect the relative activities of these promoters in the normal 
infected cell as the promoters have been separated from their normal 
products and other viral gene products which may exert control on these 
promoters. 	This is supported by the findings of Ou and Rutter (1985) 
who found that only 2% of HBsAg niRNA isolated from PLC/PRF/5 originated 
upstream of pre Si which may indicate that it is a weaker or more 
controlled promoter than the promoter at 1215. 
16 
In summary, there appear to be two distinct promoter regions 
associated with the HBsAg gene; one positioned upstream from the 
second conserved ATG which could produce the major surface and pre S2 
protein (1215), the other lies upstream of pre Si (876) and could 
produce the pre Si protein. 
It is now generally accepted that the mRNA for the surface antigen 
is not spliced although Simonsen and Levinson (1983) and Cattaneo et 
al., (1983) have reported the presence of a spliced species of HBsAg 
mRNA, but these are believed to be artefacts of the system used. 
Both classes of HB5Ag mRNA terminate and are polyadenylated 
approximately 20 nucleotides downstream from a variant polyadenylation 
signal at nucleotide position 16 TATAAA 21 which is situated within the 
core gene (Cattaneo et al., 1983). 
A second class of HBV specific poly A+ minus strand transcripts 
has also been described in both in vitro and in vivo experiments. 
These transcripts are greater than genomic length. 	Rall et al., 
(1983) showed, using in vivo and in vitro experiments, that the 5' 
initiation site of this mRNA mapped upstream of the core gene. 	Gough 
(1983), using rat cells transformed with FIBV DNA, proved that these 
large mRNAs are required for HBcAg and HBeAg expression as cells 
without these messages did not express the core protein. 	The large 
mRNAs were present in the livers of ducks, humans and ground squirrels 
infected with DHBV, HBV and GSI-IV respectively (Enders et al., 1985; 
Cattaneo et al., 1983, 1984; Buscher et al., 1985). 	More detailed 
analysis using S 1 nuclease and primer extension experiments revealed 
that this message covers the complete genome plus an additional 
sequence of 120 nucleotides. 	This message also displays the same 5' 
heterogeneity as the surface messenger RNA (Yaginuma et al., 1987). 5' 
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mapping has revealed that GSHV, DHBV and HBV transcripts from infected 
cells, have three core-specific messenger RNA initiation sites 
distributed over a 30-nucleotide region (Enders et al., 1985, Moroy et 
al., 1985 and Yaginuma et al., 1987). 	In the case of HBV the mRNAs 
were shown to initiate at nucleotide 3063 and 3072 (upstream of the 
pre-core region and therefore able to express the pre-core region) and 
at 3099 downstream of the pre-core initiating AUG, but still has the 
capability to code for mature core protein. Zelent et al., (1987) 
demonstrated that without the latter message no core protein was 
produced even when the larger message was present. It has also been 
proposed that the larger messenger RNAs are used as a template for the 
synthesis of viral minus strands as part of the replicative process. 
The production of these larger than genome messages would require 
read through of the polyadenylation and termination signals within the 
core gene during the first round of transcription with termination and 
polyadenylation occurring during the second round of transcription. 
This is similar to the strategy adopted by polyoma virus to transcribe 
its late messenger RNA5 (Tooze et al., 1973). 
No mRNA has been detected that contains the first AUG codon in the 
polymerase frame as its 5' proximal AUG indicating that such a 
transcript may only be present in very low amounts if at all. 
Translation of the polymerase frame may start at an internal AUG of the 
core mRNA (and/or longer mRNA) as is known for other polycistronic 
mRNAs (Kozak, 1986). 	Alternatively, the polymerase may be translated 
as a fusion protein with the core protein. 	This would involve a 
frameshift during translation and the subsequent cleavage of the 
polymerase from the polyprotein precursor. 	Such strategies are used 
for the production of the polymerase gene from retroviruses (Beveren et 
al., 1985). 	Will et a] (1986) have inferred the presence of a 
polymerase-core fusion in a hepatoma carcinoma. As discussed 
previously, the NH 2 terminus of the core protein has protease-like 
sequences which may be active in the cleavage of HBcAg to FIBeAg. 	This 
may also act in the processing of core-polymerase fusion proteins 
(Miller, 1987). 	It was postulated that due to the absence of the core 
protein NH2 terminus in the core-polymerase fusion protein described 
by Will et al., (1986), the viral protease is absent and thus fusion 
polyproteins would be able to accumulate. 
The presence of a small poly(A)+  minus strand message, which 
hybridises specifically to the X region in cell lines transformed with 
HBV, has been described by Gough (1983) and Treinin and Laub (1987), 
showed that this message is produced from its own independent promoter 
positioned within the region 2524-2629 (Treinin and Laub, 1987). 
The 51  end of this messenger displayed heterogeneity with 
multiple start sites at 2590, 2612 and 2620. 	The X gene promoter, 
like the internal I-IBV surface promoter, lacks a TATA box-like sequence. 
The discovery of a new promoter located upstream from the X ORE 
provides more evidence that these sequences represent a functional gene 
which is expressed from its own transcription unit. 
In summary, the two major classes of viral mRNA for the core and 
surface genes and the less abundant X message are unspliced, poly-
adenylated co-terminal and display 5' heterogeneous ends that encode 
proteins with different amino termini. 	Hence one could conclude that 
the heterogeneity displayed must have a functional significance for 
hepadna viral gene expression. 
These experiments have identified active promoters but they do not 
indicate how these promoters are regulated. 	The contrast between the 
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weak promoter activity in non-primate and non-hepatic cell types and 
the production of large amounts of core antigen during HBV infection 
in humans prompted the investigation of whether an HBV enhancer 
influences promoter activity. 
Using the CAT gene system, Shaul et al., (1985) defined a HBV 
transcriptional enhancer element. 	This enhancer element was located 
450 bp upstream of the HBcAg gene (at position 2279-2529) and was shown 
to increase the promoter activity of both the core and the X gene. The 
enhancer was shown to have strict host and tissue specificity (Jameel 
and Siddiqui, 1986) and was functional only in the liver cells of human 
origin. 	This enhancer activity functioned independently of HBV gene 
products present in the cell lines tested. 	From their data it could 
easily be assumed that some component present within the human liver 
cells is required to activate this enhancer. 	Using a nitrocellulose 
filter-binding assay and DNA5e I footprinting techniques, Shaul and 
Ben-Levey (1987) indeed found that specific liver cell nucleic proteins 
are bound to the enhancer and its adjacent sequence. 	Other DNA 
binding proteins have been discovered which modulate promoter activity 
by binding near the promoter, e.g. the SV40 large T antigen promoter 
(Dynan and Tijan, 1985). 	One particular factor, nuclear factor 1 
(NFl) is required for efficient activity of the S gene promoter which 
binds within the pre Si region. 	Standring et al., (1983) have shown 
that a short ORE (700 HBV) in the short strand is transcribed by RNA 
p01111 in an in vitro transcription system. 	This transcript could 
encode a polypeptide of 164 amino-acids starting with a methionine 
start codon. However, the sequence of theliollais group (Tiollais et 
a]., 1985) predicts an open reading frame truncated to 86 amino acids 
by an extra stop codon, while the equivalent reading frame in Woodchuck 
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virus contains no methionine start codon. 	Hence a protein encoding 
region appears unlikely for 700 HBV. As this RNA is complementary to 
the minus strand messenger RNA it may serve a regulatory or processing 
function. 
To determine whether hormonal or physiological conditions affect 
the expression of the HBV genome, Babinet et al., (1985), produced 
transgenic mice that had HBV DNA (except for the core gene) inserted 
into their genome. 	These mouse strains had high levels of HBsAg in 
their serum and HBV-specific mRNA in their livers. 	Analysing the 
amount of HBsAy and HBsAg mRNA at different times during development 
and maturation revealed that HBsAg expression varied. 	This variation 
was shown to be due to the direct effect of sex hormones on HBV 
expression as the levels rose and fell during development. 
Interestingly, it was found that in adult male mice, HBsAg levels were 
5-10 times higher than in adult females (Farza et al., 1987). 	The 
expression of HBsAg appears to be controlled at the transcriptional 
level as HBsAg mRNA levels rose, HBsAg production was increased but a 
more detailed analysis is required before this can be proven. The above 
results may explain at a molecular level epidemiological data which 
reveals that males have an increased risk of becoming a carrier of HBV 
than females have. (Beasley and Hiwang, 1984). 
In conclusion, hepadna viruses exploit the genetic information 
which is encoded in its small genome by using a mixture of 
heterogeneous transcription and translation initiation start signals to 
increase its coding capacity. 	HBV expression appears to be under 
strict specific cellular control and is regulated by both trans-
activating proteins and hormonal control. 
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1.6.3 	Replication 
Once HBV has expressed the necessary viral proteins, the virus can 
begin to replicate. 
Summers and Mason (1982) isolated viral core-like particles from 
the cytoplasm of hepatocytes of ducks infected with DHBV. 	these 
particles were shown to incorporate deoxynucleoside triphosphates into 
DNA. 	This was found to be a different polymerase reaction from that 
observed with the mature virions, as these particles synthesized the 
viral DNA minus strand as well as the plus strand. 	Plus strand and 
not minus strand synthesis was sensitive to actinomycin D which was 
consistent with plus strand synthesis from a DNA template and minus 
strand synthesis from an RNA template. 	Analysis of the products and 
template of liver cores at various times after infection revealed that 
the minus strand DNA was synthesised by copying viral RNA which was 
rapidly degraded behind the growing point, possibly by a ribonuclease 
H activity. 	Therefore, replication of DHBV involves a reverse trans- 
cription step. 	Evidence that this is a common mechanism for hepadna 
viral replication has come from analyses of DNA from HBV, WHy, DHBV and 
GSHV infected liver using specific hybridization probes. 	All these 
investigations revealed the presence of DNA or RNA intermediates of 
replication (Monjardino et al., 1982; Blum et al., 1983; Weiser et 
al., 1983; Mason et al., 1982). 	Miller et al., (1984) have also 
isolated cores from human livers that appear to synthesise HBV minus 
strands from an RNA template and hence resemble those particles 
isolated from duck livers. 
The poly(A) minus strand transcript found in the liver core 
particles is known as the pre-genome, it is longer than the minus 
strand, and has a terminal redundancy of approximately 120 nucleotides. 
22 
The template for transcription of this pre-genome is most likely to be 
the supercoiled viral genome present in the infected hepatocyte. As 
neither chimpanzees infected with HBV, nor ducks infected with DFIBV 
have been shown to exhibit integrated viral sequences as an immediate 
consequence of infection, it is assumed that unlike retroviruses, 
hepadna viruses do not require an integration step for replication. 
Once the full length pre-genome is transcribed, it is proposed 
that it is packaged with the endogenous polymerase within core-like 
structures referred to by Summers and Mason (1982), as immature cores 
(Fig .1.5) 
The RNA might be packaged before reverse transcription for several 
reasons. 	Since the pre-genome RNA serves as both a template for 
reverse transcription and as a rnRNA for the core antigen and since it 
is unlikely that both processes can occur simultaneously on one strand, 
it may be more efficient to separate the mRNA required for viral 
replication from the pool of other messengers. 	Reverse transcription 
may also be more efficient in a compartment separated from the 
cytoplasm as it allows close association of template and enzyme. 
Analysis of the 5' ends of packaged RNA revealed which of the 
three large mRNAs transcribed from the core promoter is used as the 
template for reverse transcription. This showed that the shortest core 
message, which initiates within the pre-core region, is present within 
the core particles while the other two longer messages are found 
associated with polyribosomes (Yaginuma et a]., 1987; Enders et a]., 
1987). 	These findings suggest that there exists a packaging system 
capable of specifically selecting which mRNA species is packaged-based 
on different 5' termini. 
Using primer extension techniques on deproteinised DNA, the 5' end 
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FIGURE 1.5 	A scheme for the replication of HBV. From 
Summers and Mason (1982) and Seeger et al. (1986) 
of the minus strand was mapped to the direct repeat DR1 (Seeger et al., 
1986; Will et a]., 1987). 	However, as there are two copies of DR1 in 
the pre-genome, initiation could occur either at the 3' end or the 5' 
end of the pre-genome (see Fig.1.5). Initiation at the 5' end would 
allow only synthesis of a few nucleotides of minus strand DNA and then 
require an early template switch, whereas initiation at the 3' end 
would not require any switch for a complete DNA minus strand to be 
synthesised. Reverse transcription could proceed up to the 5' end of 
the pre-genome and produce a full length DNA minus strand. 	The latter 
possibility appears to occur as the minus strand seems to be terminated 
at the 5' end of of the template RNA (Will et al., 1987). The fact 
that even the shortest minus strands in infected livers (Weiser et al., 
1983), or in isolated core particles (Molner-Kimber et a]., 1984) are 
linked to protein, suggests that this protein may prime minus strand 
synthesis. 	This protein has not been characterised but it may be the 
same protein attached to the 5' end of the minus strand in mature 
virions. 	Very little plus strand synthesis is seen until the minus 
strand is completed, indicating that plus strand uses the minus strand 
for its template. 	The 5' end of DHBV and HBV plus strand has been 
shown to map to the 5' side of DR2 (Will et a]., 1987; Seeger et a]., 
1986). Lien et a]., 1986 demonstrated that a small 20bp RNA is 
covalently linked to the 5' end of DHBV plus strand which suggests that 
this is the primer for second strand synthesis. 	Sequencing of the 
oligoribonuc]eotide showed that this RNA is derived from the 5' end of 
the pre-genome RNA which contains the DR1 sequence. It was therefore 
proposed that an oligomer containing DR1 from the 5' end of the pre-
genomic RNA was translocated to the DR2 site of the minus strand DNA to 
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prime synthesis of plus strand DNA (See Fig.1.5). After transfer of the 
primer to DR2, DNA plus strand synthesis can only proceed up to the 3 
end of the DNA minus strand. 	For further elongation, a template 
switch has to take place which could use the short terminal redundancy 
of the minus strand. This would allow an intramolecular template switch 
to take place resulting in the circular DNA conformation of the 
HBV genome. 	The DNA plus strand could then be elongated. 	The 
initiation of plus strand synthesis may cause a structural change in 
the core particles that allows it to be packaged regardless of whether 
the plus strand is completed. 	Following packaging, the nucleocapsid 
is coated with surface Ag from the host cell. 
1.6.4 	Assembly and Export of the Virus 
At some point before the completion of plus strand synthesis the 
nucleocapsid interacts with the surface antigen and is exported from 
the infected cell. 	The pre-core region of the core protein may be 
important for this. 	Experiments by Ou et al., (1986) have shown that 
the pre-core region apparently facilitates the transportation of the 
core antigen from the cytoplasm into the endoplasmic reticulum where 
interaction between the surface coat and its nucleocapsid occurs. 
The pre Si region has also been implicated in viral morphogenesis. 
Pre Si proteins, unlike the pre S2 and. surface proteins, are not 
secreted into the culture medium despite the presence of secretory 
information (Persing et al., 1986). 	Furthermore, when surface and pre 
Si proteins are synthesised together, secretion of the surface proteins 
is strongly and specifically inhibited. 	Persing et al., (1987) found 
that the pre Si protein but not the other surface proteins have been 
modified at the N-terminus by the addition of myristic acids. 	They 
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postulated that myristillation may anchor the pre Si protein in the 
endoplasmic reticulum thus preventing it from being spontaneously 
secreted and thereby allowing it to interact with the nucleocapsid. 
However, by what mechanism the pre Si protein inhibits HBsAg secretion 
remains unknown. 	As yet the exact mechanism of viral assembly is not 
understood but perhaps experiments in which both the pre-core, core, 
pre Si, pre S2 and surface proteins are expressed in hepatoma cell 
lines will allow some insight into the interactions between the viral 
components. 	Using this system it will also be possible to use site- 
directed mutagenesis and deletion studies to gain a better 
understanding of viral morphogenesis. 
1.6.5 	Integration 
A number of hepatoma cell lines and liver biopsies from chronic 
carrier patients have been analysed and found to contain integrated 
HBV DNA in their genome (Chakrabarty et al., 1980; Edman et al., 
1980). However, as neither chimpanzees infected with HBV nor ducks 
infected with DHBV have been shown to contain integrated viral 
sequences as an immediate consequence of infection, it would appear 
that an integration step is not an essential requirement for the 
propagation of hepadna viruses. 	It is more likely that integration of 
DNA is a consequence of high levels of viral sequences present in the 
cell for long periods of time. 
1.7 HBV and Hepatocellular Carcinoma 
HBV carriers have been shown to be at a much greater risk of 
developing primary hepatocellular carcinoma (HCC) compared to non-
carriers. In contrast to the very good epidemiological data linking 
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I-IBV with liver cancer, molecular biological investigations have not 
revealed any particular function or effect of HBV infection which could 
prove that HBV causes liver cancer. 
Evidence for the integration of HBV DNA into the genomic DNA in 
the livers of carrier patients and HCC patients originally led to the 
speculation that integration of HBV sequences may be the catalyst for 
oncogenesis. 	However, from extensive analysis of cell lines 
particularly from the human hepatoma cell line PLC/PRF/5 (Ziemer et 
al., 1985) of the integrated sequences it was concluded that there was 
no specificity in either HBV DNA or host DNA at or near the integration 
site. 
It was therefore proposed that HBV might encode a protein with 
oncogenic potential analogous to retroviruses. 	These viruses are 
known to assimilate pieces of cellular genes, oncogenes, into their 
genonies, which have transforming functions. If this were the case with 
HBV, it would mean that one particular gene would have to be present 
in all the hepatomas investigated. 	The only HBV gene that fulfils 
these criteria is the gene for HBsAg. 	However, it seems extremely 
unlikely that HBsAg has oncogenic activity as it is expressed for many 
years by chronic carriers without producing tumours. Moriarty et al., 
(1985) proposed that the X gene may be an oncogene as they found that 
patients with HCC had a high titre of antibody to its gene product 
although recent evidence reported by Weber et al., (1987) queries these 
findings. 	Using computer-assisted DNA and protein sequence analyses, 
Miller and Robinson (1986), found that both the X gene and the enhancer 
region have the same codon usage as genes from eukaryotic cells, in 
contrast with the other hepadna viral genes which clearly share the 
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same codon usage for virus genes (Siddiqui et al., 1987) thus 
indicating that perhaps both the enhancer and the X gene, like the 
retroviral oncogenes, were acquired recently from the host cell. It is 
still unlikely that the HBV has an oncogenic function as viruses that 
carry oncogenes result in rapid tumour formation in contrast to I-ICC 
which develops over a long period, often taking many years. 
Another possibility is that one of the FIBV genes may have a 
transactivating function capable of activating cellular genes which may 
cause tumour formation over a long period in a similar fashion to the 
pX gene of HIV I, II and III. P. Hofschneider (personal communication) 
has performed experiments indicating that the X gene of I-IBV has trans.. 
activating functions. 	Interestingly, like pX, this gene is also 
located at the 3' end of the genome (Miller and Robinson, 1986). 
Alternatively, perhaps the presence of HBV DNA within the genome may 
cause enhanced mutability in the region of the inserted DNA, or perhaps 
the viral promoters and/or the enhancer may cause regulatory genes to 
be switched on. At this stage one can only speculate how HBV may induce 
tumour formation. It may be possible that the progression from chronic 
liver disease to liver cancer is due to the continual presence of 
foreign material in the body which eventually wears down the immune 
system such that the immune surveillance breaks down, no longer 
destroying the abnormal cells and thus allows them to grow and multiply. 
1.8 Approach to the Eradication of Hepatitis B 
HBV is still a major problem in the world. With the existence of 
over 200 million carriers world-wide. 	The effect of this virus and 
the suffering it causes, produces a very large burden both economically 
and medically on the social services. 	Several approaches have been 
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suggested to eradicate HBV and these fall roughly into two directions. 
Firstly, a successful vaccination programme to protect those people 
most at risk would interrupt the transmission cycle. Secondly, the 
development of suitable drugs to terminate the carrier state would 
destroy the large infectious reservoir for HBV. 	Research into both 
these areas has reached an advanced stage and is discussed below. 
1.8.1 	Vaccination 	In the developed world a limited programme of 
vaccination has been initiated for people in high risk groups. 	The 
vaccine presently used is a purified preparation of the 22nm particles 
isolated from the serum of infected individuals (Zuckerman, 1980). 
These particles are treated with heat and formalin and have been shown 
to be effective and safe. 	The vaccine has disadvantages as it relies 
upon a supply of infected human serum and requires very elaborate 
purification and safety checks. 	This makes it very costly to produce 
and is too expensive for Third World countries, which have the highest 
incidence of HBV, other types of vaccine have been investigated. 
Valenzuela et al., (1982) were the first of many groups to 
synthesise FIB5Ag gene in yeast. 	The HB5Ag purified from these yeast 
cells has been shown to be an effective vaccine (Murray et al., 1984) 
and is now commercially available. 
The use of live vaccines has also been explored. 	Vaccinia virus 
recombinants, which are able to produce FIBsAg, have been used in trials 
with chimpanzees and shown to almost completely protect chimpanzees 
from HBV (Smith et al., 1983). 	These trials indicate the feasibility 
of using a recombinant virus as a vaccine. 	The advantage of vaccinia 
virus recombinant vaccines include low cost and ease of administration 
all of which is critically important for the Third World. 	However, 
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vaccinia is known to have some adverse effects in some populations and 
its adoption is at present fraught with both technical and political 
problems 
Experiments performed by Milich et al (1985) and Neurath et al., 
(1985) have shown that epitopes residing on the pre S region elicit a 
very strong immune response. 	It was also found that if the pre S 
region is presented with HBsAg to animals that had previously not 
responded to HBsAg, antibodies were produced to both the major surface 
and pre S proteins. 	Therefore, the inclusion of the pre S region 
allowed the animal to be converted from a non-responder to a responder. 
As these regions are also known to be involved in hepatocyte receptor 
recognition, it has been proposed that the pre S region should be 
included in present HBV vaccines. 	However, recent reports suggest 
that patients in control studies make antibodies against their own 
livers (G. Better, personal communication). 
The low titre of HBV virus in carriers producing antibodies 
against HBeAg suggests that HBeAg may also be usefully incorporated 
into a vaccine. 	Murray et al., (1984) inoculated preparations of 
HBcAg and HBeAg into two chimpanzees. 	These were subsequently 
challenged with HBV. 	One was found to be partially protected and the 
other, which had low titres of HBeAg antibodies, was completely 
protected. Similar results were seen by Stephen et al., (1984). 	These 
results imply that antibodies to HBeAg and HBcAg protect the animals 
partly or completely from HBV infection. 	These antigens are thought 
to stimulate a cell-mediated response and may play a role in future 
vaccination programmes. 
Preliminary data from Zuckerman (1986) shows that vaccination has 
been successful in the interruption of HBV infection in some areas. 
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It will be interesting, when a more widespread vaccination campaign is 
undertaken to determine whether the levels of primary hepatocellular 
carcinoma fall along with reduction in the incidence of HBV infection. 
1.8.2 	Chemotherapy 
Several types of chemotherapy have been used to treat patients 
with chronic hepatitis; most of these use drugs which inhibit the 
endogenous DNA polymerase activity, which may act in inhibiting viral 
replication. 	Hess et al., (1981) showed that the arabinoside AraA, 
(vidarabine) a nucleoside analogue, inhibited DNA polymerase. 	In 
clinical trials of the drug, 40% of the patients treated serconverted 
from HBeAg positive to anti-HBe positive (Bassendine et al., 1981). 
However, in other studies the results were not as convincing though 
combined treatment with AraA and Leucocyte A Interferon did convert 
some chronic persistent patients from HBV DNA positive to HBV DNA 
negative (Scullard et al., 1981; Smith et al., 1983). 
Acyclovir which has been so successful with the herpes virus was 
also tried but although it initially decreased the titres of hepatitis 
DNA in the serum, as soon as treatment was stopped levels in the serum 
rose again (Weller et al., 1982). 
The use of a Interferon has shown some promising results in 
limited studies reported with 50% of treated patients showing loss of 
HBV DNA and HBeAg for prolonged follow-up periods (Thomas and Scully, 
1985). 
So far the most successful treatment reported is treatment with 
the steroid Prednisolon and then subsequent treatment with AraA or 
Interferon (Omata et al., 1985). 	This combined treatment appears to 
give a higher success rate for clearing the virus from the chronic 
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carrier's system. 	All of these treatments have a higher success rate 
if the patient is treated within two years of the onset of infection; 
This may reflect the ability to eliminate the virus from the patient 
before it can integrate into the host genome. 
As yet no universal treatment is employed in the treatment of 
chronic carriers. 	Although most of the drugs discussed are targeted 
against the endogenous polymerase, not enough is known about this 
enzyme as it has not yet proved possible to purify and completely 
characterise this endogenous polymerase. 	Perhaps when this polymerase 
has been more extensively analysed, it may be possible to develop 
better and more specific drugs, which could interfere with the enzyme's 
action. 
1.9 DNA Polymerase of HBV 
In 1972, Paul Kaplan and co-workers found that a DNA polymerase 
activity was present in the serum of hepatitis B carriers (Kaplan et 
al., 1973). 	Further investigation established that this polymerase 
activity was associated with the virions. Fractionation of the serum 
showed that this enzyme activity was found in the density range 
characteristic of Dane particles on a sucrose gradient, and after 
removal of the surface coat (with NP40), it was found within the 
density range of the core particles. 	Electron microscopy of these 
fractions revealed that the enzyme activity was co-sedimenting with 
the core particles. 	The DNA polymerase activity could be precipitated 
from the infected serum using antibodies to the surface antigen and 
after NP40 treatment using antibodies to the core antigen (Robinson and 
Greenman 1974). 
These findings were consistent with the DNA polymerase activity 
being a component of the nucleocapsid. 	The DNA polymerase reaction 
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was found to be dependent on the presence of magnesium and the four 
deoxynucleoside triphosphates. 	The inhibition of the enzyme activity 
by actinomycin D indicated that the template was DNA and not RNA. 
Several pieces of evidence pointed to not only the DNA polymerase 
activity being an internal component of the nucleocapsid but the 
template and the reaction product being so as well. 	Treatment with 
DNAse and RNAse had no effect on the template or the product. 
However, when these were extracted from the nucleocapsid and then 
treated with DNAse and RNAse, they were found to be completely degraded 
by DNAse but insensitive to RNAse. 	The addition of a wide variety of 
polynucleotides which are accepted as primer/templates by other DNA 
polymerases were not utilised by the endogenous polymerase activity, 
suggesting that either the enzyme could not utilise the templates or 
that the enzyme had no access to them. 
So what is the nature of the template and primer, and what is the 
structure of the product? 
To identify the primer for DNA synthesis Robinson and Lutwick 
(1976) examined the sedimentation of the virion DNA in alkali sucrose 
gradients after being labelled for very short reaction times. 	They 
found the radioactive DNA product was attached to a molecule with a 
sedimentation coefficient close to that of the double-stranded region 
of the circular molecule before the reaction. 	This suggested that the 
open strand of the circular DNA molecule serves as the primer for the 
DNA polymerase reaction rather than a smaller DNA or RNA primer. 
The amount of DNA synthesised during the endogenous DNA polymerase 
reaction has been determined using COT analysis, electron microscopy 
and variation in electrophoretic mobility (Lutwick and Robinson 1977; 
Hruska et al., 1977). 	This established that the DNA synthesised 
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corresponded to approximately a quarter of the viral genome. 	Summers 
et al., (1978) demonstrated that the reaction product corresponded to 
the filling in of the single-stranded gap. 	Using the reverse 
transcriptase from avian myoblastosis virus (AMy), and DNA extracted 
from Dane particles as a template in an in vitro polymerase reaction, 
it was shown that the nucleotides were incorporated in the same 
restriction fragments as in the in vivo polymerase reaction by the HBV 
associated enzyme (Summers et al., 1978). These fragments corresponded 
to the region of the single-stranded gap. 	In neither reaction did the 
filling in of the single-stranded gap produce a closed circular 
molecule as detected by Si sensitive sites. 
In conclusion, the hepatitis B particles have an endogenous DNA 
polymerase which uses the minus strand as the template to fill in the 
single-stranded gap. 	The biological advantage of a virus having a 
single-stranded gap is not clear. 
1.9.1 The Origin of the Endogenous DNA Polymerase 
The origin of the HBV associated DNA polyrnerase activity has not 
been established. The small size of the HBV genome originally led to 
the belief that the virus would not have the coding capacity to encode 
its own polymerase but instead would utilise the available eukaryotic 
polymerase. 	However, sequence analysis revealed the presence of a 
long open reading frame (L.ORF) coding for a protein with a predicted 
mol. wt. of 93kd, the expected size of a DNA polymerase (Pasek et a]., 
1979). 	The assignment of this L.ORF as the gene encoding the 
endogenous DNA polymerase and the characterisation of this polymerase 
has been difficult for two reasons. 	Firstly, attempts to purify the 
polymerase have been unsuccessful and so biochemical studies have been 
34 
restricted to purified virion particles, and secondly, since no cell 
culture system was available until very recently for HBV (Surrea et 
al., 1986), the source of the virus particles was limited to infected 
humans and chimpanzees. 	Despite these difficulties, however, the 
evidence for the DNA polymerase being encoded by the long ORF is now 
convincing. 
(a) The Long ORF 
The protein encoded by this open reading frame is within the size 
range expected for a DNA polymerase. 	The long ORE and the potential 
products encoded by it are highly conserved across the hepadna virus 
family. 	The size and the conserved nature of this gene leaves little 
doubt that it does have a coding function. 
Using computer-assisted protein sequence analysis, it was found 
that the predicted amino acid sequence of the long ORE contains regions 
of homology with retroviral reverse transcriptase but not with 
bacterial or eukaryotic polymerases (See Fig.1.6) thereby implying that 
this homology is indicative of a protein with reverse transcriptase 
activity (Mandart et al., 1984; TO et a]., 1983, 1985). 
Examples 	 Reverse Transcriptase Motif 
RSV 	 Y.MDDLLL 
MMLV 	 VVDDLLL 
HTLVI 	 YMDDLLL 
HTLVIII 	 YMDDLYV 
ATLV 	 YMDDILL 
CAM 	 YVDDILV 
HBV 	 YMDDVVL 
(From Feutterer and Hohn et al., 1987) 
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As hepadna viruses replicate via an RNA intermediate this requires 
an enzyme that has RNA-dependent DNA polymerase activity, an activity 
not normally found in eukaryotic cells. 	It was thus proposed that the 
L.ORF does encode a DNA polymerase and that replication of HBV uses a 
reverse transcriptase activity of this protein. 	It should be noted 
that the putative polymerase gene does not appear to have any 
homologous sequences associated with the ribonuclease -I, endonuclease 
and protease activities of the polymerase genes of retroviruses 
(Johnson et al., 1986; Feutterer and Hohn, 1987). 
(b) Biochemical Analysis:- 
The endogenous polymerase has been extensively characterised in 
vitro by several groups using purified virions, and its properties have 
been compared with those exhibited by host polymerases and the reverse 
transcriptases of several retroviruses. 	These results are summarised 
in Table 1. 
Higher eukaryotic cells contain three distinct polymerases, a, 8 
and y • 	These enzyme activities can be separated easily on the basis 
of their chromatographic properties, molecular weights, sensitivity to 
N ethylmaleimide (NEM) salts and their ability to copy various 
templates:- 
a - is ubiquitous in growing cells and is believed to be the principal 
replicating enzyme. 	it is a large enzyme with an approximate 
molecular weight of lSOkd and is associated with smaller proteins 
forming a hetero oligomer. 	The enzyme is specific for polydeoxy- 
nucleotide templates and shows little activity with synthetic ribo- 
polymers such as poly (A) or RNA. 	It has optimal activity with gapped 
DNA and will use either deoxy or ribo primers. 	a has an absolute 
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Table 1. 
Physical and Chemical Pro 
Transcri ptase 
FN.—T. = not tested) 
ies of FIBV. z Polymerases and Reverse 
= inhibition) 
= no inhibition) 
Physical and 	 HBV 	 y 	 RT 
Chemical Props. 
MuLv-84 
Mol.Wt. (kd) 	 220 	43 	119 	AMV C 65 
(Native) 	 AMV B 95 
Aphidocolin 	 + 	- 	- 	 - 
PEA + - - - + 
PAA - - - - + 
ddTTP + - + + + 
Ara CTP + + - - + 
Ara A + N.T. N.T. N.T. N.T. 
Act.D + + + + + 
N.E.M. - + - + + 
Cationic Reqs., Mg2 
with 
activated DNA Mg 2 Mg2 Mg2 Mn2 
synth. polymers Mn2 Mn2 Mn2 Mg2 
High Ionic 




deoxy(T)/deoxy(P) (daT inhib.) Yes Yes Yes (dA inhib.) 
deoxy(T)/ribo(P) No Yes No No Yes 
ribo(T)/deoxy(P) No No Yes Yes Yes 
poly C(T)IdG12 (P) No No No No Yes 
2'-O-methyl 	citidy- 
late(T)/oligo dG 12 (P) N.T. No No No Yes 
'Natural: 
activated d.s. 
gapped DNA No Yes Yes Yes Yes 
Native DNA No No No No Yes - poor 
Table 1 cont. 
HBV 	 RT 
RNA primed DNA 	 No 	Yes 	No 	No 	Yes 
Inhibition by 
Abs Against: 
a N.T. Yes No No No 
a N.T. No Yes No N.T. 
C) y N.T. No No Yes N.T. 
d) rev.trans. N.T. No No No Yes 
Orthophenanthraline + + + + + 
Eth. 	Br. + + + + + 
Misincorporation High 1:10-4 1:104 1:10 4 High 
pH Optimum 7.2-8.0 7.2 8.5-9.0 8.0 8.3 
Associated DNase 
enzyme activities: 
3'---5' 	exo. N.T. No No No No 
5'---3' 	exo. N.T. No No No No 
RNase H N.T. No No No Yes 
endonuclease N.T. No No No Yes 
requirement for Mg2 or Mn2 and is inhibited by high salt 
concentrations. 	The requirement for sulphydryl groups for activity 
makes it very sensitive to NEM, a sulphydryl alkylating agent. It is 
resistant to ddTTP but is very sensitive to Aphidicolin, a fungal 
antibiotic, and Ara CTP, an arabinosyl nucleoside (Kornberg, 1980). 
- the level of 	activity is a tenth of a activity and is associated 
with repair and recombination functions. It is a small protein of 43kd 
and is located in the nucleus. 	0 copies gapped duplex DNA efficiently 
and, to a lesser extent, can copy poly(A) template primed with 
oligo(dT). 	However, it does not use this polymer in the presence of 
Mg2+ ions or in the presence of high concentrations of phosphate 
buffer. 	has no requirement for suiphydryl groups and is therefore 
insensitive to NEM. 	Unlike a it is not inhibited by Ara CTP or 
Aphidicolin (Kornberg, 1980). 
- - is found in the nucleus and in the mitochondria and is postulated 
to be responsible for the replication of mitochondrial DNA. 	It is a 
large enzyme with a molecular weight of 119kd. 	The enzyme is 
distinguished by its ability to copy ribohomopolymers at higher rates 
than gapped duplex DNA. 	However, both a and are inactive on any 
natural RNA used as a template whether primed or unprimed. They also 
cannot use poly 2'-O-methylcytidylate, a very specific template for a 
reverse transcriptase (Gerrard et al., 1974). 	Neither of these 
polymerase activities is inhibited by antibodies to reverse 
transcriptase. Therefore these enzymes are not reverse transcriptases 
but the synthetic templates in the presence of Mn2 1  can form a 
structure which both of these enzymes can utilise. 	requires 
sulphydryl groups for maximum activity and is inhibited by NEM. 	It 
is, like , insensitive to Ara CTP and Aphidicolin (Kornberg, 1980). 
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Reverse Transcri ptase 
An RNA-dependent DNA polymerase can be found in the virions of 
retroviruses and infected cells (Temin and Baltimore, 1972). The 
reverse transcriptase of murine retroviruses is a monomeric protein of 
approximately 80kd (Roth et a]., 1985), while AMV reverse transcriptase 
is a heterodimer of two subunits a and a . 	The a sub-unit is the 
cleavage produce of o , releasing a polypeptide of 32kd. The alpha 
subunit exhibits the DNA polymerase activity while the p32 protein 
contains a specific nuclease. The a subunit contains both of these 
activities and is thought to help stabilise the enzyme template 
reactions (Tanese et al., 1986). 
There are three enzymatic activities associated with reverse 
transcri ptase: 
(1) 	A ribonuclease H (RNAse H) activity which degrades the RNA strand 
of a DNA:RNA hybrid but does not degrade either single-stranded 
or double-stranded RNA (Johnson et al., 1986). 
A DNA-polymerase capable of copying RNA on a DNA template. 
A DNA endonuclease/integrase function. 
The DNA polymerase and RNA5e H activity resides on the same poly-
peptide but have different functional sites. 	Reverse transcriptase 
is active on a wide variety of RNA and DNA templates. 	Gerrard et al., 
(1974) showed that the enzyme can utilise poly 2 1 -O-methylcytidylate 
oligo (dG) very efficiently. 	Reverse transcriptase is sensitive to 
Ara, CTP, ddTTP and NEM. The RNA:DNA synthesis is resistant to 
actinomycin D, but the DNA:DNA synthesis is sensitive to it. 
Hepatitis B polymerase 
The endogenous polymerase of HBV was characterised in a similar 
fashion to the other DNA polymerases described. 	The endogenous 
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hepatitis B polymerase is dependent on the presence of magnesium, 
though the optimal concentration was slightly higher than for other 
polymerases [20-200m mol/l] (Hess et al., 1981). 	The enzyme had a 
strict preference for magnesium and had only very little activity when 
magnesium was replaced by other divalent cations i.e. manganese and 
zinc (Hess et al., 1981). It was active at remarkably high 
concentrations of salt (0.4M - 0.8M KCL) and this allowed the 
development of an assay that could measure HBV associated DNA 
polymerase activity in a mixture of bacterial DNA poll and a 
polymerases (Hirschman and Garfinkel, 1977b). FIBV DNA polymerase was 
found to be highly sensitive to organic solvents (Nath et a]., 1982) 
and to be insensitive to NEM. 	The insensitivity of this polymerase to 
the zinc-chelating agent 1,10 phenathroline suggests that it is not a 
zinc netaloenzyme. (Goto et al., 1984). 	In the search for anti- 
viral drugs against Hepatitis B, various compounds have been tested to 
discover whether or not they inhibit the endogenous DNA polymerase of 
HBV. 	The arabinoside analogues Ara ATP and Ara CTP wereshown to 
inhibit this enzyme activity (Hess et al., 1981. Nordenfelt et a]., 
(1979) demonstrated that although HBV-DNA polymerase is resistant to 
the anti-viral drug phosphonoacetate (PAA), which is a pyrophosphate 
analogue, it is very sensitive to phosphonoforniate(PFA). 
Intercheláting agents, ethidium bromide and actinomycin D were also 
inhibitory as was ddTTP (Hirschman and Garfinkel, 1977). 
The above results show that the HBV-DNA polymerase has a different 
biochemical profile from a and 	polymerases. 	It is similar in some 
respects to a , the repair enzyme of the host, as it operates under high 
salt concentrations, is insensitive to NEM, and is resistant to PAA. 
Interestingly, it is also very similar to the reverse transcriptase 
enzyme. 
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1.10 The Objective of the Present Study 
In conclusion, the studies performed on the HBV-associated 
polymerase cannot prove or disprove that this polymerase is an 
encapsulated eukaryotic polymerase. 	The definitive experiment would 
be to express this long ORF in either bacteria or eukaryotic cells and 
show that the protein it encodes has a DNA polymerase activity with the 
same properties as the endogenous polymerase. 
The aim of the work presented in this thesis was to determine 
whether or not the long open reading frame, present in F-IBV, is 
expressed during the course of viral infection and if so what is the 
function of the gene product. 
40 
CHAPTER 2 
MATERIALS and METHODS 
Page 
Chapter 2 	 MATERIALS AND METHODS 
2.1 Suppliers of laboratory reagents 48 
2.2 Solutions 49 
2.3 Microbiological 	strains and media 52 
2.4 Bacterial 	strains 53 
2.5 Plasmid and bacteriophage vectors 54 
2.6 Other plasmids used 54 
2.7 General 	nucleic acid methods 56 
2.7.1 	Deproteinisation of nucleic acids 56 
2.7.2 	Precipitation of nucleic acids with ethanol 56 
2.7.3 	Quantification of nucleic acids 56 
2.7.4 	Gel 	photography 57 
2.7.5 	Autoradiography 57 
2.7.6 	Measurement of radioactivity incorporated into 57 
nucleic acids 
.2.8 Nucleic acid methods 58 
2.8.1 	Small-scale preparation of plasmid DNA 58 
2.8.2 	Large-scale preparation of plasmid DNA 58 
2.8.3 	Agarose gel 	electrophoresis of DNA 59 
2.8.4 	Digestion of DNA with restriction endonucleases 60 
2.8.5 	Modification of the 3' 	and 5' 	termini 	of DNA 
2.8.6 	Ligation of DNA 61 
2.8.7 	Extraction of DNA from low melting point agarose 61 
2.8.8 	Transformation of E.coli with DNA 61 
2.8.9 	Nick translation 62 
2.8.10 Random priming 62 
45 
Page 
2.8.11 Labelling DNA termini 63 
2.8.12 Colony blotting 63 
2.8.13 Southern blotting 63 
2.8.14 Hybridisation of membrane filters with 64 
radioactive probes 
2.8.15 RNA preparation 64 
2.8.16 Electrophoresis of RNA 65 
2.8.17 Northern blotting 65 
2.9 	DNA sequencing by the dideoxynucleotide chain termination 66 
method 
2.9.1 Preparation of double-stranded replicative form(RF) 66 
DNA of the bacteri ophage M13 
2.9.2 Cloning into M13 mplO, 11, 18 and 19 66 
2.9.3 Plaque hybridisation 66 
2.9.4 Preparation of template DNA 67 
2.9.5 Sequencing reactions 68 
2.9.6 Primed synthesis 68 
2.9.7 Separation of DNA fragments in acrylamide gels 69 
2.9.8 Buffer gradient gels 70 
2.10 	Protein and antibody techniques 71 
2.10.1 Lowry protein assay 71 
2.10.2 Electrophoresis of proteins in polyacrylamide gels 71 
2.10.3 Staining of protein gels 72 
2.10.4 Protein molecular weight markers 73 
2.10.5 Small-scale preparation of protein from E.coli 73 




2.10.7 Analysis of plasmid gene products expressed by 	74 
E.coli minicells 
2.10.8 Labelling protein products expressed by minicells 	75 
2.10.9 Immunisation of rabbits 	 75 
2.10.10 Purification of antiserum 	 76 
2.10.11 Western blotting 	 77 




Reverse transcriptase assays 	 78 
2.11.1 Preparation of crude lysates of E.coli for 	 78 
reverse transcriptase assays 
2.11.2 Assay for reverse transcriptase activity 	 79 
2.11.3 Inhibition of reverse transcriptase activity by 	79 
phosphonoformate (PEA) 
47 
2.1 Suppliers of Laboratory Reagents:- 
Restriction endonucleases were purchased from Amersham International 
P.O. Box 16, Amersham, Buckinghamshire, NP7 9LL. 
Boehringer Mannheim, Boehringer Mannheim House, Lewes, East Sussex, 
BN7 1LG. 
New England Biolabs or Pharmacia, Pharmacia House, 351 Midsummer 
Boulevard, Central Milton Keynes, MK9 3YY. 
E.coli DNA polymerase I (Kienow fragment and holoenzyme) was purchased 
from Boehri nyer Mannheim. 
Deoxynucleoside triphosphates were purchased from Bethesda Research 
Laboratories. 
Dideoxynucleoside triphosphates were purchased from P-L Biochemicals. 
Radiochemicals were purchased from Amersham International. 
Ultra-pure agarose and low melting point agarose were purchased from 
Sigma. 
Standard Laboratory reagents were purchased from BDH, Fisons or Sigma. 
2.2 Solutions:- 
IE 	 Iris-I-IC] (10mM, pH 7.5), EDTA (1mM) 
Sequencing TE 	 Tris-I-IC1 (10mM, pH 8.0), EDTA (0.1mM) 
10 x TBE 	 Iris-base (0.89M), boric acid (0.89M), 
EDTA (10mM) 
DNA gel sample buffer 	EDTA (10mM), ficoil (1%, w/v), bromphenol 
blue (0.025%, w/v), xylene cyanol FF (0.05%, w/v) 
4 x Nick Translation buffer Tris-HC1 (210mM, pH 7.5), MgC1 2 (21mM), 
BSA (20.ig/ml), -mercaptoethanoi (140mM), 
dGTP, dAIP, dTIP (0.08mM each) 
OLB 	 Solution 0: MgC1 2 (0.125M), Tris-HC1 
(1.25M, pH 8.0) 
Solution A: 0.95ml of solution 0 was added 
to the following mixture: -mercaptoethano1 
(18l, 14M), dATP (251,20mM), dGTP ( 250, 
20mM), and dTTP (25iii, 20mM) 
Solution B: Hepes (2M, pH 6.6) 
Solution C: Hexadeoxyribonucleotides 
(Pharmacia) resuspended in TE to give a 
final concentration of 90 OD units/ml 
Solution OLB was made by mixing solutions 
A, B and C in the ratio 2:5:3 and was stored 
at -20°C 
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T4 DNA Ligase Buffer 	Tris-KC1 (50mM, pH 7.8), Mg C1 2 (10mM), 
OTT (20mM), ATP (10mM) 
20 x SSC 	 NaCl (3M), trisodium citrate (300mM), 
adjusted to pH 7.0 with NaOH 
50 x Denhardt's Reagent 	Ficoll (1%, w/v), polyvinyl pyrrolidine 
(1%, w/v), BSA (1%, w/v) 
Denatured salmon sperm DNA Was made up as 5mg/ml stock and sonicated 
(50 seconds, Soniprobe, Dawe Instruments) 
X-gal (BCIG) 	 5-bromo-4-chloro-3-i ndoyl--gaiactoside 
(20mg/mi in dimethyl formamide) 
IPTG 	 Isopropyl--D thiogalactoside (20mg/mi) 
10 x MOPS 	 MOPS (0.2M), Na acetate (50mM), EDTA (10mM), 
adjusted to pH 7.0 with 5M NaOH. 
Formamide sample buffer 	Formamide (50%, v/v), formaldehyde (7.5%, 
v/v), MOPS (x 1) 
RNA loading buffer 	 Glycerol (50%,v/v), EDTA (1mM), bromo- 
phenol blue (0.4%, w/v), xylene cyanol FE 
(0.4%, w/v). 
40% Acrylamide stock 	Acrylamide (38%, w/v), N-N-methylene bisacryla- 
mide (2%, w/v). Filtered and stored at 4 0C. 
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TM 	 Tris-HC1 (100mM, pH 8.0), Mg C1 2 (100mM) 
Formamide loading buffer 	Xylene cyanol (0.3%, w/v), bromophenol 
blue (0.3%, w/v), EDTA (10mM), in 100% 
formami de 
TEMED 	 NNN'N'-tetra-methyl-1, 2 diamino-ethane 
(BD H) 
AMPS 	 Ammonium persuiphate (10%, w/v) 
30% Acrylamide stock 	Acrylamide (30%, w/v), N-N'-methylene 
bis-acrylamide (0.2%, w/v), filtered and 
stored at 4 0 C 
1 x Protein gel buffer 	Iris-base (50mM, pH 6.8), glycine (384mM), 
SDS (1%, w/v) 
LTB 	 Tris-HC1 (20mM, pH 7.9), MgC1 2 (20mM), 
EDTA (1mM) 
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2.3 Microbiological Strains and Media. 
Microbiological Strains. 
All bacterial strains, plasmid vectors and bacteriophage vectors 
used in this study are described in Section 2.3 to 2.5. Bacterial stocks 
were preserved by drying, using the Stamp method (Stamp et al., 1947) and 
were also maintained on the appropriate plates. 	M13 bacteriophage were 
stored as DNA in sequencing TE at -20 0C or in LTB at 4 0C. 
Media 
Media were sterilised by autoclaving. 	Unless otherwise stated, 
all quantities below refer to 1 litre of solution. 	Where 
appropriate, antibiotics were added to plates and media: ampicillin 
(100tg/m1), tetracycline (50 jig/mi), or kanamycin (25jig/mi). 
Luria broth (LB) 	 Difco Bacto Tryptone (10 g), Difco Bacto 
yeast extract (59), NaCl (5g); pH 7.2 
Luria agar (L-agar): 	Agar (15g, Difco) added to LB (1L) 
BBL top agar 	 Trypticase (lOg, Baltimore Biological 
Laboratories), NaCl (Sg) and agar (6.5g, Difco) 
Spizizen minimal salts 	(NH4) 2 SO4 (lOg), K2HPO4 (20g), KH2PO4 
(30g),tri-sodium citrate (5g), MgSO4(19) 
Minimal agar 	 Spizizen minimal salts (80m1), glucose (4ml, 
20%, w/v), Vitamin B 1 (0.2ml,lmg/ml), Difco Bacto 
agar (6g); made up to 400 mis with water 
52 
2.4 Bacterial strains 
Strain 	 Genotype 	 Reference 
HB101 	 F 	hsdS20 	 Boyer and 
recA13 ara14 2A2 lacYl, 	Roulland- 
gjK2 LpsL20 (SMr) 	j5 	 Dussoix, 1969 
intl-i LupE44 A 
NM522 	 hsd(MSR) 41ac A2ro 	 Gough, 1983 
yE t h i F' 
iaciq lacZM15 
NFl 	 K12Hi42lacZ am 	 Stanley and Luzio, 
xNani7 Nam53 c1857A1-l1 	 1984 
WL542 	 F 	DT65minA 	Ex- 	 Manson et al., 
pdxc minB his 5 r T3N 	 1986 
x,yl ilv SyCAN çBN it 
SG935 	 Flac(am) j(am) 	am) 	 S. Goff(unpublished) 
LuRC (ts) LpsL i(!) 	R(am) 
tsx::TN10 lon100 
53 
2.5 Plasmid and Bacteriophage Vectors. 
Vector 	 Description 
	
Source/Reference 
pEX1/2/3 	Aff I pr(_ga1acto s idas e_ 	 Stanley and 
fusion protein expression vector) 	Luzio, 1984. 
ptac322 	 AIflP r (Expression vector 	 Stahl 
using tac promoter) 	 (unpublished) 
M13mplO, 11, 	E.coli bacteriophage 	 Norrander 
18 and 19 	M13-based vectors; 	 et a]., (1983) 
lacZ gene 
2.6 Other Plasmids Used. 
P1 asmi d 	 Description 	 Source/Reference 
pRl-11 	 Ampr (contains HBV core 	 Stahl, et al., 
gene under the control of 	 1982 
the Lac promoter) 
pI-IBVCB 	 Tetr (contains the HBV 	 Gough and Murray, 
genome inserted into Pstl 	 1982. 
site of pBR322). 
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pHPL-1 	 Ampr (contains the sequences 	McGarvie 
encoding the first 28 amino acids 	(unpublished) 
of HBV core antigen fused to the 
sequences encoding residues, 40-210 
of the HBV polyrnerase gene. 
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2.7 General Nucleic Acid Methods. 
2.7.1 Deproteinisation of nucleic acids. 
DNA or RNA solutions were deproteinised by extraction with an 
equal volume of phenol. 	This was accomplished by vortexiny until a 
white homogeneous emulsion was formed. 	The phases were then separated 
by centrifugation (17,500 g, 2 mm.) and the upper aqueous layer 
recovered. 	The aqueous layer was extracted three times with ether to 
remove residual phenol and the nucleic acid was then precipitated with 
ethanol (see below). 
2.7.2 Precipitation of Nucleic Acids with Ethanol 
DNA was precipitated from aqueous solutions by the addition of 
sodium acetate (0.1 vol., 3M, pH 5.8) and ethanol (2.5 vol.). 	The 
solution was cooled (-70 0C, 15 mm.) and the DNA pelleted by 
centrifugation (17,500 g, 15 mm.). 	The supernate was removed and the 
pellet dried in a vacuum desiccator before being redissOlved in TE. 
2.7.3 Quantification of Nucleic Acids 
The optical density at 260nm was used to quantify nucleic acids. 
An 0D260 of 1.0 is equivalent to 50ig/m1 for DNA or 40ig/m1 for RNA. 
2.7.4 Gel photography 
Nucleic acid was visualised in gels stained with ethidium bromide 
using an ultraviolet transilluminator (254nm). 	Photographs were taken 
through a red (Al) filter on Ilford HP5 film (f 4.5, 20s). 	Films were 
developed in Ilford microphen (5 mm.), stopped in acetic acid (3%, v/v, 
30s), and fixed in Ilford Hypam (5 mm.) at room temperature. Films were 
washed well in water, dried, and the relative mobilities of the bands 
measured directly from the negative (distance migrated is inversely 
proportional to log10 M wt.). 
2.7.5 Autoradiography 
Autoradiography was performed using Cronex 4 X-ray film and 
cassettes. 	For 32P, films were preflashed and exposed at -70 0 C 
using intensifying screens. 	Films were developed in an Agfa x 1 
automatic film processor. 
2.7.6 Measurement of Radioactivity incorporated into Nucleic Acids 
The efficiency of incorporation of radiolabel into nucleic acids was 
estimated by measuring acid-precipitable counts. 	Aliquots (2 pl) were 
transferred onto Whatman GF/C glass fibre discs and dried, then 
placed in a beaker containing ice-cold TCA (5%, w/v) and incubated 
for 10 mm. on ice. Following this the filters were washed three times 
with ice-cold TCA (5%,w/v) and twice with 100% ethanol and dried. As a 
control, another aliquot (2j.l) was spotted directly onto a Whatman GF/C 
filter and dried. Each filter was transferred into a scintillation vial, 
immersed in scintillant (butyl-PBD, 6g/L in toluene) and counted in a 
liquid scintillation spectrometer. 	The percentage incorporation of 
label into nucleic acid was estimated by comparing the two values. 
57 
2.8 Nucleic Acid Methods 
2.8.1 	Small-scale Preparation of Plasmid DNA 
(Modified from Birnboim and Doly, 1974). 
Small-scale plasmid DNA preparations were obtained by a modification 
of the rapid extraction method of Birnboim and Doly (1974). 	Cells were 
grown overnight in 2 mis of LB-ampiciiiin or LB-tetracycline, pelleted 
by centrifugation (17,500 g, 2 mm.), resuspended in 1 ml of Tris-HC1 
(10mM, pH 8.5), EDTA (1mM) and peileted as above. 
The cells were resuspended in 150l sucrose mix; sucrose (15%, w/v), 
Tris-HC1 (50mM, pH 8.5), EDTA (50mM), lysozyme (0.25mg), and incubated 
at room temperature (30 mm.), then at 40C (30 mm.). 	Water (400i.il, 
40C) was then added, mixed and incubated at 4 0C (10 mm.). 
Following this, the Eppendorf tube was incubated at 70 0C (15 mm.) and 
the cell debris and chromosomal DNA pelleted by centrifugation (17,500 g, 
15 mm.). 	The supernate was transferred to another microcentrifuge tube 
and DNA precipitated by the addition of NaC10 4 (75ul. 5M) and 
isopropanol (200.1). The DNA was pelleted by centrifugation (17,500 g, 
15 mm.) and the supernate removed. 	The DNA was resuspended in Na acetate 
(100i1, 0.3M, pH5.8) and reprecipitated by the addition of ethanol 
(300il). 	Following centrifugation (17,500, 15 mm.) the DNA pellet was 
resuspended in TE (801il). 
2.8.2 Large-scale Preparation of Plasmid DNA 
(Modified from Maniatis et al., 1982) 
A single bacterial colony was used to inoculate L-broth (lOml, with 
added antibiotics) and grown to stationary phase (normally at 370C). 
The culture was diluted 1:50 in L-broth (with added antibiotics) and 
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grown at 37 0C to A650=1. Chioramphenicol was added (final 
concentration of 150g/ml) and the culture grown for a further 12 h. 
Cells were pelleted by centrifugation (4,000g, 10 mm, 4 0C) and 
resuspended in 6m1 of sucrose solution [sucrose (25%, w/v), Tris-HC1 (50mM, 
pH 8.1) and EDTA (40mM)]. Lysozyme (imi, 10mg/mi, in sucrose solution) 
and EDTA (0.5m1, 0.5M, pH 8.1) were added. Following incubation (4 0C, 
5mm.), 13ml of triton mix [Triton X-100 (0.1%, v/v), EDTA (62.5mM, pH 
8.1), Tris-HC1 (50mM, pH 8.1)] were added, mixed and left at 4 0C (10 
mins.). 	Cell debris was then peileted by centrifugation (31,000g, 30 
min., 4 0C) and the supernate recovered. CsC1 (9g) and ethidium 
bromide (0. 8m1, 10mg/mi) were added to supernate (9m1) and the mixture 
transferred to a polyaliomer centrifuge tube (1.6 x 7.6 cm, Beckman). 
Following centrifugation (95,0009, 60 h, 20 0C) DNA was visualised 
with long wavelength UV light and plasmid DNA (the lower of the two 
fluorescent bands) recovered through the side of the tube with a 19-gauge 
needle and syringe. 	Ethidium bromide was removed by repeated extraction 
with an equal volume of butan-2-ol (equilibrated with TE). The CsCl was 
then removed by dialysis against several changes of TE (4 0C), and the 
DNA precipitated with ethanol. 
2.8.3 Agarose gel Electrophoresis of DNA 
DNA was fractionated according to size by agarose gel 
electrophoresis. Molten Sigma agarose (0.75 - 1.5%, w/v in 1 x TBE gel 
buffer) was cooled to 600C and ethidium bromide (final concentration 
of 0.5ig/ml) added. The mixture was poured into horizontal gel formers. 
59 
Set gels were submerged in Bethesda Research Laboratories electrophoresis 
tanks containing 1 x TBE gel buffer. 	DNA gel sample buffer (0.25 vol.) 
was added to the DNA sample and then applied to the sample well. 
Electrophoresis was performed at various voltages (5-100 V/cm) until the 
required separation was achieved. 
2.8.4 Digestion of DNA with Restriction Endonucleases. 
DNA was incubated with a three-fold excess of restriction 
endonuclease in a microcentrifuge tube for 1 h. (using the manufacturers' 
recommended conditions). 	Digestion was terminated by extraction with an 
equal volume of phenol or by heating. 
2.8.5 Modification of the 3' and 5 termini of DNA. 
Treatment with the Klenow fragment of E.coli DNA polymerase I will 
convert a 3' recessed terminus to a blunt-ended terminus. DNA (2-10g) 
was incubated (37 0C, 60 mm.) with 5-15 units of the Klenow fragment in 
the following: Tris-FIC1 (lOmM,pH 8.0), MgC12 (10mM) and dATP, dCTP, 
dGTP and dTTP (0.25mM each). 
Treatment with Si nuclease will remove single-stranded tails from 
DNA fragments to produce blunt ends. 	DNA (2-10Mg) was incubated at 
4 0C, (1 h.) with 4 to 8 units of 51 nuclease (Sigma) in 51 buffer; Na 
acetate (30mM,pH 4.8), zinc acetate (3mM), Na Cl (300mM) (final volume 
100M1). 
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2.8.6 Ligation of DNA 
Linearised vector and insert DNA bearing complementary cohesive ends 
were mixed at a molar ratio of 1:3 (final vector concentration of 
5-30igIml) in a volume of 10.l containing 1 x T4 DNA ligase buffer and 1 
unit of T4 DNA ligase. The reaction was incubated at 16 0C for 18 h. 
For ligation of DNA molecules with a blunt end, reactions were carried 
out in a similar fashion to those with cohesive ends, but with higher 
concentrations of DNA (200-500pg/ml). 
2.8.7 Extraction of DNA from low melting point Agarose. 
The required DNA fragment was excised from the gel and transferred 
into a microcentrifuge tube. An equal volume of 1 x TBE, NaCl (0.2M) was 
added, and the tube incubated at 65 0C for 15 mm. 	The mixture was 
extracted twice with phenol at room temperature (saturated with 1 x TBE, 
NaCl (0.1M)). To remove residual phenol and reduce the volume to 200.il 
the aqueous phase was extracted several times with butan-2-ol. 	Finally 
the DNA was precipitated from sodium acetate/ethanol, pelleted and re-
dissolved in TE. 
2.8.8 Transformation of E.coli with DNA 
E.coli strains were made competent for the uptake of plasmid DNA by 
the following method: 
Cells were grown at the appropriate temperature to stationary phase 
in L broth, diluted 1:10 in L.-broth and grown to A650=0.5 (A650=0.25 
for NM522). 	Cells were pelleted by centrifugation (4,000 g 10 mm., 
4 0C), resuspended in CaC1 2 (0.5 vol., 100mM) and left on ice 
for 30 mm. 	Cells were pelleted as above and resuspended in CaCl2 
(0.05 vol., MOM). 	After incubation (30 mm., 4 0C) cells were then 
transformed with DNA. 
61 
Competent cells (0.2ml) were added to the DNA sample (<bong) in 
glass tubes and left on ice for 30 mm. 	The tubes were transferred to 
420C for 4 minutes, imi of L-broth was added and the mixture shaken for 
45 mm. at 37 0c or 30 0c. Aliquots of the mixture were plated onto 
selective media. 
Labelling of DNA 
2.8.9. Nick Translation (Rigby et al., 1977). 
Plasmid DNA (1ig) was incubated at 14 0C for 1-3h. with 2 x 10 5 .ig 
of DNase I and 0.5 unit of E.coii DNA polymerase I in 201 of 1 x nick 
translation buffer containing 32P dCTP (final concentration of bOrn Ci/mi). 
Labelled DNA was separated from unincorporated nucleotides by two 
precipitations from sodium acetate/ethanol with the addition of 5ig 
E.coli tRNA. 
2.8.10 Random-priming (Feinberg and Vogeistein 1983, 1984) 
The desired DNA fragment was excised from a low melting point gel, 
weighed and placed in a 1.5m1 microcentrifuge tube. 	Water was added 
(3ml/g of agarose) and the tube incubated at 100 0C (7 mm.), to melt 
the agarose and denature the DNA. The reaction was set up by adding the 
following: 
OLB (100), BSA (2jtl, 10mg/mi), DNA (60ng), Klenow fragment of 
E.coii DNA polymerase I (5 units), and dCTP (final concentration of 
bOrn Ci/ml). The reaction was incubated at room temperature for 2 h. 
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2.8.11 Labelling DNA Termini 
The termini of DNA fragments were labelled when the appropriate 
( 32 P)dNTP was used in the repair of recessed 3' termini using the 
Kienow enzyme as described in section 2.8.5. 
2.8.12 Colony Blotting (Grunstein and Hogness, 1975). 
Transformed E.coli colonies were arranged in a grid formation on L-
agar containing the appropriate antibiotic and grown overnight at the 
appropriate temperature. 	Plates were placed at 4 0C for 30 mm. then a 
nitrocellulose membrane (0.4 pm pore size, Schleicher and Schull) was 
gently laid on top and left for 2 mm. 	The membrane was lifted off 
gently and cells were lysed and DNA bound to the nitrocellulose membrane 
by the following method: The membranes were placed, colony-side up, onto 
filter paper soaked in NaOH (0.5M) for 7 mm. then neutralised by trans-
ferring the nitrocellulose to filter paper soaked in Tris-HC1 (1M, pH 7.4) 
for 4 mm. The nitrocellulose filters were then transferred onto filter 
paper soaked in Tris-HC1 (0.5M, pH 7.4) containing NaCl (1.5M), for 4 mm. 
The membranes were dried and baked at 80 0C for 90 mm. under vacuum. 
2.8.13 Southern Blotting (Southern et a] 1975). 
After electrophoresis of DNA through an agarose gel, the gel was 
soaked in HCl (0.25M, 15 mm.) to partially depurinate the DNA, then 
rinsed in water. The gel was then immersed in NaOH (0.5M) containing NaCl 
(1.5M) for 30 mm. to denature the DNA and then in NaOH (0.02M) 
containing ammonium acetate (1M) to neutralise the gel. To allow 
bidirectional transfer, two sheets of nitrocellulose (Schleicher and 
Schull) were soaked in the neutralising solution described above. 	These 
were placed on both sides of the gel and sandwiched with 3MM Whatman 
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filter paper. 	After leaving for 8 to 18 h. the nitrocellulose membrane 
was removed and rinsed in 2 x SSC then baked for 90 mm. at 80 0C under 
vacuum. 
2.8.14 Hybridisation of Membrane Filters with Radioactive Probes 
Filters were prehybridised in 10-30 mls of hybridisation solution 
[1 x Denhardt's reagent, 4 x SSC, formamide (50%, v/v), sonicated salmon 
sperm DNA (100ig/ml)] at 37 0C for 30 mm. with constant agitation. 
The filters were then incubated overnight (37 0C) in hybridisation 
solution (lOmi) containing the denatured radiolabelled probe. 	Following 
hybridisation, filters were washed twice in the following solution: 
2 x SSC, SDS (0.1%, w/v) then in a buffer containing 1 x SSC, SDS (0.1%, 
w/v) for a further two hours. 	Filters were then dried and exposed to 
X-ray film. 
2.8.15. RNA Preparation (Squires et al., 1981) 
A single bacterial colony was used to inoculate a lOmi culture in 
L-broth (with antibiotics as required) and grown to stationary phase. 
The culture was diluted 1:50 in L-broth (with antibiotics) and grown to 
A650=1.0. 	Cells were harvested by centrifugation (4,000 g, 10 mm.) 
washed in 50m1 of TE and harvested again as above. 
Cells were resuspended in 6.5m1 of the following solution: KC1 
(10mM), MgCl2  (5mM), Tris-HC1 (10mM, pH 7.3) containing 2mg of lysozyme. 
Following incubation at -700C for 30 mm. the suspension was allowed to 
thaw and SDS (0.9m1, 10%, w/v) was added. 	After incubation (64 0C, 5-10 
mm.) sodium acetate (0.33m1, 2.5M, pH 5.2) was added and the solution 
mixed with hot phenol (64 0C) and shaken at 64 0C for 4 mm. 
Following centrifugation (2000g, 10 mm.) the aqueous phase was removed 
and NaCl (ig) was added. 
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2.8.16 Electrophoresis of RNA 
RNA was fractionated according to size by electrophoresis through 
a 1.3% agarose gel. Agarose (1.95g) was melted in 109 mis of H20 and 
allowed to cool to 600C, 10 x MOPS (15 ml) and formaldehyde (26 ml) were 
added and the mixture poured into horizontal gel formers. RNA samples 
were added to formamide sample buffer, incubated at 60 0C for 5 mm. and 
cooled immediately on ice. 	Following addition of RNA loading buffer 
(0.25 vol.) the samples were subjected to electrophoresis (5V/cm for 18 
h. in 1 x MOPS gel buffer at room temperature). Gels were stained for 20 
mm. with ethidium bromide (5g/ml) in ammonium acetate (0.1M) at room 
temperature and destained for 2 h. in ammonium acetate (0.1M). 	Xenopus 
borealis 18S and 28S RNA were used as size markers. 
2.8.17 Northern Blotting (Thomas, 1983). 
Following electrophoretic separation of RNA, the gel was directly 
assembled into a capillary blot. 	For this purpose, a glass plate was 
placed over a reservoir of 20 x SSC and a large double sheet of Whatman 
3MM paper (pre-soaked in 20 x SSC) positioned on the plate with its ends 
dipping into the reservoir. 	The gel was then placed on top of this, 
followed by a nitrocellulose sheet (cut to the exact dimensions of the 
gel) and several sheets of 3MM Whatman paper (soaked in 20 x SSC). Twenty 
sheets of dry, Whatman 3MM paper were placed on top of this assembly and 
held in place by a large weight. 	Blotting was carried out for at least 
16 h. after which the nitrocellulose membrane was removed, dried and baked 
at 800C for 90 mm. under vacuum. 	The nitrocellulose membrane was 
treated for hybridisation as described previously (see section 2.8.14). 
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2.9 DNA Sequencing by the Dideoxynucleotide Chain Termination Method 
(Sanger et al., 1977). 
2.9.1 Preparation of Double-Stranded Replicative Form (RF) DNA of the 
Bacteriophage M13. 
A single blue plaque was used to inoculate a 2.5m1 culture of NM522 
(A650=0.25) and shaken at 37 0C for 6 h. 	Following growth, imi of 
this culture was added to 2 x 250m1 cultures of NM522 (A650=0.25) and 
grown for a further 4 h. at 37 0C with constant agitation. 	The RE 
form of the bacteriophage M13 DNA was then isolated as described in 
Section 2.8.2. 
2.9.2 Cloning into M13mp 10, 11, 18 and 19 
DNA to be sequenced was purified as a convenient restriction 
fragment from a low melting point agarose gel and sub-cloned into M13 
vectors. 	The a fragment of the -galactosidase coding region, along with 
its operator and promoter regions have been inserted into the intergenic 
region of M13. 	Many unique restriction sites have been engineered into 
this region to facilitate sub-cloning of DNA fragments with many different 
termini. 	Insertion of DNA into this poly-linker region results in the 
inactivation of the a fragment and provides a convenient screening 
procedure for the identification of recombinant plaques. 	Insertional 
inactivation prevents the cleavage of X-gal. Hence recombinant phages 
show up as "white" plaques and non-recombinants as blue plaques in the 
presence of X-gal and IPTG. 
2.9.3 Plaque Hybridisation (Benton and Davis, 1977). 
"White" plaques were picked, using a toothpick, and transferred into 
50il of LTB. 	Aliquots of the mixture were placed in a grid formation on 
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minimal plates overlaid with 3 mis BBL top agar containing 0.2mls NM522 
(A650=0.25), IPTG (201, 20mg/mi) and X-gal (201i1, 20mg/mi), and 
incubated at 37 0C (16 to 18 h.). The plates were then incubated at 4 0 C 
for 30 mm. and a nitrocellulose membrane was placed in contact with the 
plaques (2 mm.). The membrane was then gently lifted off and placed 
sequentially, plaque side up, onto filter paper soaked in NaOH (0.5M), 
NaCl (1.5M) for 2 mm. then Tris-HC1 (0.5M, pH 7.4), NaCl (3M) for 5 mm. 
The filters were then washed twice (5 mm. each) in 2 x SSC, dried and 
baked at 800C for 90 mm. under vacuum. 	The filters were then 
hybridised as described previously (section 2.8.14). 
2.9.4 Preparation of Template DNA 
Single-stranded template DNA was prepared for sequence analysis 
by the following method. Cultures of NM522 (1.5ml, A650=0.25) were 
inoculated with individual recombinant plaques. The cultures were grown 
for 4 to 5 h. at 37 0C and then transferred to microcentrifuge tubes and 
cells pelleted by centrifugation (17,5009, 5 mm.). The supernate was 
transferred to a fresh tube and the phage precipitated by the addition of 
200jil of: PEG (20%, w/v), NaCl (2.5M). 	Following incubation (30 mm., 
room temperature) phage were pelleted by centrifugation (17,500g, 5 mm.). 
The supernate was discarded and the pellet re-suspended in sequencing TE 
(100il). To remove the capsid proteins, phenol (Soul) was added, vortexed 
and left at room temperature for 30 mm. After centrifugation (17,500g, 
5mm.) single-stranded template DNA was precipitated from the aqueous phase 
by ethanol precipitation (twice) and the pellet redissolved in sequencing 
TE (500) and stored at -20 0C. 
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2.9.5 Sequencing Reactions 
Annealing 
The yield of the single-stranded template DNA prepared as described 
above was approximately 5iig. 	To template DNA (8pl), in a 1.5m1 micro- 
centrifuge tube, TM (1l) and M13 univeral primer (1l,0.2 pmol/il, New 
England Biolabs) were added. This mixture was incubated at 60 0C for 
60 mm. then briefly centrifuged to drive any condensation to the bottom 
of the tube. 
2.9.6 Primed Synthesis 
All sequencing reactions were carried out in 1.5ml uncapped Sarstedt 
tubes in plastic 10-hole centrifuge racks. 	Aliquots (2iil) of the 
annealed mix were dispensed into the 4 sequence reaction tubes containing 
21,1 of.dideoxy A/G/C/T nucleotide mixes respectively (see Table 2.1). 
Finally, 21tl of Klenow mix [lii Ci [a35S]-dATP (400 Ci/m mol), Klenow 
enzyme (0.4 units),Tris-I-ICl (10mM, pH 8.5), DTT (10mM)] were added to 
each reaction tube. After 20 mm. at room temperature, 2il of sequencing 
chase (dATP, dTTP, dCTP, dGTP, 0.25mM) were added to each tube, 
centrifuged briefly and left for a further 15 mm. at room temperature. 
Sequencing reactions can be stored at -20 0C at this stage. Prior to gel 
electrophoresis,231l of formamide loading dye were added to each tube and 
centrifuged again. 	Racks were placed into a boiling water bath for 3 
mm. and reaction products analysed by polyacrylamide gel electrophoresis 
(PAGE). 
TABLE 2.1 Composition of ddNTP Solutions. 
(all volumes in rnicrolitres) 
"T a mix "C" mix 	"G" mix "A" mix 
50mM dTTP - 2.5 2.5 2.5 
50mM dCTP 2.5 - 2.5 2.5 
50mM dGTP 2.5 2.5 - 2.5 
10mMddTTP 30 - - - 
1OmMddCTP - 7.5 - - 
1OmMddGTP - - 15 - 
1mMddATP - - - 15 
0.5mM dTTP 12.5 - - - 
0.5mM dCTP - 12.5 - - 
0.5mM dGTP - - 12.5 - 
Sequencing TE 500 500 500 250 
H20 500 500 500 750 
2.9.7 Separation of DNA Fragments in Acrylamide Gels 
The Standard Gel System 
Electrophoresis was performed on a 0.3mm x 20cm x 40cm gel, cast 
between flat glass plates. 	The notched plate was siliconised on the 
inner surface before assembly. The glass plates were assembled by placing 
0.5cm x 40cm x 0.3mm spacers along both 40cm edges between the plates, 
and then the sides and bottom were sealed with PVC tape. 	Each gel 
required approximately 35ml of gel mix, [acrylamide stock (6%, v/v), 1 x 
TBE, urea (7M)]. 	Polymerisation of this mixture was initiated by the 
addition of AMPS (240.i1,10%, w/v) and TEMED (35i.il) then poured into the 
prepared glass plates and a well-former placed in position. 	After the 
gel was set, the tape was removed, the gel mounted on the gel tank, and 
the reservoirs filled with 1 x TBE. 
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Samples were prepared as described above and applied to the sample wells. 
The gel was run at constant power (40 watts). 
Following electrophoresis gels were fixed in acetic acid (10%, vlv), 
methanol (10%, v/v), for 15 mm. The gels were then transferred to 
Whatman 3MM paper, covered in Saran Wrap and dried in a vacuum gel drier. 
When the gel was dry, the Saran Wrap was removed and the gel subjected to 
autoradiography (see section 2.7.5). 
2.9.8 Buffer Gradient Gels 
The gradient gel was prepared as follows: 40m1 of 0.5 x TBE gel mix 
[urea (17g), sucrose (2g), 10 x TBE (2m1), acrylamide stock (6m1) made up 
to 40 ml with dH201, AMPS (240pl, 10%, w/v) and TEMED (35Ml) were mixed. 
lOmi 2.5 x TBE gel mix [urea (4.25g), acrylamide stock (1.5ml), 10 x TBE 
(2.5ml), made up to lOmi with dH201, AMPS (70111, 10%, w/v) and TEMED 
(7i.il) were mixed: 4m1 of the polymerising 0.5 x TBE gel mix were taken up 
in a lOmi pipette, then 6m1 polymerising 2.5 x TBE gel mix were taken up 
in the same pipette, a crude gradient was formed by introducing 4 air 
bubbles then pipetting the mixture between the glass plates assembled as 
described above. The rest of the polymerising 0.5 x TBE gel mix was added, 
a well-former was inserted and the gel allowed to set. When the gel had 
set,the tape was removed and the gel mounted on the vertical gel tank. 
The top reservoir was filled with 0.5 x TBE and the bottom reservoir was 
filled with 1 x TBE. 	The rest of the procedure was as described above. 
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2.10 	Protein and Antibody Techniques 
2.10.1 Lowry Protein Assay. 
Protein concentrations were estimated as described by Lowry et al., 
(1951). 	The reagents used were as follows: Solution A anhydrous Na 2 
CO 3 (2%, w/v in 0.1M NaOH), Solution B CuSO4.5 H 20 (0.5%, w/v) in 
sodium citrate (1%, w.v), 	Solution C (lml Solution B plus 50m1 Solution 
A); Solution D (Folin and Ciocalteau's phenol reagent diluted with 
dH20, 50:50). 
Various concentrations of BSA,ranging from 0 to 300.tg/ml (total 
volume of 0.4ml) were used to provide a standard protein concentration 
curve. Test samples were diluted to 1:50, 1:100 and 1:200 in 400l 
dH20. 	Each sample was mixed with 2m1 of Solution C in a glass tube and 
the mixture incubated for 10 mm. at room temperature. Solution D (0.2m1) 
was then added, and the mixture incubated for a further 30 mm. The 
absorbance of these samples was measured at A550nm  and the absorbance 
related to protein concentration using the standard protein concentration 
curve. 
2.10.2 Electrophoresis of Proteins in Polyacrylamide Gels 
Polyacrylamide gel electrophoresis (PAGE) was carried out using the 
discontinuous buffer system of Laemmli (1976). Stacking gels of 170mm x 
150mm x 1.5mm were polymerised between glass plates separated by perspex 
spacers. 	The composition of the separating and stacking gel is described 
in Table 2.2. The gel mould was sealed by placing it in a trough in which 
lOmi of the separating gel solution had been polymerised by the addition 
of AMPS (1501,10%, w/v) and TEMED (lOiil). After 15 mm. the 
polyacrylamide in the trough had set and the remainder of the separating 
gel, following the addition of SDS (400ul,10% wlv), AMPS (200il,10%, w/v) 
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and TEMED (20i.il) was poured. The polymerising gel was overlaid with 
dH20 and allowed to set (2 hours). The water was then poured off and the 
gel left to drain (2 mm.). SDS (150i1, 10%, w/v), AMPS (10il, 10%, w/v) 
and TEMED (10u1) were added to the stacking gel which was then poured 
above the running gel. 	A well-former was placed in position and the gel 
was allowed to set. To protein samples were added an equal volume of 2 x 
loading buffer. [2 x contains Tris-HC1 (2m1, 0.6M, pH 6.8), glycerol (2m1) 
SOS (4ml, 10%, w/v), H 20 (2m1)] and DTT to a final concentration of 0.06M 
and heated to 1000C for 5 mm. before loading. 	Gel electrophoresis was 
carried out at 2-12 V/cm for 12-16 h. in 1 x protein gel buffer. 
TABLE 2.2 Composition of SDS-Polyacrylamide Gel Mixes (All volumes in ml) 
Stock 	 Stacking Gel Mix 	Separating Gel Mix 
Solutions 	 (3.75% acrylamide) 	7% acrylamide 	10% acrylamide 
30% (w/v) Acrylamide 	1.875 	 11.6 	 16.67 
0.2% (w/v) bis-Acrylamide 	1.875 	 11.6 	 16.67 
3M Tris-HC1 pH 8.8 	 - 	 6.25 	 6.25 
1M Tris-HC1 pH 6.8 	 1.875 	 - 	 - 
dH20 	 9.35 	 20.5 	 10.4 
2.10.3 Staining of Protein Gels 
Following electrophoresis, gels were stained with Coomassie Brilliant 
Blue R to reveal protein bands. This was carried out by gently agitating 
the gel for 30 mm. at room temperature in staining solution: Coomassie 
Brilliant Blue R (2g/L), methanol (45%, v/v), glacial acetic acid (10%, 
vlv), distilled water (45%, v/v). The gel was then destained by gentle 
agitation at room temperature in repeated changes of the above solution, 
lacking Coomassie Brilliant Blue R. 
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2.10.4 Protein molecular Weight Markers 
To calibrate SDS-PAGE, high and low molecular weight markers 
(Pharmacia) were loaded on one track of each gel. 	For a Coornassie 
Brilliant Blue R stained gel, one fifth of a high and one tenth of a low 
molecular weight marker kit vial was loaded per track. 	One high 
molecular weight marker kit vial contained: ferritin (220K and 18.5K, 
50ig), albumin (67K, 40pg) catalose (60K, 36ig) and lactate dehydrogenase 
(30K, 48iig). 	One low molecular weight marker kit vial contained: 
phosphorylase b (94K, 64kg) albumin (67K, 83.ig), ovalbumin (43K, 147iig) 
carbonic anhydrase (30K, 83ig), trypsin inhibitor (20.1K, 80g) and a-
lactalbumin (14K, 121.ig). 
2.10.5 Small-scale Preparation of Protein from E.coli 
For rapid screening procedures, a single colony was used to inoculate 
L-broth (with the appropriate antibiotic added). After growth to 
stationary phase the culture was diluted 1:50 in L-broth and grown at 
370C or 300C to A650nm=O.5. 	At this stage the cells carrying the 
recombinant plasmids were induced according to the respective promoters. 
For Tac and Lac promoters, transcription was induced by adding IPTG to a 
final concentration of 2mM for 1 hour. 	For the rightward promoter of 
lambda, induction was produced by incubating the cells at 42 0C for 30 
mm. Cells were harvested from a lml culture by centrifugation (17,500g, 
2 mm.), the pellet resuspended in sample loading buffer (40iil), lysed by 
incubation at 100 °C (5 mm.) and loaded onto the gel. 
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2.10.6 Large-scale Preparation of Fusion Protein from E.coli 
A single colony was used to inoculate L-broth (with the appropriate 
antibiotics added) and the culture grown until it reached stationary 
phase. The culture was diluted 1:50 in 500m1 of L-broth and grown at 
300C until A650 = 0.5. 	Cells were incubated at 44 0C for 45 mm. 
with constant agitation and then returned to 30 0C for a further 30 mm. 
Cells were harvested by centrifugation (4,000g, 10 mm.) and the bacteria 
resuspended in 2mls of 1 x PBS or 2mls of TEN [Tris-HC1 (50mM, pH 7.5), 
EDTA (0.5mM), NaCl (0.3M)]. 	The mixture was sonicated 5 times (10 
seconds each time, Soniprobe, Dawe Instruments type 7530A), then centri-
fuged (4,000g, 10 mm.). The pellet, which contained the majority of the 
insoluble fusion protein was resuspended in 2mls of 1 x PBS or 2mls of TEN. 
2.10.7 Analysis of Plasmid Gene Products expressed by E.coii Minicells 
The miniceli-producing strain, WL542, carrying the plasmid of 
interest was grown to stationary phase in 2 Litres of L-broth from a 2m1 
inoculum. Cells were peileted by centrifugation (4,000g, 3 mm.) and the 
supernate collected and centrifuged again (8,200g. 10 mm.). 	The pellet 
was resuspended in 18m1 of L-broth then agitated vigorously for 10 mm. 
using a magnetic stirrer (at 4 0C). 	The mixture was layered onto 4 	x 
35m1 sucrose gradients (in 50m1 polycarbonate tubes). These gradients 
were prepared by making 20% (w/v) sucrose in M9 glucose (M9 glu) [water 
lOOml, M9 x 4 (25m1), glucose (1ml,20%, w/v), MgSO4 (O.lmi, 1M), 
Vitamin B 1 (0.025m1, 0.8mg/mi)] freezing (-20 0C) and then thawing (at 
40C overnight) prior to use. The gradients were centrifuged (4,000g. 20 
mm., 4 0C), and the minicell band, which lies midway down the gradient, 
was removed with a syringe and a needle (which had been bent at an angle 
of 900 ). 	The miniceils were harvested by centrifugation (20,000g, 
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10 mm.), and the pellets were resuspended in a total of 5ml M9 glu. This 
mixture was layered onto 2 x 35ml sucrose gradients and the minicell 
band collected and pelleted as above. 	The pellet was resuspended in 
2.5rnl M9 glu and layered on one 35m1 sucrose gradient and the minicell 
band collected as described above. The minicells were harvested finally 
by centrifugation (8,000g, 10 mm.). 	The pellet was resuspended in lml 
M9 glu, glycerol (30%, v/v), and the minicells were frozen at -70 0C. 
2.10.8 Labelling Protein Products expressed by Minicells 
The minicell preparation was thawed at room temperature, the 
preparation was diluted with M9 glu to A600=0.2 and cells harvested by 
centrifugation (17,500g, 2 mm.). 	The pellet was resuspended in M9 glu 
(0.1rnl) and incubated at 37 0C for 60 mm. Methionine [ 35s] (20 P Ci; 
1,000 Cl/rn rnol:Amersham) in 20jil of methionine assay medium (Difco) was 
added and incubated for 45 mm. at 37 0C. This was followed by the 
addition of unlabelled methionine (51, 8mg/ml) and incubation for a 
further 5 mins. 	Cells were collected by centrifugation (17,500g, 2 mm.) 
washed with Tris-HC1 (lrnl, 0.05M, pH 6.8), pelleted as above and 
resuspended in sample loading buffer (401il). 	Samples were heated at 
100°C for 5 mm. and subjected to SDS-PAGE. After electrophoresis the 
gel was stained, destained, dried and exposed to X-ray film. 
2.10.9 Immunisation of Rabbits 
A sample of the required fusion protein was prepared by 
electrophoresis of 1.5m1 of the induced E.coli cell extract on the whole 
width of a protein gel. 	Three narrow longitudinal strips were cut from 
the gel, one from each side and one from the middle. 	These were stained 
with Coomassie Blue and destained. With reference to the stained strips, 
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the region of unstained gel that contained the protein band of interest 
was excised with a scalpel blade and homogenised in 3-5 volumes of PBS. 
The rabbits used in this study were New Zealand Whites. 	Before any 
injection, 5m1 of blood was taken from the ear as a preimmune control. 
The protein solution (400il, lOOpy protein) was mixed with Freund's 
complete adjuvant (400pl) for the first injection and with Freund's 
incomplete adjuvant for the second and subsequent injections. At 
intervals of one month the preparation was injected subcutaneously at 
several locations on a single rabbit, and 8-9 days after each 
injection approximately lOml of blood was collected from the ear vein. 
Collected blood was transferred to a glass tube, incubated at room 
temperature for 30 mm. and the clot removed. 	After incubation at 4 0C 
for 6-15 h.,serum was decanted into centrifuge tubes, cleared by 
centrifugation (17,500g, 30 seconds) and stored at -20 0C. 
2.10.10 Purification of Antiserum 
A single colony of NFl carrying the vector was used to inoculate a 
lOmi culture of L-broth (with added ampicillin), and grown to stationary 
phase, diluted 1:50 in 500m1 of L-broth and grown to A 650=0.5. 
Following induction of expression by incubation at 42 0C (45 mm.), the 
cells were incubated at 300C (30 mm.) and harvested by centrifugation 
(4,000g, 10 mm.). 	The pellet was resuspended in IS [NaC1 (0.15M), Iris- 
HC1 (10mM, pH 7.4)], and added to SDS (final concentration of SDS was 1%, 
w/v), prior to heating (100 0C, 5 mm.). 	This lysate was then diluted 
1:10 with IS. 	Equal volumes of the lysed cell mixture and antiserum were 
mixed by rotation for 12-16 h. (4 0C). 	This was centrifuged (17,500g, 
15 mm.), supernate transferred to a fresh tube, and an equal volume of 
lysed cell mixture added. The procedure was repeated 4 times and the 
supernate stored at -20 0C. 
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2.10.11 Western Blotting 
Proteins were electrophoretically transferred from SDS-polyaCrylamide 
gels to nitrocellulose filters by the Western blotting procedure of Towbin 
et al., (1979). 	A gel sandwich was constructed in a Bio-Rad transfer 
cassette. All components were first soaked in transfer buffer, and 
layered onto the cassette in the following order: Scotchbrite pad, 3 
sheets of blotting paper cut to the same size as the gel, the gel, 
nitrocellulose (0.45.im Schleicher and Scheul) the same size as the gel, 
3 more sheets of blotting paper, and finally another Scotchbrite pad. The 
cassette was closed and placed in a Bio-Rad electrotransfer kit, 
(nitrocellulose towards the anode), containing transfer buffer [Tris base 
(12.11g), glycine (55.8g), methanol (1 litre) and dH 20 (4 litres)]. 
Proteins were transferred at 60V for 5 hours at 4 0C. 	After transfer, 
the nitrocellulose membrane was stained with Ponceau S (0.5%, w/v), in 
TCA (3%), and washed in dFl 20 to visualise the transferred proteins. 
2.10.12 Immunological detection of Antigens Bound to Nitrocellulose 
This procedure was used to detect antigens bound to nitrocellulose 
membrane. 	Following transfer of proteins to the nitrocellulose 
membrane,unoccupied binding sites were blocked by agitation for at least 1 
hour at room temperature in IS containing ovalbumin (5%, w/v) (Sigma) 
(OIS). Immunological probingwas carried out by agitation at room 
temperature with antibody diluted in OTS (for 12-16h.). 	Before and after 
each antibody was applied, the nitrocellulose was washed in 5 changes of 
IS over a 30 minute period. 	After washing the filter, it was incubated 
for 2 hours at room temperature with either affinity purified goat anti-
human IgG conjugated to peroxidase or goat anti-rabbit IgG when rabbit 
antisera was used. Both IgG fractions were diluted 500-fold in OTS. 
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After extensive washing in TS at room temperature, the colour was 
developed by incubation in imidazole (0.01M, pH 7.4), dianisidine 
(250jg/ml),hydrogen peroxide (0.3% vlv); this reagent was prepared 
immediately prior to use. 	Brown bands appeared after approximately 5 
mm. at positions where the first antibody had bound. 	The reaction was 
stopped by washing in water. 	Filters were blotted dry and stored in 	the 
dark at room temperature. 
2.11 Reverse Transcriptase Assays 
2.11.1 Preparation of Crude Lysates of E.coli for Reverse Transcriptase 
Assays 
Crude lysates were prepared by a modification of a method described 
by Kleid et al., 1981. 	E.coii NFl cells carrying the plasmids were grown 
at 300C to stationary phase in L-broth (containing ampicillin) diluted 
1:50 in L-broth (500 mls) and grown at 30 0C to A650 = 0.4. 	Shifting 
the temperature to 42 0C induced expression. 	Cells were harvested by 
centrifugation (4,000g, 10 mm.). The bacteria were resuspended in 1:200th 
vol. of TEN: Tris-HC1 (50mM, pH 7.5), EDTA (0.5mM), NaCl (0.3M). 
The suspension was then sonicated (5 times, 10 seconds each time, 
Soniprobe, Dawe Instruments, type 7530 A) and 4.5m1 of the following: 
NaCl (1.5M), MgC1 2 (12mM), and deoxyribonuclease (final concentration 
of 2ig/m1), was added and stirred on ice for 1 hour. 	This treatment 
produced an E.coli lysate in which the -gaiactosidase fusion proteins 
were largely insoluble. These were recovered by centrifugation (4,000g. 
10 mm.) and washed three times by resuspension in TEN (2 mis) and 
centrifugation. The final pellet was resuspended in 1:200th the original 
culture volume in TEN. 
fffl 
2.11.2 Assay for Reverse Transcriptase Activity 
Crude lysates were adjusted to; 50mM Tris-HC1 (pH 8.3), 50mM KC1, 
10mM MgC1 210  0.1% NP40, 90g/ml poly rC:oligo dG( 1 2_ 18) (Sigma), 5mM 
DTT, 14.2 PM [ 3 H]-dGTP (16.9 Ci in mole 	Amersham) (Takatsuji et al., 
1986). 	After incubation (37 0C, 60 mm.), acid precipitable material 
was collected by adding sonicated salmon sperm DNA (100p1, lmg/ml), 
Na pyrophosphate (lOOjil, 0.1M) and TCA (ml, 10%, w/v, 4 0C), incubating 
on ice (10 mm.) and centrifugating (17,500g, 10 mm.). The pellet was 
washed twice with TCA (imi, 10%, w/v, 4 0C), once with ethanol (imi, 100%, 
v/v),dried and counted in a liquid scintillation spectrometer after 
addition of scintillation fluid (Butyl PBD, 0.5m1, 6g/L in toluene). 
2.11.3 Inhibition of Reverse Transcriptase Activity by Phosphonoformate 
(PFA) 
PFA, a gift from Astra Ltd., was prepared as an aqueous solution (2%, 
w/v), stored at 4 0C and adjusted to p1-I 7.4 with FIC1 (2M) prior to use. 
PFA was mixed with template and reaction buffer (as described in Chapter 
6) before addition of crude lysates. 
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Expression of the large open reading frame (L.ORF) of KBV in 
bacterial cells could provide an abundant and safe source of the 
protein encoded by this gene and, it is hoped, allow detailed analysis 
of its product. 
Synthesis of a protein at high rates in Escherichia coli (E.coli) 
depends upon frequent transcription of its gene and efficient 
translation of the transcript. 	In contrast to the expression of 
cloned bacterial genes, those from eukaryotes are expressed poorly, if 
at all, in E.coli. 	In order to express efficiently in bacteria, 
cloned eukaryotic genes must be placed under the control of bacterial 
transcription and translation signals. 
Transcription of a gene is controlled by the binding of RNA 
polymerase to the promoter, normally located upstream of the gene. 
In E.coli it has been shown that a promoter contains, at the nucleotide 
level, two highly conserved regions. The first is located approximately 
35 base pairs upstream from the transcription initiation site (-35 
region), the second is found 10 base pairs upstream of the initiation 
site (Pribnow box or "core" recognition region). The consensus sequence 
of these two regions is 5'-TTGACA-3' and 5'-TATAAT-3' respectively 
(Rosenberg and Court, 1979). 	Promoters from the lactose (Lac) and 
tryptophan (Trp) operons (Backman and Ptashne, 1978, and Hershfield et al., 
1974), the left hand promoter of the bacteriophage lambda (FL)  (Moir 
and Brammar, 1976) and a synthetic hybrid of the Trp and Lac promoters 
(Tac) (de Boer et al., 1982) have been incorporated into cloning 
vectors for this purpose. 	The choice of vector is limited, to some 
extent, by the restriction enzyme sites used to place the gene under 
the control of the promoter. 	For the expression of the recombinant 
HBV long ORF, vectors that carried the bacterial promoters Lac and Tac 
were used. 
The Lac promoter is subject to two forms of control; positive 
regulation by the catabolite gene activator (CAP) system, and negative 
control by the Lac repressor (Reznikoff and Abelson, 1978). 	The 
version of the Lac promoter most widely used in cloning vectors is the 
promoter Lac UV5. 	Lac UV5 carries the regulatory region of the Lac 
operon and contains the L8 mutation conferring CAP independence and the 
UV5 "up-promoter" mutation which enhances the rate of transcription 
(Backman et al., 1976). 	This has been used successfully to express a 
number of viral and eukaryotic genes in E.coli (Table 3.1). 
Promoter strength has been shown to be directly proportional to 
the degree of similarity with the consensus sequence of the -35 region 
and Pribnow Box (Russell and Bennett 1982). 	Therefore a hybrid 
promoter has been constructed, which consists of the optimal consensus 
sequence, by fusing the -35 region of the Trp promoter to the -10 
region of the Lac promoter. 	This promoter, known as the Tac promoter, 
has been used for the expression of the Human Growth Hormone (HGH) 
(Table 3.1) (de Boer et al., 1982). 
	
0.05% 	 Charnay et al., 
1980. 
0.3% 	 Gilmer and 
Erikson, 1981. 
0.2-0.3% Garapin et al., 
1981. 
0.15% Horwich et al., 
1980. 
0.8% Roberts et al. 
1-5 x 103 1979. 
Table 3.1 	Expression of viral and Eukaryotic Proteins in E.coli. 
Protein 
(mol .wt.) 





Rat Lac s-gal fusion Low Talmadge et al. 
proinsulin 1980. 
Human Lac s-gal fusion 12mg/3229 Wetzel 	et al. 
proinsulin wet cells 1981. 
-endorphin Lac -gal fusion 5% Shine et al., 
1980. 
Chicken Lac Short s-gal 1-1.5% Fraser and 
Ovalbumin fusion Bruce, 1978. 
Hepatitis B Lac s-gal fusion Low Stahl 	et al., 
virus core 1982. 
antigen. 
Hepatitis B Lac Long s-gal 
virus surface (in phage) fusion 
antigen. 
Rous Sarcoma Lac 8 amino acid 
virus protein s-gal 	fusion 
kinase (Src) 
HSV thymidine Lac Short s-gal 
kinase (TK) fusion 
Polyoma Small Lac s-gal 	linker 
t antigen fusion 
SV40 t ag Lac rbs fusion 
mol/cell 
Human 	 Tac 	rbs fusion 
	
de Boer et al., 
Growth 1982. 
Hormone (HGH) 
Inducible control is important when over-expressing genes in 
E.coli as the resulting gene product may be toxic to the cells. 
An example of this was found by Shimatake and Rosenberg (1981) 
when they tried to express large amounts of the Acil protein using the 
L promoter. 	They found that clones carrying ?LcII could transform a 
A lysogen (carrying a ts c1857 gene) very well but could not, however, 
transform cells that did not make any A repressor, demonstrating that 
the Acli protein is toxic to E.coli. 	Expression of Acil could be 
induced by growing the cells at 42 0C. 
Both the Lac and Tac promoters are regulated by the Lac repressor. 
However, when these promoters are carried on multicopy plasmids, they 
over-titrate the Lac repressor within the cell resulting in 
constitutive transcription. 	These promoters can be repressed in 
strains which over-produce the Lac repressor, i.e. Lac 1q  (Backman et 
al., 1976; O'Farrel et al., 1978) and then induced by the presence of 
lactose or by the addition of a non-metabolisable inducer isopropyl-
thiogalactosidase (IPTG) which binds to the repressor and removes it 
from the operator. 
Efficient translation of mRNA in prokaryotic cells requires the 
presence of an efficient ribosome-binding site. 	For most E.coli 
messenger RNAs the ribosome-binding site consists of two components; 
the initiation codon AUG, and a Shine Dalgarno sequence (SD). The SD 
sequence is found 3-12 bases upstream of the initiation codon and is 
complementary to the 3' end of the 16S ribosomal RNA (Shine and 
Dalgarno, 19Th). 
A common strategy to ensure translation of a gene normally 
expressed in E.coli is to generate a fusion protein by joining the 
initial portion of a gene which is efficiently translated to the gene 
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whose expression is sought. 
AUG of the E.coli gene provid 
proceeds into the cloned gene 
has been used successfully in 
(Stahl et al., 1982). 
To detect the expression 
The ribosome-binding site and initiating 
the start signals for translation which 
producing a fusion protein. This method 
expressing the HBcAg in E.coli(Table 3.1) 
of the cloned genes one can either use 
immunological methods, or phenotypic selection to detect the synthesis 
of the gene product. 	However, to detect the expression of cloned 
genes when the function is not known, or when a specific antibody is 
not available, is more difficult. 	In these cases one can directly 
analyse the protein if expressed at a high level, or if not, use 
mutant E.coli cells in which the background of the host proteins is 
minimised, e.g. minicells or alternatively an in vitro transcription 
translation system could be used. 
Minicells are small, spherical cells which are produced throughout 
the growth cycle of minicell-producing mutant strains of E.coli. They 
contain RNA and protein but little or no chromosomal DNA. 	Because 	of 
their size difference, minicells and normal cells can be separated 
easily on sucrose gradients. 	Plasmid DNAs segregate into minicells, 
and purified minicell preparations allow the labelling of plasraid-
encoded proteins in the absence of any background from chromosomal 
proteins (Frazer and Curtis, 1975), and hence are ideal for detecting 
the expression of novel proteins carried by recombinant plasmids. 
In vitro transcription and translation systems are very useful for 
two reasons. Firstly, incorporation of radioactive label into 
protein in vitro is much more efficient than in vivo thus increasing 
its sensitivity. 	Secondly, the apparent inability to express some 
genes in E.coli has been due to proteolytic degradation of the foreign 
L.7 
LI1•J 
gene product. 	This problem can be overcome using an in vitro 
transcription translation system. An example of this was described by 
Mellado and Murray (1983) when they cloned histone genes under the 
control of a bacterial promoter and were unable to detect the presence 
of any histone protein in vivo. 	However, using an in vitro 
transcription translation system, histones expressed from the 
recombinants were visualised. 
In conclusion, using the methods and approaches discussed, this 
chapter describes the construction and expression of the I-IBV long open 
reading frame in E.coli. 
3.1 The origin of HBV Genomic Clones 
HBV DNA isolated from Dane particles from a single FIB5Ag and HBcAg 
donor was labelled with 3H-dTTP using the endogenous polymerase. 
This DNA was then digested with EcoRI or BamHI and hybrid plasmids 
constructed by insertion of these HBV DNA fragments into pBR322 at the 
PstI cleavage site via a 3' oligo dG and oligo dC tail (Burrell et al., 
1979). 	Two of these clones, pHBV130 and pHBVCB, carried inserted 
fragments with slightly over a genome length of viral HBV DNA 
(Fig.3.1a) (Gough and Murray, 1982). 	Unfortunately, neither of these 
constructs contained the long open reading frame in an intact form,thus 
the cloning of this gene involved the reconstruction of this long ORE 
piece by piece using several fragments (Fig.3.1b). 
3.2 Construction of pR1-pol8 and pTac-pol8 
The plasmid pR1-11, expresses the core antigen of HBV as a fusion 
with 8 amino acids of 8-galactosidase, using the Lac promoter to drive 
expression (Stahl et a]., 1982) (Table 3.1). This plasmid contains 1kb 
Th 
FIGURE 3.1(a) 
pHPV130, and pHBVCB. 	The heavy lines represent HBV 
sequences and the thin lines represent pBR322 sequences. 
The location and direction of open translational reading 
frames within the I-IBV genome are indicated by arrows. 
The surface antigen and putative polymerase genes are 
interrupted by pBR322 sequences (Gough and Murray, 1982). 
FIGURE 3.1(b) 	The genome of HBV. 	Heavy lines denote the DNA 
strands, the broken line showing the region of variable 
length of the short strand. 	Arrows represent the four 
open reading frames (as coding sequences) with the numbers 
of initiation and termination triplets in the system 
adopted by Pasek et al., (1979). 
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of HBV DNA. 	Removal of a 439bp BqlII fragment, which deletes most of 
the core gene, results in a fused product consisting of the first 84 
nucleotides (equivalent to the N-terminal 28 amino acids of the core 
antigen gene fused to the polymerase gene at a position corresponding 
to amino acid residue 40). This construct, pHPL-1, was kindly given by 
Dr. Michael McGarvie (Fig.3.2). 
The reading frame of the polymerase component of pHPL-1 was 
extended by the insertion of a 1678 bp BamHI fragment from pHBV130. 
pI-IBV130 was digested with BamHI and the resulting restriction fragments 
separated by agarose gel electrophoresis. 	The desired fragment was 
purified by electro-elution and then added to Bami-lI linearised pHPL-1 
in a ligation reaction containing 14 DNA ligase. 	Following ligation, 
the mixture was used to transform competent E.coli w111 cells and 
plated out in the presence of ampicillin. 	Plasmid DNA was prepared 
from overnight cultures of ampicillin-resistant transformants using a 
rapid isolation technique. 	Recombinant plasmids were identified on 
the basis of size by agarose gel electrophoresis. 	A recombinant 
containing the insert in the correct orientation was then identified by 
restriction mapping; this construct is called pR1-130. 
pR1-pol8 was constructed in a manner analogous to that used for 
pR1-130, i.e. by ligating an XbaI fragment from pHBV CB into XbaI-
digested pR1-130, thereby introducing the rest of the coding region 
including the translation termination signal of the long ORF. 	The 
identity of this construct was confirmed by restriction mapping 
Conservation -of the reading frame at the BglII deletion was 
verified by sequencing across the junction. 	This was achieved by sub- 
cloning the EcoRI-BamHI fragment covering the junction sequence of the 
recombinant plasmid into M13 mpll and sequencing by the dideoxy chain 
FIGURE 32 	The construction of pR1-.pol8 and ptac-po180 
pHPL-1 contains HBV DNA sequences equivalent to the 
first 28 amino acids of the core protein fused in frame to 
amino acids 40 to 201 of the polymerase gene product,. 
A BamHI fragment encoding the internal sequences of 
the putative polymerase gene was inserted into the unique 
BamHI site of pHPL-1 to form pRl-130. 3) The rest of the 
coding information, including the translation termination 
signal of the long ORF, was inserted into an XbaI fragment 
from pHBVCB to form pR1-pol8. 4) ECORI and Sail sites 
flank the polymerase region of pR1-pol8. 	This plasmid 
was restricted with these enzymes and the fragment 
containing the polymerase gene was inserted into the 
unique EcoRI and Sail sites of the expression vector pBR-
Tac to produce ptac-pol8. 
Key: filled area, HBV Long ORF. 
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termination procedure. 	Likewise, an XhoI-PstI fragment was sub-cloned 
into M13 mp19 and sequenced to confirm that insertion of the XbaI 
fragment from pHBVCB into pR1-130 did not disrupt the reading frame. 
pBR Tacl is a vector that carries the tacl promoter inserted into 
pBR322. 	It has unique EcoRland Sail sites. 	EcoRI and Sail sites 
flank the polymerase region of pR1-pol8. 	Restriction of this plasmid 
with these enzymes and isolation of the appropriate fragment allowed 
the polymerase recombinant gene to be inserted between the EcoRI and 
Sail sites of pBR tad. 	This construct, called plac-pol8,a derivative 
of pRl-pol8, would express the recombinant polymerase gene under the 
control of the Tac promoter. Its identity was confirmed by restriction 
mapping and,like pR1-pol8, was made and propagated in WjjOIq cells. 
Both pTac-pol8 and pR1-pol8 have all but the first 38 amino acids of 
polynierase fused to the N-terminal 28 amino acids of core (HBV core Ag) 
3.3. Construction of pT.R.T 
A third plasmid was constructed (Fig. 3.3) which contained all the 
coding information of the long ORE of IIBV except for the first N-
terminal 11 amino acids which were replaced by 8 amino acids from the 
N-terminal -ga1actosidase protein (Fig. 3.3). 
The plasmid pHBVCB which contains HBV DNA inserted into pBR322 
(see Section 3.2) was restricted with jjII and treated with Si 
nuclease. 	The reaction was stopped by phenol extraction and then 
ethanol-precipitated. 	The products were then digested with XbaI and 
separated on a 1% low melting point (L.M.P.) agarose gel. The purified 
fragment containing the N-terminal region of the long ORE was ligated 
to M13 mph, digested with Smal and XbaI. Following ligation, the 
reaction was used to transform competent NM522 cells. 	White plaques 
MWI 
FIGURE 3.3 	The construction of pT.R.T. (1) The plasmid 
pHBVCB was restricted with jII treated with Si nuclease, 
and digested with XbaI. 2) The purified fragment 
containing the N-terminal region of the long ORF was 
inserted into M13 mpii, and digested with Smal and XbaI to 
form clone 8. 3) Clone 8 was opened at the EcoRI site, 
treated with the Klenow fragment in the presence of dTTP 
and dATP, and digested with SalI. 	A 1075bp fragment 
containing the long ORF region was isolated. pBR-tac was 
restricted with EcoRI, treated with Kienow in the presence 
of dTTP and dATP, digested with Sail, and the 1075 bp 
fragment was inserted to produce pEM1. 	The remainder of 
the coding information was supplied by inserting an XbaI 
fragment from pHBVCB. 	This construct is called pT.R.T. 
Key: Filled area, HBV long ORE. 
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were picked and purified and a battery of recombinants was sequenced to 
determine the extent of Si nuclease digestion. One recombinant, clone 
8 (nucleotide position 454) was selected for further use (Fig. 3.3). 
Clone 8 was opened at the EcoRI site and treated with the Kienow 
fragment of E.coli DNA poll in the presence of dTTP and dATP to 
maintain the reading frame restricted with Sail and the digestion 
products separated on a 1% L.M.P. agarose gel. 	A 1075bp fragment 
containing the putative polymerase region was isolated. pBR tacl was 
restricted with EcoRI and the recessed end was made blunt by treating 
with the Klenow fragment as described above after which it was digested 
with SalI and the 1075bp fragment was inserted using T4 DNA ligase. 
Competent W110Iq cells were transformed with the ligation reaction 
mixture and plated out in the presence of ampicillin. 	Anipicillin-. 
resistant, tetracycline-sensitive transformants were characterised and 
a recombinant plasmid identified by restriction mapping. This 
construct is called pEM1. 
The remainder of the coding information, including the translation 
termination signal of the long ORF, was supplied as described for the 
construct pRl-pol8 by inserting an XbaI fragment (nuleotide position 
1529-90) from pHBVCB. 	This construct is called pT.R.T. and has been 
characterised by restriction mapping. 
Conservation of the reading frame at the point of fusion of the 
vector and inserted sequence was confirmed by sequencing across the 
junction. This was achieved by transferring the HindII- .j!jI fragment 
into M13 mp18 and M13 mp19 and sequencing by the dideoxy chain 
terination procedure. An Xho-PstI fragment from pT.R.T. was sub-
cloned into M13 mp19 and sequenced to ensure that the reading frame had 
not been disrupted by the insertion of the XbaI fragment from pFIBV CB 
into pEM1. 
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3.4 Expression of the recombinant long ORF in E.co]i 
The minicell system was used to identify novel proteins expressed 
from the recombinant plasmid in the absence of an antibody specific for 
the translation product from the long ORF. 	The expected molecular 
weight from the computer predicted amino acid sequence for the 
recombinants as follows: 
Table 3.2. 	Predicted Molecular Weight of the Recombinant Proteins 









The composition of these proteins is illustrated in Figure 3.4. 
Recombinant plasmids were used to transform the competent, 
minicell-producing strain W1542. 	Transformants were selected as 
ampicillin-resistant colonies and minicells were prepared from them. 
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FIGURE 3.4 	The composition and molecular weight of the 
translation gene products expressed by the recombinant 
plasmids. 
Key: Open area, -galactosidase polypeptide; crossed 
area, N terminal, 28 amino acids of the core protein; 
filled area, HBV polymerase polypeptide; dotted area, 
amino acids encoded by the pBR322 sequence. 
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Plasmid-encoded proteins were labelled for 30 minutes by incubation of 
the min icells in a medium containing [ 35 S]-L-methionine, amino acids 
and 2mM IPTG then analysed by electrophoresis in SOS polyacrylamide 
gels. 	Figure 3.5 shows that the recombinant plasmid, pRi-11, directs 
the synthesis of a novel protein of about 22kd, which has been 
previously identified as the FIBcA9 (Stahl et al., 1982). 	pHPL-1 also 
expresses a novel protein of the expected molecular weight. 	However, 
neither pR1-130 nor pR1-pol8 appeared to express any novel proteins. 
Similarly, polypeptide produced by pEM1, pT.R.T., and pTac-pol8 were 
analysed. It was found that none of these plasmids appeared to 
produce a novel protein. 	These experiments were repeated several 
times using various induction times ranging from 10 minutes to 3 hours, 
but the expected translation products could not be detected. 
In conclusion, although HBcAg could be readily detected in 
minicells, there was no evidence for the synthesis of polypeptides of 
the anticipated size in minicells carrying pR1-130, pR1-pol8, pEM1 and 
pT.R.T., or indeed, significant quantities of any polypeptide that did 
not appear in cells harbouring the vector alone. 
The constructs which do not produce the expected translation 
products may not be transcribed, but this is unlikely as they are under 
the inducible control of the strong bacterial promoters Tac and Lac. 
It is unlikely that failure to detect the anticipated synthesis of the 
fused -galactosidase-polymerase polypeptides results from a lack of 
sequences necessary for translation of the corresponding messenger RNA, 
as this ribosomal binding site was shown to direct efficent translation 
when fused to the coding sequence for FIBcAg, and the first 160 amino 
acids of the putative polymerase gene. 
It is possible that the secondary structure of the messenger RNA 
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FIGURE 3.5 	Identification of polypeptides encoded by 
recombinant plasmids. 	Proteins encoded by the 
recombinant plasmids were detected in minicells of WL542 
transformed with pRi-11, pHPL-1, pR1-130 and pR1-pol8, 
The polypeptides were labelled with [ 35S]L-methionine in 
the presence of IPTG and separated on a 10% (w/v) 
polyacrylamide gel containing SDS, and visualised by 
autoradiography. 1) pR1-pol8; 2) pR1-11; 3) markers; 
4) pR1-130; and 5) pHPL-1. 
00 
U) 
o 	- w() I 
0— —J 
rr 









HBcAg 	 20,000 
- 14,000 
12 	345 
transcribed from pUll or pT.R.T. leads to very inefficient translation 
(Inserentant and Fiers, 1980) or, in the case of pHPL-1, when 
additional sequences are inserted the resulting messenger RNA may form 
undesirable secondary structures thus reducing the efficiency of 
translation. Alternatively, the messenger RNA produced may be labile, 
or the polypeptides produced may be particularly sensitive to E.coli 
proteases. 
In order to establish that the recombinant DNA sequences were 
being transcribed, RNA from these clones was extracted and analysed. 
The predicted secondary structure of messenger RNA produced by these 
constructs was also deduced and using an in vitro-coupled transcription 
translation system, the polypeptides from the recombinant plasmid were 
analysed in vitro. 
3.5 Analysis of RNA produced by pEM1, pTac-pol8, pT.R.T. etc. 
E.coli cells (strain W110,) harbouring the recombinants were 
grown in the presence of ampicillin to A650 = 0.5. 	Cells were then 
induced by the addition of 2mM IPTG and grown for a further 60 minutes. 
The RNA was extracted and fractionated by electrophoresis on a 1.3% 
agarose formaldehyde-denaturing gel, and transferred to a nitro- 
cellulose filter. 	The filter was then baked and hybridized with an 
HBV genome-specific probe (3.2kb XhoI fragment from HBV130) which had 
been labelled with 32P, using the random oligonucleotide method. The 
HBV-specific probe hybridised to mRNA produced by cells carrying either 
pEM1 or plac-pol8. 	The same probe did not hybridise to mRNA produced 
by cells carrying the vector pBRtac alone (Fig. 3.6a). 
Treating the RNA with RNAse and DNA5e confirmed that the probe was 
hybridising to RNA transcripts and not to any contaminating plasmid DNA 
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FIGURE 3.6(a) Identification of long ORF-related transcripts 
in E.coli transformed with the recombinant plasmids. 	RNA 
was prepared as in Methods Section and separated on 1.3% 
(w.v) agarose gel containing formaldehyde. 	The RNA was 
transferred to nitrocellulose and probed with a  32 P- 
labelled HBV-specific probe. 	The transcripts which 
hybridised to the probe were visualised by auto- 
radiography. Markers were yeast ribosomal RNA. 	The 
samples were as follows: tracks 2 and 3, Ri-li, bug and 
16ig respectively of RNA; tracks 4 and 5, ptac-pol8, 10.ig 
and 16jig respectively of RNA; tracks 6 and 7, pEM1, iOig 
and 16ug respectively of RNA; tracks 8 and 9, pBR-tac, 
lOug and 16ig respectively of RNA. 
FIGURE 3.6(b) 	Northern blot analysis of the recombinant 
plasmid transcripts using a 32P-labelled HBV-specific 
probe. 10g of each of the RNA samples were loaded in the 
following order: Lane 1, yeast ribosomal markers; 
Lane 2, pHBV GB digested with BamHI; Lane 3, Ri-li; 
Lane 4, ptac-pol8; Lane 5, pEM1; Lane 6, pBR-tac; 
Lane 7, pEM1 treated with DNase 1 before loading; Lane 8, 
pRi-11 treated with DNase 1 before loading; Lane 9, ptac-. 
p018 treated with RNase before loading; Lane 10, pRi-11 
treated with RNase before loading; 	Lane ii, ptac-pol8 
treated with RNase before loading; Lane 12, pEM1 treated 



















































































































































































































(Fig. 3.6b). The fact that the RNA from Ri-li did not hybridise to the 
probe is puzzling as the plasmid expresses HBcAg; perhaps this mRNA 
has a very short half-life. 
This experiment shows that the recombinant plasmids are being 
transcribed within E.coli. 	Transcription is initiated at nucleotide 
position -22 in both the Lac and Tac promoter region but it is not 
clear where the transcription terminates. 
As the HBV DNA has been cloned into the T etr gene of pBR322, it 
is reasonable to expect that RNA polymerase will recognise the 
transcription termination signals used in the normal expression of the 
Tetr gene (Stuber et al., 1981). 	If this were so then transcripts 
of approximately 4kb and 1kb ought to be produced from pTac-pol8 and 
pEM1 respectively. 	However, single bands on the Northern blot, 
corresponding to such species of ruRNA, were not detected though smears 
were identified which did not extend beyond approximately 4kb for plac-
p018 and 1kb for pEM1. 
Two observations led to the conclusion that the RNA has not been 
degraded during extraction. 	Firstly, on ethidium bromide-stained 
agarose gels of the RNA from the recombinant plasmids and the vector, 
the E.coli ribosomal bands are clearly visible, although as these RNA5 
have a very strong secondary structure they are not as susceptible to 
degradation. 	Secondly, RNA extracted in the presence of RNAse 
inhibitors still displayed the same pattern of hybridisation. Smearing 
may be the result of premature termination, or rapid degradation within 
the cell, or alternatively the product of partial transcription which 
is interrupted by extraction. 
In conclusion, these experiments show that the recombinant 
plasmids are being transcribed but they do not give any indication of 
the processing or stability of these transcripts. 
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3.6 Messenger RNA Secondary Structure 
Initiation of translation involves interaction between an 
activated 30S ribosomal subunit and the 5' terminal region of a 
messenger RNA which is already folded in a specific secondary 
structure. 	Greater efficiency of translation occurs if the initiated 
codon and, to a lesser extent, the Shine Dalgarno sequence is freely 
accessible to the 30S ribosomal subunits (Iserentant and Fiers, 1980). 
The predicted secondary structure for mRNA of the -ga1actosidase gene 
and the recombinant plasmids pT.R.T and pTac-pol8 around the initiation 
codon was determined (Fig. 3.7) and the thermodynamic stability of each 
structure was calculated following the rules of Tinocco et a]., 1973. 
The initiation codon AUG in pTac-pol8 is freely accessible in a 
hairpin loop. 	In the case of pT.R.T, a third of the initiation codon 
is in a hairpin loop while the other two bases are involved in base 
pairing within a stem structure. 	However, this is identical to the 
environment of the initiation codon of the -galactosidase messenger 
RNA which is translated very efficiently. 	Therefore, the predicted 
secondary structure of the mRNA produced by the recombinant plasmids 
shows that the initiation codon and the Shine Dalgarno sequence are in 
a favourable position for the initiation of translation. 
3.7 Coupled in vitro-Transcription Translation Systems 
The previous experiments showed that the recombinant plasmids are 
being transcribed and that these transcripts should be translated. The 
translation products from these transcripts were analysed using an in 
vitro-coupled transcription-translation system. 	As incorporation of 
label into proteins is more efficient in vitro, and the presence of 
E.coli proteases is reduced in this system, it was hoped that 
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FIGURE 37 	Postulated secondary structure of the mRNA 
synthesised by the recombinant plasmids,. 	The thermo- 
dynamic stability of each structure was calculated 
following the rules of Tinoco et a]0, 1973 
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previously unidentified proteins expressed from these constructs would 
be detected. 
DNA from the recombinant plasmids and vector controls were used as 
templates. The polypeptides synthesized were labelled with [ 35S]-L-
methionine and analysed by gel electrophoresis and autoradiography 
(Fig. 3.8). 
The protein which was detected in minicells harbouring pHPL-1 was 
again found in vitro. 	A very faint novel polypeptide of approximately 
80kd was seen when pR1-130 was used as a template. 	High molecular 
weight polypeptides were synthesised uniquely when pTac-pol8 was used 
as a template though these were not found with pR1-pol8. 	Using pEM1 
as a template, a novel protein of approximately 60kd, the expected size 
of a translation product from this construct, was synthesised 
efficiently. 	A series of weak, high molecular polypeptides was also 
detected when pT.R.T. was used as a template. 
In conclusion, novel proteins within the size range expected for 
translation products were synthesised by the recombinant plasmids 
(with the exception of pR1-pol8) which had not been detected in vivo. 
Disappearance of the proteins from the gel, if the insert DNA is 
cleaved, would confirm that the novel protein products were coded for 
byHBV DNA. 	This experiment, however, proved to be technically 
difficult as a linear template was transcribed so poorly that it did 
not allow comparison of products from the linear and supercoiled 
templates. Alternatively, 35S-labelled polypeptides could be purified 
and characterised via Edman degradation but with the exception of pEM1 
and pHPL1, the proteins of interest are not expressed in high enough 
quantities to allow such analysis. 
FIGURE 3.8 	Proteins encoded by the recombinant detected by 
transcription and translation of plasmid DNA in a cell-
free system from E.coli. 	The polypeptides were labelled 
with [35S]L-methionine and separated on a 16% (w/v) 
polyacrylamide gel containing SDS and visualised by auto-
radiography. The samples were as follows: 1) pRi-11; 
2) ptac-core; 3) pR1-pol8; 4) ptac-pol8; 5) pHPL-1; 
6) pR1-130; 7) pEM1; 8) pT.R.T; 9) pBR-tac; 10) ptac-
core; 11) pBR-322; 12) markers. (Gel by Mohamed El 
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In summary, novel proteins of the expected size are being 
synthesised by the recombinant plasmids. 	This allows one to 
tentatively conclude that these polypeptides are being expressed from 
these constructs and represent -galactosidase-polyrnerase fusion 
proteins. Why these proteins have not been detected in vivo is not 
clear, particularly the abundant protein expressed by the construct 
pEM1. 	As RNA has been shown to be produced from these constructs 
(Section 3.5), and the RNA is most likely to be translated, the problem 
with the synthesis of these proteins in vivo may be due to some 
translational event within the cellular environment, and the simplest 
explanation is that hybrid s-gal actosi dase polymerase molecules 
expressed from pRl-130, plac-pol8, pRl-pol8, pEM1 and pT.R.T. are 
susceptible to attack by one or more of the proteases that are present 
in E.coli. 
If the instability of the newly synthesised polypeptides is indeed 
the reason for the failure to detect these novel proteins, transferring 
these recombinants into protease-deficient strains may allow the - 
galactosidase polymerase fusion to be expressed in vivo. 
3.8 Expression of the Recombinant Plasmids in Protease-minus Strains 
of E.coli 
S. Goff and co-workers have constructed an E.coli cell line, 
SG935, which is deficient in La, an ATP-dependent protease encoded by 
the ion gene (Goff and Goldberg, 1985). 	This protease has been shown 
to play an important role in the degradation of abnormal proteins and 
Ion mutants have been found to degrade abnormal proteins two or four 
times more slowly than the wild-type cell. 
pDM1, a plasmid which carries the 1q gene of the lac operon, and 
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the kanamycin resistance gene, is compatible with pBR322 (D. Simmons, 
personal communication). 	Competent SG935 cells were transformed with 
this plasmid and kanamycin-resistant cells were selected; these were 
then made competent and were transformed with the recombinant plasmids. 
kanamyciri-resistant, ampicillin-resistant transformants were 
characterised. 	Cells harbouring the recombinant plasmids were grown 
to stationary phase in L-broth containing kanamycin and ampicillin 
(LB.amp/kan) diluted 1:50 in LB.amp/kan and grown to A6 50=0.2. Cells 
were induced by adding IPTG to a concentration of 2mM and grown for a 
further 60 minutes. 	Cells were harvested and the proteins analysed by 
electrophoresis on an SDS-polyacrylamide gel (Fig. 3.9) 
Figure 3.9, track 3 shows that cells harbouring pEM1 synthesise a 
novel protein of approximately 60kd, corresponding to the protein 
detected during in vitro-transcription translation of this construct 
and also is the correct size for the translation product expected from 
this recombinant plasmid. 	A smaller, unique protein migrating at 
approximately 45kd is also seen in these cells and is presumably a 
breakdown product of the larger protein. 	The 27kd protein, which is 
shown to be expressed by pHPL-1 in vivo and in vitro, is also 
synthesised in these protease-minus strains. 	The translation product 
from pHPL-1 is obviously present in greater abundance in the Lon-minus 
strains as this protein can be visualised, by staining with Coomassie 
blue, from extracts of the protease-minus strains, but is not detected 
by this method using minicells. 	The recombinant plasmids which 
should express longer segments of the long ORE did not synthesise any 
novel polypeptides. 	Perhaps the additional polypeptide sequence 
contains a site which is particularly sensitive to proteolytic 
degradation. 
FIGURE 39 	Expression of the recombinant plasmids in 
protease-minus strains of E.coli. The bacteria were grown 
to OD.4. 	After inducing for 1 hour at 37 0C with 2mM 
WIG the proteins were separated on a 10% (w/v) polyacryl- 
amide gel containing SDS. 	The gel was stained with 
Coomassie blue. Lane 1, pT.R.T; Lane 2, pHPL1; Lane 3, 
pEM1; Lane 4, pBR-tac; Lane 5, pR1-pol8; Lane 6, ptac-
















A number of proteases are present in E.coli which are used to 
degrade abnormal and normal proteins throughout the life cycle of the 
bacteria. 	These are also involved in processing secretory and 
membrane proteins. 	At present seven proteolytic activities have been 
isolated which are capable of hydrolysing polypeptides to acid-soluble 
material; these are - Do, Re, Mi, Fa, So, La and P1, and these are 
found in different locations within the cell; in the cytoplasm, the 
periplasmic space, and the cell membrane (Goldberg et al., 1982). 
These proteases have also been found to rapidly breakdown proteins when 
the cells are in a stationary phase or are starved (Goldberg and St. 
John, 1976). 
Proteolytic degradation appears to involve an initial endo 
proteolytic hydrolytic incision rather than exoproteolytic cleavage. 
This would imply that a specific recognition signal is required for a 
protein to be degraded by proteases. 	This is supported by the work of 
Bachmairet_al.,(1986) who found that the half lives of different 
proteins can be correlated with the amino-terminal amino acid of the 
protein (N- end Rule) ranging from proteins with methionine, serine, 
alanine, threonine, valine and glycine at their N-terminus which have 
half lives of more than 20 hours to proteins with half lives of 2 
minutes which have an arginine N-terminus. 	Rogers et al (1986) have 
also proposed that selective proteolytic degradation is a result of a 
"signal sequence". 	Using a eukaryotic system, it was found that 
proteins which contain one or more regions rich in proline (P), 
glutamic acid (E), serine (S) and threonine (T) in PEST sequences are 
subject to rapid intracellular degradation. 
Eukaryotic proteins expressed in E.coli have been shown to be very 
susceptible to proteolytic degradation (Davis et al., 1981). 	The 
problem of degradation of foreign proteins may be difficult to resolve. 
The observation that hybrid sequences can be used to transport insulin 
into the periplasmic space which increased its half life by a factor of 
ten, allows one to build constructs designed to ensure secretion 
(Talmadge et al., 1982; Talmadge and Gilbert, 1982). Alternatively, 
the gene of interest could be fused to various amounts of a bacterial 
gene. 	Heiland and Gething (1981) obtained low levels of haernoglutin 
activity (HA) in E.coli cells with constructs carrying the Lac promoter 
directing transcription of short -galactosidase HA fusion. 	However, 
high levels of expression of HA (5-7% of total cell protein) were 
achieved by using long -glactosidase fusions (Davis et al., 1981). 
It was found that these longer fusions are insoluble and thereby 
partially protected from proteolysis (Stanley and Luzio, 1984). 
The use of bacterial cells lacking one or more of the normal 
complement of proteins may be another way of slowing down degradation 
of eukaryotic proteins. 	The ATP-dependent protease La, the product of 
the ]on gene, has been shown to play an important role in the 
degradation of abnormal proteins. 	Interestingly, it was found that 
the presence of the abnormal proteins increases transcription of the 
lon gene via positive induction of a heat-shock regulatory gene htpR. 
E.coli mutants are now available which are deficient for the function 
of htpR and ion (Goff and Goldberg, 1985). Simon et al.,(1984) showed 
that the bacteriophage T4 carries a gene which causes the decrease in 
the degradation of abnormal proteins. 	This gene was identified and is 
called Pin, protease inhibition gene. 	It was found that the labile 
eukaryotic proteins, e.g. fibroblast interferon, expressed in E.coli is 
stabilised in cells in which the 14 gene is expressed. 
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At present there are few studies on the stability of the analogue 
of eukaryotic messenger RNA in E.coli. 	Structural features, but not 
the size of the messenger RNA, determine its susceptibility to decay 
(Belasco et al., 1986). 	Protection of the messenger RNA by 3 
terminal structures act as barriers against nucleolytic attack and a 
site-specific incision will generate an exposed 3' terminus. Three 
enzymes appear to be involved in degradation. RNAse III appears to be 
an endonuclease and RNAseII and polynucleotide phosphorylse act as 3' 
exonuclease. 	Messenger RNA from a eukaryotic source has been 
stabilised in strains lacking polynucleotide phosphorylase and the 
expression of dehydroquinase from N.crassia and insulin has been 
increased. 
In conclusion, it is highly probable that the N-terminus of the 
protein encoded by the long ORF does not contain a region which is 
particularly sensitive to degradation, or if it does, it lies in a 
conformation not readily accessible. 	Addition of the rest of 	the 
protein may introduce such a site, or alternatively could cause 
unfolding, and hence exposure of this region thus causing the protein 
to be rapidly degraded. 
The inability to express the mature form of the HBV long open 
reading frame in E.coli has also been reported in other laboratories: 
G. Darby, Wellcome, England, and W. Gerlich, Hygiene Institut, 
University of Gottingen, West Germany, (personal communication). 
In an effort to obtain greater expression of the N-terminal region 
and to express other regions of the long ORF, recombinant plasmids were 
made in which various segments of the long ORF were fused to 
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Segments of the long open reading frame of HBV were fused in 
frame to a truncated cro--ga1actosidase gene carried on expression 
vectors which were constructed by Stanley and Luzio (1984) (Fig.4.1). 
These vectors contain all the necessary signals for transcription and 
translation of foreign DNA fragments in E.coli. 	The righthand 
promoter (ER)  of the bacteriophage X directs the expression of the 
cloned DNA, which can be inserted in all three reading frames via a 
polylinker at the 3' end of the LacZ gene. 	Immediately downstream of 
this polylinker are transcription and translation stop signals. 	The 
fusion proteins should be expressed with equal •efficiencies as 
inserting the fragment at the 3' end of the gene should not affect the 
5' secondary structure of the messenger RNA. 	Expression of the 
desired product can be controlled by using a bacterial strain which 
expresses the temperature-sensitive lambda repressor. 	The E.coli 
strain NFl (Stanley and Luzio, 1984) carries the Xc1857 gene on a 
defective lambda prophage. 	Amplifying the plasmids at 30 0C blocks 
transcription from the P R  promoter and by shifting the temperature to 
420C, transient expression of the fusion protein can be induced. 
This chapter describes the expression of the hybrid cro-LacZ-L.ORF 
gene (LacZ-pol gene) in E.coli and the generation of antiserum to the 
cloned gene product. 
4.1 Construction of the recombinant Plasmids; pRCT, pRCD and pRCJ 
The recombinant plasmids pHPL-1 and pR1-130 (see Section 3.2) 
contain DNA which codes for 28 amino acids of the core gene fused to 
either 160 or 719 amino acids respectively of the putative polymerase 







FIGURE 4.1 	Map of pEX2. Unique restriction enzymes sites 
are shown. 
both pFIPL-1 and pR1-130 (Fig. 4.2). The plasmids were restricted with 
these two enzymes and the resulting fragments separated on a 1% low 
melting point gel. 	The appropriate fragments were purified and 
ligated to EcoRI and SalI digested pEX2. 	The ligated mix was used to 
transform competent E.coli NFl cells and plated out in the presence of 
ampicillin and grown overnight at 30 0C. Plasmid DNA was prepared from 
overnight cultures (grown at 30 0C) of ampicillin-resistant 
transformants and recombinant plasmids were identified by restriction 
mapping. The two resulting recombinant plasmids are called pRCT and 
pRCD. 	pRCJ was constructed in a similar manner to that used for pRCT 
and pRCD. 	Plasmid pI-IBVCB carries the HBV genome (Section 3.1). This 
was digested with BgIII and Pstl to produce a fragment that codes for 
424 amino acids of polynierase and none of the core antigen (Fig. 4.3). 
This fragment was isolated as described above and inserted between the 
BamHI and Pstl sites of pEX3 to give the recombinant plasmid pRCJ which 
was characterised by restriction mapping. 
Conservation of the reading frame at the point of fusion between 
vector and insert DNA was confirmed by sequencing across the junction. 
This was achieved for pRCT and pRCD by transferring the EcoRV-iII 
fragments covering the junction sequences of the recombinant plasmids 
into M13 mp18 and for pRCJ by cloning the Smal Pstl fragment covering 
the LacZ-pol fusion into M13 mp19. 	The junctions were then sequenced 
by the dideoxy chain termination procedure. 
4.2 Analysis of Proteins encoded by pRCT, pRCD and pRCJ 
E.coli NFl cells transformed with pRCT, pRCD or pRCJ were grown at 
300C to a stationary phase in L-broth containing ampicillin and grown 
at 300C to A650 = 0.4. 	Cells were induced by shifting the 
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FIGURE 4.2 	The construction of pRCT and pRCD. 1) PHPL-1 
contains HBV DNA sequences equivalent to the first 28 
amino acids of the core protein fused in frame to amino 
acids 40 to 201 of the polyrnerase gene product. 2) A 
Bami-lI fragment encoding the internal sequences of the 
polymerase gene was inserted into the unique BamHI site of 
pHPL-1 to form pRl-130. 3) pR1-130 and pHPL-1 were 
digested with EcoRI and SalI, the fragments carrying HBV 
sequences recovered, and transferred to the expression 
vector pEX2. 
Key: hatched area, HBV core gene; filled area, HBV 
polymerase gene; open area, X-cro-lacZ. 
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FIGURE 4.3 	The construction of pRCJ. 1) a !II-PstI 
fragment encoding sequences of tTipolymerase 
gene was inserted into the BamHl-PstI sites 
of the vector pEX3. 
Key: filled area, polymerase gene; open area 
X-cro-lacZ gene. 
temperature to 42 0C for 45 minutes, then returning to 30 0C for a 
further 30 minutes. 	Cells were harvested and resuspended in protein 
loading buffer, boiled for 5 minutes and the proteins separated by 
electrophoresis on an SDS-polyacrylamide gel. 	The gel was then 
stained with Coomassie blue to visualise the proteins. 	Novel proteins 
were synthesised in cells harbouring pRCD, pRCT or pRCJ with molecular 
weights of 143,000, 195,000 and 158,000, respectively, which correspond 
to the size of the expected B-galactosidase polymerase fusion products 
(Fig. 4.4). 	As cells harbouring the recombinant plasmid only 
synthesise the novel proteins under conditions in which transient 
expression from P R is induced, one can conclude that this promoter is 
driving the expression of these unique polypeptides. 
Interestingly, pRCD, which is a derivative of pRl-130, was shown 
previously to synthesise no novel proteins in vivo (Section 3.4). 
However, when the polymerase region of pR1-130 is preceded by a large 
portion of the .-galactosidase protein (as in pRCD), the fusion protein 
of the expected size is produced. 	Thus it would appear that the - 
galactosidase polypeptide stabilises or protects the foreign gene 
product from degradation. 	Using various induction times it was shown 
that the fusion protein synthesised in cells harbouring pRCD was 
sensitive to proteolytic degradation. 	Figure 4.5, tracks 7 and 8, 
shows that after induction at 42 0C for 30 minutes the fusion protein 
is synthesised in high amounts by pRCD. 	However, if it is induced for 
a further 60 minutes, the fusion protein is completely degraded. 
Although there is a slight reduction in the amount of fusion protein 
synthesised by pRCT, under these conditions there is not a dramatic 
degradation as seen with pRCD. Interestingly, pRCT is a derivative of 
pHPL-1 which does produce a novel protein in vivo (Section 3.4). 
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FIGURE 44 	Polypeptides encoded by pRCT, pRCD and pRCJ. 
Extracts from E.coli cells were fractionated on 7% (w/v) 
polyacrylamide gel containing SDS. 	The gel was stained 
with Coomassie blue. 	The arrows identify the -galacto- 
sidase and fusion proteins produced by pEX2, pRCT pRCD, 
and pRCJ, respectively. 	The samples were the following: 
1) NFl cells; 2) pEX2 at 30 0C; 3) pEX2 induced for 30 
min at 42 0C; 4) pRCT at 30 °C; 5) pRCT induced for 30 
min at 420C; 6) pRCD at 30 0C; 7) pRCD induced for 30 
min at 42 0C; 8) pRCJ at 30 0C; 9) pRCJ induced for 30 
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FIGURE 4.5 	Analysis of polypeptides encoded by pRCT and 
pRCD at various times of induction 	Extracts from E,col 
cells were fractionated on a 7% (w/v) polyacrylamide gel 
containing SOS. 	The gel was stained with Coomassie blue. 
The arrows identify the -ga1actosidase and fusion 
proteins produced by pEX2, pRCT and pRCD respectively. 
The samples were the following: 2) NFl cells; 3) pEX2 
induced for 90 min at 42 0C; 4) pRCT induced for 10 mm 
at 420C; 5) pRCT induced for 30 min at 42 0C; 6) pRCT 
induced for 90 min at 42 0C; 7) pRCD induced for 30 mm 
at 420C; 8) pRCD induced for 90 min at 420C; 9) pRCT 
induced for 90 min at 420C. 
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This observation suggests that when the cells reach stationary 
phase, during the extended induction times, the proteolytic activity 
which is stimulated under these conditions (Goldberg and St. John, 
1976) is recognising a particular sequence or conformation present in 
the polymerase region encoded by pRCD but not pRCT. 
Protein extracts from cells harbouring the recombinant plasmids 
and vector control were separated electrophoretically and transferred 
to nitrocellulose membranes. 	The identity of these proteins as 
products of the gene fusion was confirmed by immuno-blotting these 
membranes with antiserum raised against -galactosidase (Fig. 4.6). 
4.3 Preparation of Antiserum to the Putative Polymerase Gene Product 
To prepare antiserum that should recognise a wide spectrum of 
epitopes on the putative polymerase protein, three types of 
immunisation procedures were performed, using different antigen 
preparations. 	Isolating the recombinant -galactosidase polymerase 
fusion proteins from an SDS-polyacrylamide gel will expose linear 
sequential determinants, purification of the fusion proteins using 
sonicated cell extracts, and gel exclusion chromatography will allow 
the polypeptide to be isolated such that the conformational epitopes 
will be exposed and lastly, by using HBV core preparations treated with 
non-ionic and ionic detergents a wide variety of antigens of the in 
vivo product will be exposed. 
The 143,000 and 195,000 Dalton proteins synthesised by cells 
containing pRCT and pRCD respectively were used for the preparation of 
antiserum for two reasons; both are present at higher levels than the 
novel proteins synthesised by either pHPL-1 or pEM1, and since they are 
high molecular weight proteins, they migrate to a region of the gel 
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FIGURE 4.6 	Reaction of -galactosidase antiserum with 
polypeptides encoded by recombinant plasmids. 	Western 
blot analysis of E.coli cells NFl transformed with 
recombinant plasmids. 	Samples were run on a 7% (wlv) 
polyacrylamide gel containing SOS. 	After transfer to 
nitrocellulose the samples were probed with antiserum to 
the denatured -galactosidase protein. 	The reactions 
were visualised by addition of peroxidase-conjugated 
donkey anti-rabbit serum and stained in 0.01M imidazole 
p117.4, dianisidine (250 ug/ml, 0.3% (v/v) hydrogen 
peroxide. 	The arrows identify the t3-galactosidase and 
fusion proteins produced by pEX2, pRCT, pRCD and pRCJ 
respectively. The smaller sized species of immunoreactive 
proteins are breakdown products of the larger fusion 
proteins. 	1) pRCJ induced for 30 min at 42 0C; 2) pRCJ 
at 30 0C. 3) pRCD induced for 30 min at 42 0C; 4) pRCD 
at 300C; 5) pRCT induced for 30 min at 42 0C; 6) pRCT 
at 30 0C; 7) pEX2 induced for 30 min at 42 0C; 8) pEX2 
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where there is less likelihood of contamination with other E.coli 
proteins. 	The fusion proteins were fractionated from an E.coli lysate 
by electrophoresis in a 7.5% polyacrylamide gel in SOS and identified 
by staining strips cut from the edge of the gel with Coomassie blue. 
The corresponding band was cut from the remainder of the gel and 
homogenised in an equal volume of PBS. 	Samples of the homogenate, 
containing about lOOjig of protein, were emulsified with Freund's 
complete adjuvant and injected into rabbits. 	The immunisation 
procedure is described in more detail in the Materials and Methods 
Section. 	Cultures of cells containing pRCT or pRCD were grown at 
300C to A650 = 0.4 induced by raising the temperature to 42 0 C, as 
described previously, harvested and then sonicated in 0.5% of the 
original culture volume of TEN buffer. 	The membrane and supernatant 
fraction were separated by centrifugation. 	Repeated attempts to 
purify the fusion proteins to homogeneity were unsuccessful because of 
the insolubility of the hybrid proteins which precipitated with the 
pellet fraction. 	These pellets were therefore used as antigens and 
emulsified with an equal volume of Freund's complete adjuvant. 	As the 
fusion proteins are synthesised at high levels in the cells, it was 
hoped that an antibody response would still be mounted against these 
polypeptides as was reported by Burrell et a]., (1979) who injected 
whole E.coli cell extracts of clones producing minute quantities of 
HBsAg and induced an anti HBsAg response. 
Hepatitis B core particles were isolated from the liver at the 
autopsy of a patient suffering from chronic hepatitis B virus. 	These 
core preparations were treated with 1% SOS and 5% NP40 and incubated at 
370C for 30 minutes. 	The mixture was diluted 1:10 with PBS and 
emulsified with an equal volume of Freund's adjuvant and injected into 
rabbits as before. 
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4.4 Analysis of Antisera 
Antisera raised against the fusion proteins extracted from an SDS 
polyacrylamide gel, will react with numerous epitopes present on these, 
including the highly immunogenic -ga1actosidase moiety. In order to 
determine whether the antisera contain antibodies which react with the 
polymerase region of the fusion proteins, antibodies against -ga1acto-
sidase were first removed. Removal of such antibodies was carried out 
by incubating the antisera with cellular extracts of E.coli, containing 
the vector pEX2. The resulting immunoprecipitate was removed by 
centrifugation. 	This process of adsorption was repeated three more 
times and allowed the detection of antibodies in the antisera that 
react specifically with the polymerase moiety of the fusion proteins 
(Fig. 4.7 and Fig. 4.8). 	However, while the antiserum against the 
fusion product encoded by pRCD also cross-reacted strongly with the 
gene fusion product from pRCJ, cross-reaction with the pRCT fusion 
product was weak (Fig. 4.8). 	Antibodies against the fusion protein 
synthesised by pRCT also cross-reacted weakly against the two 
heterologous antigens (Fig. 4.7). These results suggest that at least 
two distinct epitopes are located in the amino terminal and central 
regions of the gene product. 
The antiserum raised to the pellet fraction from crude lysates of 
pRCD and pRCT, barely recognised the fusion protein using the Western 
blot technique. 	Likewise, the rabbits that were exposed to core 
preparations treated with NP40 and SOS, produced anti HBcAg, and anti 
HBe antibodies respectively (detected by using radioimmuno- assays) but 
not antibodies that cross-react with the fusion protein. 
These results suggest that the antibodies produced by the latter 
two procedures recognise, perhaps, only conformational epitopes and so 
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FIGURE 4.7 	Reaction of monospecific antiserum with 
polypeptides encoded by recombinant plasmids. 	Extracts 
from cells bearing pEX2, pRCT, pRCD and pRCJ were 
separated electrophoretically and transferred to nitro- 
cellulose membranes. 	After transfer samples were probed 
with antiserum raised to the -ga1actosidase-po1ymerase 
fusion protein synthesised by pRCT. 	The antiserum was 
preabsorbed with extracts from cells carrying the vector 
the following number of times: panel A, once, panel C 
twice, and panel B, three times. The blot was hybridised 
and developed as described in Section 2.10.12. 	Lane 1, 
pRCJ; Lane 2, pRCT; Lane 3, pRCD; Lane 4, pRCJ; Lane 
5, pRCD; Lane 6, pRCT, and Lane 7, pEX2. 	The samples in 
Lanes 8-11 are duplicates of those in Lanes 4-7. 
FIGURE 4.8 	Reaction of monospecific antiserum with 
polypeptides encoded by recombinant plasmids. Samples 
were run on a 7% (w/v) polyacrylamide gel containing SDS. 
After transfer to nitrocellulose the samples were probed 
with antiserum raised to the -ga1actosidase-po1ymerase 
fusion protein synthesised by pRCD. The antiserum had 
been previously adsorbed three times, with extracts from 
cells carrying the vector. The blot was hybridised and 
developed as described in Section 2.10.12. 	Lane 1, pRCD; 
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would not react with the fusion proteins in Western blots. 	To 
determine whether or not the antisera produced against cell pellet 
fractions, or Dane particles treated with detergents, recognise 
conformational antigens on the fusion proteins, one would have to use 
the techniques of either radioirnmunoassay or irnmunoprecipitation. Due 
to the lack of purified antigen and the presence of a large variety of 
antibodies capable of cross-reaction with E.coli proteins, it has not 
yet been possible to carry out such experiments. 	Further work, 
involving purification of the fusion proteins and removal of non-
specific antibodies, will have to be carried out before the antibodies 
raised against the crude preparations of fusion proteins and Dane 
(core) preparations can be properly analysed. 
4.5 Discussion 
In conclusion, segments of the long ORE of HBV were fused in frame 
to the -ga1actosidase gene of E.coli. 	Expression of the recombinant 
plasmids in E.coli produced fusion proteins which were sufficiently 
abundant and stable for direct detection after electrophoresis of the 
total bacterial proteins. 	The fusion proteins contained regions of 
the putative polymerase polypeptide which had not been previously 
synthesised. 	Rabbit antisera were raised to the hybrid proteins and 
this was shown to contain antibodies that recognised epitopes on the 
putative polymerase protein. Cross-reaction experiments tentatively 
identified at least two distinct epitopes located in the central and 
amino terminal region of this I-iBV polypeptide. 
This rabbit antisera can now be used as a probe to confirm that 
the protein encoded by the HBV long ORF is present within the virion 
particle and expressed during the course of the virus life cycle. At 
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present Professor Eddleston (King's College, London) is using this 
antiserum to detect any cross-reactivity with proteins from liver 
biopsies of patients infected with HBV. 	In future experiments this 
antiserum will be used to analyse Dane particles and cell lines 
transformed with HBV for the presence of the putative polymerase gene 
product. 	The polymerase gene fusion product synthesised in E.coli 
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The polymerase gene fusion products provide a reagent which allows 
one to determine firstly, if and how this gene is expressed during the 
life-cycle of HBV, and secondly, whether or not the infected host 
mounts an antibody response to it. 
It may be expected that a viral polymerase, normally an internal 
component, would not induce an antibody response. 	However, it has 
been shown that, in the course of infection of both human immuno-
deficiency virus (HIV) and Moloney murine Leukaemia virus (M-MuLV), an 
antibody response against the viral polymerase is induced. 	Antibodies 
to M-MuLV reverse transcriptase and some but not all antibodies to HIV 
reverse transcriptase have also been shown to inhibit enzyme activity 
in disrupted virions (Aaronson et al., 1971; Oroszlan et al., 1977; 
Laurence et al., 1987). 	Likewise, Cappel et a]., (1976) reported the 
presence of antibodies to the endogenous HBV DNA polymerase in the sera 
of patients infected with HBV. 	These antibodies, which appeared 
transiently, were detected by their ability to inhibit the repair of 
the single-stranded gap in the HBV genome by the endogenous polymerase. 
They were found to be specific in that they did not inhibit Rous 
sarcoma or bacterial polymerases (Cappel et al., 1977). 	However, it 
is not obvious how these antibodies could inhibit the endogenous DNA 
polymerase within the intact core particle. 	This inhibition of the 
HBV polymerase by antibodies has not been observed by others (Hess et 
a]., 1980. 	Therefore, the inhibitory antibodies observed by Cappel 
and his co-workers have yet to be proven unequivocally to be specific 
to the hepatitis B associated polymerase. 
To investigate this phenomenon immunoblotting experiments with 
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bacterial extracts carrying the -ga1actosidase polymerase fusion 
protein were performed and are discussed in this chapter. 	The results 
showed that convalescent sera from chimpanzees infected with FIBV 
contain antibodies that cross-react with the -ga1actosidase polymerase 
fusion but with no other polypeptide encoded by HBV. 
5.1 Detection of Antibodies to the Polymerase Gene Product in 
Convalescent sera. 
Before trying to detect antibodies against the putative polymerase 
gene product in convalescent sera, using the fusion proteins produced 
by pRCD and pRCT as antigens, it was necessary to show that the N-
terminal segment of HBcAg, present in both of the fusion proteins, did 
not show detectable cross-reaction with antibodies against either HBcAg 
or 1-IBeAg. 	Crude extracts from cells carrying the recombinant plasmids 
or vectors were fractionated electrophoretically on an SDS polyacryl- 
amide gel and transferred onto nitrocellulose membranes. 	Serum 
samples from nine separate rabbits that were anti-HBcAg positive after 
being immunised against various native or denatured core preparations 
were then tested against the proteins bound to nitrocellulose 
(Fig. 5.1a). Bound antibodies were detected by incubating with either 
alkaline phosphatase or peroxidase conjugated to anti-rabbit/human IgG 
and stained as described in Materials and Methods section. 	No anti- 
bodies that cross-react with either of the fusion protein were found. 
In addition, the antiserum generated to the fusion proteins showed no 
reactivity in immunoblotting experiments with HBcA9 or HBeAg. 	Hence 
one can conclude from the data that in the first 28 amino acids of the 
core polypeptide there is no epitope for HBcAg or HBeAg, which agrees 
with extensive epitope mapping of the HBeAg carried out by R. Tedder 
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FIGURE 5.1(a) 	Antibodies against HBcAg do not cross-react with 
fusion proteins. 	Proteins from cell lysates harbouring 
pRi-11, pEX2, pRCD and pRCT were fractionated by 
electrophoresis in a 10% polyacrylamide gel containing SDS 
and transferred electrolytically to a cellulose nitrate 
membrane. 	This membrane was probed with HBcAg 
antibodies. 	The reactions were detected by addition of 
peroxidase-conjugated donkey anti-rabbit serum and stained 
as described.previously. The arrows identify where the 
fusion protein migrates. Cross-reacting polypeptides 
across all tracks may be due to the serum (raised against 
a bacterial preparation of HBcAg) containing antibodies to 
these E.coli proteins. 1) NFl; 2) pEX2 induced at 42 0C 
for 30 mm; 3) pRCT at 30 °C; 4) pRCT induced at 42 0C 
for 30 mm; 5) pRCD at 30 0C; 6) pRCD induced at 42 0 C 
for 30 mm; 7) Purified HBcAg expressed by Ri-il. 
FIGURE 5.1(b) 	Antibodies against HB5Ag do not cross-react 
with fusion proteins. 	Purified HB5Ag expressed by yeast 
and crude lysates of cells carrying the plasmids of 
interest were run on a 10 (w/v) polyacrylamide gel 
containing SDS, then transferred onto nitrocellulose. The 
blot was probed with HBsAg antibodies and developed as 
described in Section 2.10.12. The arrows identify where 
the fusion proteins migrate. 1) FIBsAg; 2) pRi-11; 
3) pBBX-1 expressing FIBxA9; 4) pRCD induced at 42 0 C 
for 30 mm; 5) pRCT induced at 42 0C for 30 mm; 
6) pEX2 induced at 42 0C for 30 mm; 7) NFl. 
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(personal communication). 	It also shows that the fusion proteins, 
synthesised by pRCT, pRCD and pRCJ, the latter of which has no core 
sequences, can be used as antigens to detect antibodies to the gene 
product of the long ORF. 
As the levels of the HBeAg and the endogenous Hepatitis B 
polymerase activity rise and fall at the same time during the course of 
HBV infection it was postulated that an antibody response to the 
endogenous polymerase would correlate with the appearance of anti-
HBeAg. 	Therefore, serum samples taken serially from three chimpanzees 
recovering from HBV infection, which were anti-HBeAg positive, were 
tested against the fusion proteins bound to nitrocellulose. 	Cross- 
reacting antibodies were found in the serum of the infected animals 
(Fig. 5.2 and 5.3), but these antibodies were present only transiently 
and reached a maximal level 25 weeks after inoculation of the virus, 
which correlates exactly with the maximal levels of anti-HBe. 
Similar cross-reacting antibodies were not found in the serum of 
chimpanzees that had been vaccinated prior to inoculation with HBV 
(Fig.5.2b). 	Furthermore, antibodies raised against HBsA9 (Fig.5.1b), 
as well as HBcAg and HBeAg (Fig. 5.1a), did not react with the - 
galactosidase-polymerase fusion products. 	Hence these results clearly 
show that during HBV infection a specific antibody response, directed 
against the gene product of the long ORE, is elicited. 
A panel of human sera from patients infected with HBV was examined 
for the presence of antibodies to the putative polymerase gene product. 
None of the human sera contained antibodies which cross-reacted with 
the -galactosidase-po1ymerase fusion proteins. 	The negative results 
for the human serum may reflect the small panel of blood samples (five) 
used and the stage of infection when they were taken; late acute and the 
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FIGURE 5.2 	Detection of antibodies that cross-react with 
the fusion proteins expressed by pRCT and pRCJ. 	Extracts 
from cells bearing pEX2, pRCT and pRCJ were separated 
electrophoretically and transferred to nitrocellulose 
membranes. 	These membranes were either stained with 
Coomassie blue, or incubated with chimpanzee serum samples 
listed below. 	Membranes incubated with serum were then 
washed and incubated with goat anti-human serum conjugated 
with horse radish peroxidase for staining with peroxidase 
as described in the Methods section. 	A) Membranes 
incubated with serum samples from a convalescent 
chimpanzee following acute hepatitis B infection. 	Lanes 
1,2,12,13 and 14, correspond to pEX2, pRCT, pRCJ, pRCT and 
molecular weight markers stained with Coomassie blue. 
Lanes 3-5 are pRCJ, pEX2 and pRCT, respectively, probed 
with pre-immune serum. 	The samples in Lanes 6-8 are 
duplicates of those in Lanes 3-5, but incubated with serum 
taken 25 weeks after HBV challenge. 	Lanes 9-11 are 
duplicates of the two previous groups, but probed with 
serum taken 30 weeks after HBV challenge. 	B) Membranes 
probed with serum from a chimpanzee vaccinated (with 
purified HBsAg synthesised in yeast) prior to inoculation 
with HBV. 	The samples in Lanes 4-6 contain pRCJ, pEX2 
and pRCT incubated with pre-immune serum. The samples in 
Lanes 1-3 are duplicates of those in Lanes 4-6 probed with 
serum taken 25-30 weeks after challenge with the virus, 
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carrier state. 	As the antibodies present in the chimpanzees were 
shown to occur only transiently, it is possible that such antibodies 
have been produced but are no longer present in the sera. 	At present 
a larger panel of human sera, consisting of over 50 samples (some of 
which had been taken very early in the course of the disease), are 
being tested for the presence of the cross-reacting antibodies. 	To 
investigate whether or not the antibodies found in the chimpanzee serum 
also react with the homologous polymerase gene products of Moloney 
murine Leukaemia virus (M-MuLV), and Avian murine Leukaemia virus 
(AMy), samples of the purified reverse transcriptase from both these 
viruses were separated electrophoretically on an SOS polyacrylarnide gel 
and transferred onto nitrocellulose membranes. These membranes were 
then probed with serum samples which cross-reacted with the - 
galactosidase-polymerase fusion proteins. 	It was found that the 
convalescent chimpanzee sera showed no cross-reaction with either 
reverse transcriptase and hence is specific for the putative polymerase 
of HBV (Fig. 5.4). 
5.2 Discussion 
These experiments provide clear evidence that the putative 
polymerase gene of HBV is expressed and its product exposed to the 
immune system of the host during normal viral infection. 	They also 
show that the two epitopes tentatively identified at the amino terminal 
and central regions of the gene product (Section 4.4) elicit an 
antibody response during HBV infection. 
Whether the antibodies described by Cappel et al., (1976), which 
inhibited the endogenous DNA polymerase, are related in any way to the 
antibodies generated to the translation product of the long ORF remains 
117 
FIGURE 5.3 	Demonstration of antibodies to the - 
galactosidase-polymerase fusion proteins in serum by 
immunoblotting. Proteins were separated by SDS-PAGE on a 
10% gel and transferred onto nitrocellulose strips. 
These strips were incubated with chimpanzee serum samples 
as described below. 	The reactions were visualised by the 
addition of goat anti-human serum conjugated with 
peroxidase and stained as described in the Materials and 
Method Section. 	Lanes 1-5; extracts from cells carrying 
pRi-11, pRCD, pRCT, pEX2 and NFl, respectively probed with 
serum taken 30 weeks after HBV challenge. 	The samples in 
Lanes 18-22 were duplicates of those in lanes 1-5 but 
incubated with serum taken 11 weeks after HBV challenge. 
Lanes 6-11; extracts from cells carrying pR1-11, pEX2, 
pRCT, pRCD, pRCJ and pRCJ respectively, incubated with 
serum taken 25 weeks after HBV challenge. 	Finally, Lanes 
12-17 are duplicates of those samples in Lanes 6-11, 
probed with pre-immune serum serum. 
FIGURE 5.4 	Antibodies which cross-react to the recombinant 
fusion protein do not recognise either AMV or M-MuLV 
reverse transcriptase. 	Crude extracts from cells 
carrying the recombinant plasmids and purified reverse 
transcriptase from AMV and M-MuLV were separated on a 10% 
(w/v) polyacrylamide gel. 	Proteins were Western-blotted 
onto nitrocellulose and probed with antiserum from a 
chimpanzee taken 25 weeks after HBV challenge. 	The blot 
was developed as described in Section 210.12. 1) pRi-11; 
2) pEX2; 3) pEX2; 4) NFl; 5) M-MuLV; 6) AMV; 7) pRCD 
8) pRCT. 
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to be determined. 	It is of interest to note, however, that both sets 
of antibodies appeared transiently in the early stages of infection. 
The transient nature of the antibodies showing cross-reaction with the 
fusion proteins may reflect the system used. 	The Western blot method 
will only detect antibodies which recognise linear epitopes rather than 
conformational epitopes. 	Antibodies raised to sequential 
determinants are known to be shorter lived (Weber et a]., 1987). 
Perhaps, by using immunoprecipitationmethods,a more persistent class 
of antibody to the gene product of the long ORE could be identified. 
The production of antibodies against the X antigen has been 
observed in the same group of animals (Weber et a]., 1987). This is 
interesting as both the endogenous polymerase and the HBxAg are 
believed to be internal components of HBV and the appearance of 
antibodies may reflect exposure of both of these antigens to the 
immune system. 	Perhaps at a particular stage in HBV morphogenesis 
these proteins are exposed due to their presence in the cell membrane. 
This is the method by which the core antigen is proposed to elicit a 
humoral response. 	The polymerase of M-MuLV, which induces an 
antibody response, has also been detected on the membrane of cells 
infected with mutant M-MuLV, which are unable to complete the latter 
stages of viral assembly (Aaronson et al., 1971; Witte and Baltimore, 
1978). 	Alternatively, the cellular components may be exposed as a 
result of host cell lysis. 
In conclusion, it remains to be seen whether or not antibodies 
against the polymerase protein are produced in humans, and if so, 
whether or not such antibodies play a protective role. 
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CHAPTER 6 
EXPRESSION OF THE RECOMBINANT -GALACTOSIDASE POLYMERASE GENE 
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INTRODUCTION 
In the previous chapter it was shown that the long ORE of HBV is 
expressed by the virus during HBV thfection. 	As discussed earlier, 
this long ORE is thought to encode the endogenous polymerase. 
However, to definitively assign this function to the long ORE it is 
n.ecessary to prove that the translation product has DNA polymerase 
activity. 
The polymerase gene of both M-MuLV and HIV have been expressed 
in E.coli either as a fusion or native protein and shown to induce the 
synthesis of reverse transcriptase activity. 	In the case of M-MuLV 
reverse transcriptase, part of this gene, when fused to the TrpE gene, 
was shown to produce high levels of reverse transcriptase activity even 
though the amino and carboxy termini of the protein product were not 
present (Tanese et al., 1985) 
It was also found that when the HIV polymerase gene was expressed 
as a fusion protein with TrpE much of the polymerase gene could be 
removed without affecting activity but the TrpE portion of the 
construct was essential for good activity (Tanese et al., 1986). 
As a result of the above observations, it was decided to test 
extracts of cells expressing the -galactosidase HBV fusion proteins 
for a novel DNA polymerase activity. 	Although originally described as 
a DNA-dependent polymerase (Kaplan et al., 1973), the HBV polymerase is 
now believed to function as a reverse transcriptase in the generation 
of an RNA intermediate during viral replication (Summers and Mason, 
1982). Accordingly an assay for reverse transcriptase was adopted. 
The assay measures the incorporation of radioactively labelled dGTP 
into acid precipitable material in a reaction that uses poly r(C) as 
template and oligo d(G) as primer (Takatsuji et al., 1986). 	The 
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results presented in this chapter show that extracts of E.coli 
expressing the HBV gene fusion products exhibit a polymerase activity 
with the characterisatics of a reverse transcriptase. 
6.1 The -galactosidase-Polymerase Fusions induce Reverse 
Transcriptase Activity 
Cultures of E.coli NFl transformed with the vector pEX2 and the 
three recombinant plasmids, pRCT, pRCJ, and pRCD, were grown at 30 0C 
to A650=0.4 induced for 45 minutes at 42 0C, harvested and 
resuspended in Tris EDTA NaCl buffer (T.E.N.) (See Methods Section). 
The cells were lysed by sonication and treated with deoxyribonuclease 
1. 	Cell debris was pelleted by centrifugation and the supernatant and 
pellet fractions were separated. 	The pellet was washed three times by 
resuspension in TEN and centrifugation, and used in various assay 
reactions. 	Aliquots of the crude lysate mixture from cells carrying 
pRCT, pRCD and pRCJ, and the vector were added to the following:- the 
reaction buffer, poly r(C) oligo dG( 12_ 18 ), and radioactive labelled 
3H dGTP. 	After incubation at 37 0C for 60 minutes, acid- 
precipitable material was collected and counted (see Methods Section). 
Extracts from cells carrying the vector exhibited small but 
significant activity in this assay, but equivalent extracts from cells 
carrying the plasniids pRCD, pRCJ or pRCT consistently gave 
significantly higher activity in the polyrnerase assay than cells 
carrying the vector. 	The highest specific activity was obtained 
repeatedly with extracts of pRCT (Fig.6.1a) and cells transformed with 
this plasmid were therefore used for further experiments. 	Extracts 
from cells harbouring pRCD and pRCJ had polymerase activities 
approximately twice that of cells carrying the vector. 
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FIGURE 6d(a) 	Lysates prepared from E.coli NFl cells carrying 
pEX2 and pRCT assayed for polymerase activity. 
FIGURE 6.1(b) 	Lysates prepared from E.coli NFl cells carrying 
pEX2 and pRCT assayed for polymerase activity in the 
presence of PEA. 
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The polymerase activity of cells carrying pRCT was for the most 
part associated with the insoluble material which made purification 
very difficult. The crude lysate mixture was therefore used for all the 
studies of enzyme activity. 
The basal polymerase activity of the E.coli cells carrying pEX2 
could be due to the ability of E.coli DNA polymerase I (DNA poll) to 
carry out either DNA or RNA directed DNA synthesis and its ability to 
utilise the template poly r(C) oligo dG(12_18) (Karkas, 1973; 
Loeb et al., 1973). The polymerase activity of crude extracts from 
cells carrying pEX2 and pRCT were therefore compared (Table 1). 
Table 1 
Assay dGTP incorporated Specific Activity Specific Activit, 
Conditions (Cpm/60 mm.) (Cpm/jig protein/60 mm.) (pmoles/ng protei 
pEX2 pRCT pEX2 pRCT pEX2 pRC 
 703 12466 5.6 99 0.17 3. 
 149 1042 1.2 8.2 0.04 0. 
Heat 	(c) 164 154 1.3 1.8 0.04 0. 
No Mg2 229 0 1.9 0 0.05 0 
Mn2 (d) 2326 5575 18.0 44 0.53 1. 
Lysates were prepared from E.coli NFl cells carrying pEX2 and pRCT 
were assayed for polymerase activity (see Methods). In all the 
reactions, unless otherwise stated, lOpl of the preparation was 
used 
These reactions were as in (a), but with liil of the preparation. 
Crude lysates were heated for 15 mm. at 70 0c, cooled on ice 
then assayed. 
Mn2 at 2mM replaced Mg2 (10mM) in the assay conditions 
described in the Methods Section. 
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The polymerase activity of both lysates could be abolished by heat 
treatment and was shown to be dependent on the presence of a divalent 
cation. 	The activity from the vector extracts was stimulated when 
manganese replaced magnesium, but the activity from cells carrying pRCT 
was markedly reduced in the presence of manganese. 	This is of twofold 
interest. Firstly, it supports the hypothesis that DNA poll is 
responsible for the basal polymerase activity of the vector cells as 
the reverse transcriptase activity of DNA poll is stimulated by 
manganese (Karkas, 1973), and secondly, the loss of polymerase activity 
from pRCT in the presence of manganese reflects the cation 
requirement for the polymerase activity associated with HBV (Goto et 
al., 1984). 
6.2 Inhibition of the Polymerase Activity by Phosphonoformate 
Phosphonoformate (PFA), a pyrophosphate analog, is an inhibitor of 
reverse transcriptase and other viral polymerases (Nordenfelt et al., 
1980; Hess et al., 1980). 	It has also been shown to inhibit HBV 
polyrnerase and has in fact been used to treat patients with fulminant 
Hepatitis (Heden et al., 1986). 
Treatment of extracts of E.coli carrying pRCT with PFA inhibited the 
polymerase activity while the addition of PFA to extracts of E.coli 
carrying pEX2 had little effect on the polymerase activity (Fig. 6.1B). 
The sensitivity of the polymerase activity in cells carrying pRCT is 
therefore similar to the endogenous HBV polymerase. 
6.3 Discussion 
It is interesting that cell extracts carrying the smallest of the 
recombinant gene fusion, pRCT, has the highest polymerase activity and 
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that extension of the 3' end of the gene results in a dramatic loss in 
enzyme activity. 	This is analogous to the situation found with M-MuLV 
reverse transcriptase gene fusions. It was found that progressive 
deletions at the 3' end of the gene resulted in increased levels of 
reverse transcriptase activity in cell extracts carrying these 
deletions (Roth et al., 1985). 	This may reflect the fact that these 
smaller fusion proteins are more soluble than the parental fusion 
proteins and therefore more accessible to the substrates, or 
alternatively the template or triphosphate binding sites are in a more 
favourable conformation for efficient synthesis. 
To try to specifically inhibit the DNA polymerase activity in 
cells carrying pRCT, cell extracts synthesising the -galactosidase-
polymerase fusion protein were incubated with rabbit and chimpanzee 
sera that had previously been shown to cross-react with this protein in 
immunoblotting experiments. These experiments were unsuccessful which 
may be a correct indication of cross-reaction without blocking enzyme 
activity as has been observed in other systems(e.g. several antibodies 
that cross-reacted with HIV reverse transcriptase were found not to 
inhibit its enzyme activity (G.Derby, personal communication). 	The 
sensitivity of the polymerase activity in extracts of cells carrying 
pRCT to PFA, and the marked preference for magnesium, leads to the 
conclusion that the major component of the polymerase activity is due 
to the polymerase activity encoded by the segment of the long ORE of 
HBV. 	The limited tests carried out so far show that the biochemical 
profile of the cloned enzyme activity is similar to that of the 
endogenous Hepatitis B polymerase and the gene product of the long ORF 
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In the world today there are same 200 million carriers of HBV. 
The prognosis for any patient carrying FIBV is not good. 	Although some 
carriers spontaneously revert, and eliminate the virus, more than 50% 
will die of a liver-related disease. 	At present no universal 
chemotherapy is employed in the treatment of HBV carriers. 	The main 
approach is to use drugs that have been shown to inhibit the endogenous 
DNA polymerase with the assumption that this will stop viral 
replication. 	The major limitation in this approach is that the drug 
is being analysed with respect to the repair function of the endogenous 
polymerase and it may or may not affect the reverse transcriptase 
activity of this enzyme which is believed to be involved in the 
replication of HBV (Summers and Mason, 1982). 	Hence it is important 
that more is known about this enzyme, in particular the origin of this 
encapsulated polymerase. 
The main purpose of this study was to determine whether the long 
ORE of HBV, previously assigned as the putative polymerase gene is 
expressed during the course of viral infection and whether its product 
has polymerase activity. 	The long term aim was to provide a safe and 
abundant source of the HBV polymerase, using recombinant DNA techniques 
thereby allowing detailed analysis of the DNA-. and RNA-dependent 
polymerase activities of the enzyme with the hope of providing an 
effective and specific drug against the HBV polymerase. 
7.1 Expression of the long ORF in E.coli 
Several fragments of the putative polymerase gene were expressed 
in E.coli under the inducible control of the Lac and Tac promoters. It 
was found that the only construct that synthesised a detectable novel 
protein of the expected size was one that expressed 160 amino acids 
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from the N-terminal putative polymerase gene product. 	Synthesis of 
novel proteins by E.coli cells carrying plasmids with extended 
polymerase coding information could not be detected. Although the 
translation products could not be detected it was shown, using Northern 
blotting, that plasmids were producing HBV-specific transcripts. 
The predicted secondary structure of the messenger RNA showed that 
the initiation codon and the Shine dalgarno sequence were in a 
favourable position for the initiation of translation. 	These 
observations indicated that the failure to detect novel proteins was 
possibly due to instability of the protein products as opposed to any 
block during expression. 	This was confirmed by using a coupled in 
vitro transcription translation system. Using this system, novel 
proteins of the predicted size were expressed by the recombinants which 
had not been detected in vivo. 
Therefore, in an attempt to overcome this problem in vivo, the 
plasmids were transferred to a protease-deficient strain of E.coli 
(SG935). 	This bacterium is deficient in the protease La which plays 
an important role in the degradation of abnormal or foreign proteins 
(Goff and Goldberg, 1985). 	Using this strain it was possible to 
detect a novel protein with the expected molecular weight in cells 
carrying pEM1. 	It was also found that the level of the translation 
product expressed by pHPL-1 was dramatically increased. 	However, the 
larger constructs, pR1-130, pR1-pol8, ptac-pol8 and pT.R.T., which 
should have expressed the rest of the putative polymerase gene product, 
did not produce any novel polypeptides. 	Therefore it is highly 
probable that the central or carboxy region of the translation product 
from the long ORF carries a region that is particularly sensitive to 
proteolytic degradation, e.g. the PEST sequence (Rogers et al., 
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1986). Similarly, the polymerase gene products of HIV and M-MuLV, have 
been found to be sensitive to proteolytic degradation when synthesised 
in bacteria (Tanese, et al., 1985, 1986; Kotewicz et al., 1985). 	For 
M-MuLV, stable expression of its reverse transcriptase was achieved by 
the removal of DNA from the 3' terminus of the gene (Roth et al., 
1985). 	Likewise when the reverse transcriptase of HIV was expressed 
in a mature form, most of its protein product was present in smaller 
sized species (Farmierie et al., 1987). 	The use of Lon mutants to 
express the M-MuLV recombinant, doubled the enzyme activity previously 
seen in Lon+  cells (Kotewicz et a]., 1985). 
The fusion of a eukaryotic or viral sequence to a bacterial gene 
has often led to the stable synthesis of the hybrid fusion protein 
whereas the expression of the same recombinant gene fused to only a 
short bacterial polypeptide has been unsuccessful. 
Therefore, in an effort to obtain greater expression of the N-
terminal region and to express other regions of the long ORF stably in 
bacteria, recombinant plasmids were constructed in which various 
segments of the long ORF were fused in-frame to practically all of the 
-galactosidase genes of E.coli. 
Expression of the -galactosidase-polymerase fusion genes in 
E.coli produced proteins that were sufficiently abundant and stable 
for direct detection after electrophoresis of the total bacterial 
proteins. 	Interestingly, this included regions of the putative 
polymerase gene, the product of which had previously been undetectable 
in vivo. 	However, during extended induction times constructs 
containing the central and carboxy termini of the putative polymerase 
protein were selectively degraded. 	This suggests that when the cells 
are allowed to reach stationary phase, the proteolytic activity 
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stimulated under these conditions recognises a particular sequence or 
conformation encoded at the central or carboxy terminus of the fusion 
proteins (Goldberg and St. John, 1976). However, constructs containing 
only the N-terminus of the putative polymerase protein express their 
translation product in a native form in E.coli without such specific 
proteolytic degradation. 
7.2 Analysis of Antisera that cross-react with the Putative 
Polymerase Gene Product 
Rabbit antisera were raised to the hybrid fusion proteins. 	The 
antiserum recognised specific epitopes on the putative polymerase 
protein. 	Cross-reaction experiments with this antiserum and the 
various fusion proteins demonstrated that at least two distinct 
epitopes were located in the central and amino terminal regions of the 
putative polymerase. 
The polymerase gene fusion product synthesised in E.coli provided 
a reagent for the detection of antibodies to FIBV polymerase. 	Cross- 
reacting antibodies that recognise these fusion proteins were found in 
the sera of chimpanzees recovering from acute Hepatitis B infection. 
The presence of these antibodies was found to be transient; they were 
not observed in the serum of a chimpanzee that had been vaccinated 
prior to inoculation with HBV. 	Furthermore, antibodies raised to HBV 
surface, core, e and X antigen showed no cross-reaction with the - 
galactosidase polymerase fusion proteins. 
These experiments provide clear evidence that the putative 
polymerase gene of HBV is in fact expressed and antibodies to its 
protein product are produced during FIBV infection. 
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At present it still remains to be estabished whether or not 
antibodies that cross-react with the putative polymerase gene product 
are produced in humans following HBV infection. 	However, it is very 
likely that they are, as antibodies against HBxAg which have been 
observed in the same group of animals have also been observed in humans 
(Weber et al., 1987). 	It is not clear whether antibodies to the 
putative polymerase gene product would play a protective role. 	In the 
case of HIV, antibodies to the endogenous polymerase have been shown to 
interfere with virion assembly, and budding in vitro (Wong et I., 
1987).They may also reflect a particular point in the course of viral 
infection. 	Laurence et al., (1987) showed that asymptomatic HIV sero 
positive carriers with high titres of antibodies to reverse 
transcriptase lost these antibodies prior to the development of the 
acquired immune deficiency syndrome (AIDS). 	However, it is more 
likely that the antibodies seen to the putative HBV polymerase gene 
product and also the X antigen, are actually surrogate markers for a 
protective cellular immune response. 	In this way both HBcAg and HBeAg 
have been shown to play a protective role in stopping HBV infection by 
stimulating cell mediated response (Vento et al., 1985; Murray et a]., 
1984). 	It is possible that both the HBV polymerase and HBxA9 may also 
be involved in this process if only to a limited extent. 
7.3 The Protein Product of the Long ORE has Polymerase Activity 
Extracts of E.coli expressing the recombinant -ga1actosidase 
polymerase fusions had significantly higher polymerase activity than 
cells bearing the vector. Interestingly, the smallest gene fusion 
alone, expressing 160 amino acids of the N-terminal polymerase 
polypeptide, gave the highest specific activity. This may be due to 
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the increased solubility of the smaller fusion product and greater 
accessibility to the substrate. 	This portion excludes the region of 
strong homology which exists between the reverse transcriptases of a 
number of viruses located in the centre of the polypeptide (Toh et al., 
1983, 1985); this particular motif is homologous with an amino acid 
sequence in the ce-subunit of the E.coli DNA-directed RNA polymerase 
which has been suggested to have a role in template of primer binding 
(Kamar and Argos, 1987). 
For HIV reverse transcriptase it has also been shown recently that 
the amino terminal region of the polypeptide is essential for 
polymerase activity. 	By changing an asparagine residue to a glutamine 
residue within this region, enzyme activity was completely lost. 
(Larder et al., 1987). These experiments pinpoint a small area of 
the putative polymerase protein which carries several important 
regions for the polymerase activity. 	Using site-directed mutagenesis 
of pRCT it should be possible to pinpoint the amino acid residues that 
are responsible for polymerase activity. 
7.4 Inhibition of the Polymerase Activity by Phosphonoformate 
Since the polymeraseactivity produced by pRCT is sensitive to 
PFA, a site of action of this drug must reside within amino acid 
residues 40 to 201 of the Hepatitis B polymerase. 	Interestingly, the 
N-terminal region of the reverse transcriptase of HIV has been shown to 
be essential for inhibition by PEA. Hence pRCT provides a useful 
substrate for the study of PEA action. 	Using site-directed 
mutagenesis of pRCT it should be possible, by creating drug-resistant 
mutants, to identify a site of drug action. 	Hence by understanding 
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drug interaction at this level it should also be possible to design 
more specific drugs which would interact and interfere with the 
function of the polymerase activity encoded by the HBV long ORF. 
Although one can use the recombinant polymerase expressed in E.coli to 
some extent to identify drugs that inhibit the enzyme activity, this 
approach is limited as the clone produces only part of the polyrnerase 
protein and is expressed in a bacterial environment. 	A more 
comprehensive approach to screening would be to express the polymerase 
gene in eukaryotic cells. 	To this end the long ORE of HBV had been 
cloned into a vaccinia virus. The recombinant virus should express the 
polymerase gene under the control of vaccinia transcription signals. 
At present the products of this recombinant virus are being analysed by 
Dr. M. Mackett, Paterson Laboratory, Manchester. 
7.5 Conclusion 
Segments of the long ORE of the Hepatitis B virus genome have been 
fused to the E.coli -galactosidase gene and expressed as fusion 
proteins. 	Antisera raised to these fusion proteins recognise two 
distinct epitopes in the amino and central regions of the putative 
polymerase gene product. Using imniunoblotting, convalescent sera from 
chimpanzees infected with HBV were shown to contain antibodies that 
cross-reacted with the fusion proteins. Extracts of E.coli expressing 
the gene fusion products were also shown to exhibit a polymerase 
activity with the characteristics of the authentic endogenous Hepatitis 
B polymerase. 
Thus, the long ORE of HBV is expressed during the course of viral 
infection and its product has polymerase activity (McGlynn and Murray, 
1987). 
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Indeed from these findings there is little doubt that the 
endogenous polymerase associated with HBV is encoded by the long ORE 
and is not a host polymerase encapsidated during maturation of the 
virus. 	The antibodies that specifically recognise the polymerase 
could be used to detect the presence of this protein in hepatomas, Dane 
particles, and cell lines transformed with HBV. 	The biochemical 
characteristics of the polymerase and the action of antivirals upon 
it can now be investigated using the fusion proteins. Information of 
this nature will be of fundamental interest and may lead to the 
development of more effective drugs against hepatitis B virus. 
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